Idiopathic menorrhagia : clinical and endometrial effects of local and systemic progestagens by Irvine, Gillian Anne
Idiopathic Menorrhagia: Clinical and Endometrial Effects of Local and Systemic
Progestagens
Gillian Anne Irvine MB ChB, MRCOG





This thesis has been composed by myself, and I have been responsible for
recruitment of patients, clinical management and laboratory studies unless otherwise
acknowledged.
The contents of this thesis have not been submitted elsewhere for any other degree,








Chapter One. A Review of the Literature
Structural and Functional Changes in the Endometrium 3
Nitric Oxide and Nitric Oxide Synthase 22
Endothelins and their Receptors 37
Clinical Aspects of Menorrhagia 52
Chapter Two. 74
Out-Patient Hysteroscopy and Endometrial Biopsy in the
Investigation of Abnormal Uterine Bleeding
Chapter Three. 89
Randomised Comparative Study of the Levonorgestrel






Epithelial Cell Morphometry, Scanning Electron Microscopy
Assessment, and a2 Laminin and Dolichos Biflorus Agglutinin
Immunohistochemistry of the Endometrium of Patients with
Proven Menorrhagia, Before and After Treatment with Oral
and Intrauterine Progestagens
Chapter Five. 134
Expression of Endothelial and Inducible Nitric Oxide Synthase
in the Endometrium of Patients with Proven Menorrhagia,
Before and After Treatment with Exogenous Progestagens.
Chapter Six. 147
Autoradiography for Endothelin A and B Receptors in the
Endometrium of Patients with Proven Menorrhagia, Before and
After Treatment with Exogenous Progestagens.
Conclusions 160
References 164
Appendix One. Abbreviations 202
Appendix Two. Published papers 203
iv
Acknowledgements
1 am indebted to lain Cameron for his support, encouragement and guidance during all
stages of the compilation of this thesis.
1 thank Steve Campbell for his unstinting and enthusiastic advice with all aspects of the
laboratory work, and am also grateful to fellow-members of the Endometrial Group for
practical advice on laboratory techniques, in particular Gaby Kohnen and Gavin Collett
regarding endothelin autoradiography and Joan Telfer regarding nitric oxide synthase
immunocytochemistry.
1 thank Fiona McLachlanwho performed most of the Dolichos biflorus agglutinin and
a2 laminin immunohistochemistry, Sam Cameron who prepared the endometrial
specimens for scanning electron microscopy studies, and Anne Young who provided
general guidance on laboratory techniques.
The clinical study in chapter three was funded by Leiras Oy, Turku, Finland and 1 am
grateful to them for allowing me the opportunity to carry out this work, and to Ilkka
Rauramo, Irja Korpela and Marja Oinonen for their technical assistance in analysing
the clinical data.
Finally, I gratefully acknowledge the Consultant staff at Glasgow Royal Infirmary,
Stobhill Hospital and the Western Infirmary, Glasgow who allowed their patients to be
recruited for study, the assistance of the nursing staff at the Hysteroscopy Clinic of
Glasgow Royal Infirmary with the endometrial biopsies and levonorgestrel intrauterine
system insertions, and the patients themselves who were willing participants in the
study at no little inconvenience to themselves.
1
Idiopathic Menorrhagia: Clinical and Endometrial Effects of Local and Systemic
Progestagens
The complaint of excessively heavy periods, or menorrhagia, leads to a significantly
reduced quality of life for many women. The definitive cure for menorrhagia is
hysterectomy, however hysterectomy is unsuitable for many women and in these
cases medical management is indicated.
The first part of this thesis reviews the possible aetiologies for idiopathic
menorrhagia, discusses the investigation of patients complaining of abnormal
menstrual bleeding, in particular the role of outpatient management, and summarises
the medical therapies currently available with emphasis on the synthetic
progestagens. Evidence for the involvement of the endothelins, a family of powerful
vasoconstrictors, and nitric oxide, a vasodilator, in endometrial haemostasis is
reviewed. The structural changes seen in the endometrium following exposure to
synthetic progestagens are considered.
A review of 400 patients referred for outpatient hysteroscopy and endometrial biopsy
to investigate abnormal vaginal bleeding is presented and its clinical implications
discussed. Results from a randomised comparative parallel group study comparing
the efficacy of systemic and local progestagens are presented. 44 patients with
objectively proven idiopathic menorrhagia were randomised to receive oral
norethisterone or local progestagens via the levonorgestrel intrauterine system.
Outcome measures included the change in menstrual blood loss after three cycles of
treatment, side effect profiles and patient satisfaction with treatment.
Endometrial biopsies were taken from patients participating in the above trial before
and after treatment to examine the effects of exogenous progestagens on the
endometrium. The following areas were investigated and are presented: changes in
the distribution of endothelin A and B receptors; changes in the expression of
endothelial and inducible nitric oxide synthase; the effects of exogenous
progestagens on the luminal epithelium using scanning electron microscopy, and on
morphological measurements of glandular and luminal epithelium under light
microscopy; alterations to the secretory function of epithelial cells using Dolichos
biflorus agglutinin histochemistry, and to the stromal cells using a.2 laminin, a
marker of stromal cells which have undergone decidualisation.
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Chapter One
A Review of the Literature
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Introduction
The human endometrium is a remarkable organ. In the absence of pregnancy, it
undergoes a cycle of shedding (menstruation), remodelling, cellular proliferation and
secretory change, all within an average of 28 days. In the event of pregnancy, the
endometrium is able to postpone menstruation, establish physical and nutritional
contact with the conceptus and facilitate implantation. Ovarian steroids exert overall
control over the changing functions of the endometrium and the endometrium also
functions as a paracrine organ, with the different compartments of the endometrium
interacting with each other via a number of mediators. Abnormalities of endometrial
function can result in menstrual disturbances such as excessively heavy menstrual
blood loss (menorrhagia), the subject of this thesis, and abnormal endometrial
development in the luteal phase is associated with unexplained infertility (Li et al,
1991) and carries a poor prognosis for subsequent pregnancy (Klentzeris et al, 1992).
The first part of this review will examine the structural changes occurring in the
endometrium during the normal menstrual cycle, in early pregnancy and following
exposure to exogenous progestagens. Alterations in endometrial function will also be
examined, with particular emphasis on endometrial haemostasis and the changes
associated with stromal decidualisation. The potential roles of endothelin and nitric
oxide in these processes will be highlighted.
The second part of this review will consider clinical aspects of menorrhagia. The
clinical definition is reviewed and the aetiology discussed. The medical treatment of
menorrhagia is assessed, with emphasis on the role of synthetic progestagens in the
reduction of menstrual blood loss.
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Structural and Functional Changes in the Endometrium
Within the endometrium, four cellular compartments may be recognised, the lining
surface epithelium, the endometrial glands, stroma and blood vessels. All respond to a
changing pattern of ovarian steroids, with cyclical alterations in the non-pregnant state
and a pattern of progesterone dominance in the pregnant state. The response to the
ovarian steroids varies between compartments and is mediated via intracellular
oestradiol (ER) and progesterone receptors (PR). The concentrations of both receptors
increase during the proliferative phase, the rise in PR lagging behind that of ER
(Lessey et al, 1988), and return to low levels during the secretory phase.
Immunohistochemical studies have identified maximal ER expression in endometrial
glands and stroma in the late proliferative phase (Snijders et al, 1992). Progesterone
receptors show maximal expression in glands and stroma in late proliferative phase
endometrium, with stromal staining persisting into the secretory phase of the cycle.
Three distinct layers can be identified in the endometrium, a superficial zona compacta,
an intermediate zona spongiosa and the zona basalis next to the myometrium.
Together the zona compacta and spongiosa make up the functional layer of the
endometrium (stratum functionalis), which undergoes more dramatic changes than the
deeper layer (stratum basalis) during the menstrual cycle. This section reviews the
response of the four endometrial compartments to endogenous and exogenous
steroids.
Endometrial glands and stroma: an overview
The histological changes occurring within the endometrium during the menstrual cycle
are well-established. Work published in 1950 by Noyes, Elertig and Rock reviewed
5
the criteria used to date an endometrial biopsy and thus provided a detailed description
of the morphological changes occurring within endometrial glands and stroma in
approximately 8 000 endometrial biopsies (Noyes et al, 1950).
In the early proliferative phase, Noyes etal described the endometrial glands as short,
straight and narrow with mitoses indicating proliferation; the stroma was compact. In
the mid proliferative phase the glands had become longer and were lined with
columnar epithelial cells. Transient stromal oedema was noted and stromal mitoses
were common. In the late proliferative phase the glands were described as tortuous
with active growth and pseudostratification of the epithelium. The stroma was
moderately dense and actively growing. During the secretory phase, changes in
endometrial glands and stroma were more marked than in the proliferative phase, such
that the authors felt able to categorise changes on a daily basis. In the first part of the
secretory phase, these changes were mainly confined to the glandular compartment.
By the 16th day of the cycle the glands showed subnucleolar vacuolation, and by day
17 the gland nuclei were lined in a more or less orderly row with homogeneous
cytoplasm above the nuclei and large vacuoles below. By day 18 the vacuoles had
decreased in size as their contents entered the gland lumen, and the nuclei had
approached the base of the cell. By day 19 there were few vacuoles remaining and by
day 20 the gland lumena were seen to contain a central collection of secretion.
Changes in the rest of the secretory phase were mainly categorised by changes
occurring in the stromal compartment. Tissue oedema was evident by day 21,
reaching its peak on day 22. By day 23 the spiral arterioles had become more
prominent and periarteriolar stromal cells underwent early decidual change with larger
nuclei and an increase in cytoplasm . By day 24 decidual cells were evident around the
arterioles, and mitoses were visible within the stroma. By day 25 decidual
differentiation had occurred below the surface epithelium, and by day 27 appeared as
solid sheets of well developed decidua-like cells. Infiltration by polymorphonuclear
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leukocytic cells began on day 27 and areas of focal necrosis and haemorrhage were
seen to occur a few hours before the onset of overt menstruation.
Endometrial glands and secretory markers
This work, while including very large numbers of biopsies, has been criticised
because it used subjective methods to assess the tissue and the date of the last
menstrual period to date the biopsy (Li et al, 1988). Other studies have undertaken
objective morphometric analyses of endometrial glands and stroma, and have used the
day of the luteinising hormone (LH) surge as a reference point (Johannisson et al,
1987; Li et al, 1988). Measurements of the functional layer of endometrial biopsies in
90 women with regular menstrual cycles showed that the number of glands per mm-
was 20 and that this did not vary over the course of the cycle (Johannisson et al,
1987). Glandular mitoses, counted per 1000 glandular cells and expressed per 48
hours, remained stable from days LH -11 /-10 to days LH -5 /-4, then decreased
significantly from days LH -3 1-2 to days LH +5 1+6 suggesting a reduction in
proliferative activity as ovulation approached. Glandular lumen diameter remained
constant throughout the proliferative phase, showed a highly significant linear increase
by day LH +11 /+12 while gland cell height decreased significantly from days LH +3
/+4 to the end of the cycle. Li and co-workers described in detail the events occurring
in the days following the LH surge (Li et al, 1988), and showed a highly significant
correlation between five morphometric measurements (number of mitoses per 1000
gland cells, amount of secretion in the gland lumen, volume fraction of gland occupied
by gland cell, amount of pseudostratification of gland cell and amount of decidual
reaction) and chronological dating based on the LH surge. The importance of
progesterone in effecting secretory change within the endometrium was emphasised in
a study in which an anti-progestin was administered to women two days following the
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LH surge (Cameron et al, 1996). This resulted in an endometrium with retarded
secretory changes compared to a control cycle, and immunostaining demonstrated
persistent ER and PR staining in glands and stroma following treatment.
In addition to light microscopy studies of glandular epithelium, molecular changes
occurring in the glycoproteins associated with glandular epithelial cells are of interest
since such changes respond to changes in the function of such cells. Luminal and
glandular epithelium is associated with a thick glycocalyx at the apical surface of the
cells which may play a role in implantation. Lectins are haemagglutinins isolated from
a variety of plant and animal sources with combining sites specific for carbohydrates,
and several lectins have been demonstrated to bind selectively to endometrial epithelial
cells and their secretions (Aplin, 1991). Using a panel of lectins, Aoki and colleagues
demonstrated that the incidence and intensity of staining for Dolichos biflorus
agglutinin (DBA) and soybean agglutinin (SBA) increased in glands in secretory phase
endometrium (Aoki et al, 1989) and that the reaction product of DBA localised to the
Golgi apparatus in the supranuclear region of the glandular epithelial cell. DBA
staining can be detected at the apical surface of glandular epithelial cells and in
intraluminal secretions in proliferative phase endometrium, but expression is increased
following ovulation, suggesting up-regulation from a basal level of secretory activity
(Aplin, 1991).
Endometrial stroma and decidualisation
Decidualisation of the stroma is central to both key functions of the endometrium,
implantation of the developing blastocyst and menstruation. Decidualisation is found
in species where the trophoblast penetrates the stroma to gain access to the maternal
vasculature. This may occur in response to the invading blastocyst, as in rodents, or
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independent of a stimulus from the blastocyst, as in primates. Menstruation is
restricted to fewer species than decidualisation, and appears to occur only in species in
which decidualisation is part of the normal menstrual cycle (Finn, 1987). Three
components of endometrial stroma are considered further here, stromal cells,
extracellular matrix and cellular basement membrane, all of which undergo changes in
response to the changing pattern of ovarian steroids during the normal menstrual cycle
and in pregnancy.
Stomal cells: fibroblasts / decidual cells
The endometrial stroma contains mesenchymal cells. During the proliferative phase of
the cycle the major cellular component is the fibroblast. These show a slow steady
growth, the number of stromal mitoses per 1000 stromal cells expressed per 48 hours
showing a significant increase between days LH -11 /-10 to LH +1 1+2 (Johannisson
etal, 1987). Following ovulation and exposure of the endometrium to progesterone,
the volume density of stroma decreases as the volume density of the glandular
compartment increases. The main changes in the stroma occur in the mid- to late
secretory phase, when the stroma becomes oedematous and decidual cells are
apparent, first appearing in peri-arterial and subluminal areas (Noyes et al, 1950).
Under light microscopy, decidual cells exhibit a vesicular nucleus and abundant clear
cytoplasm. Ultrastructural studies of the decidual cells have demonstrated that the cells
are larger than the stromal cells of the early secretory phase with rounded nuclei,
dilated rough endoplasmic reticulum and more prominent Golgi bodies and lysosomes
(Verma, 1983; Cornille et al, 1985). Intermediate filaments accumulate as decidual
cells differentiate and provide information about their cellular origin with both rat and
human studies demonstrating expression of vimentin and desmin by decidual cells,
suggesting that they are derived from stromal fibroblasts (Glasser and Julian, 1986;
Khong et al, 1986).
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Stromal cells: largegranular lymphocytes
The endometrial stroma contains a unique population of granulated cells. Similar to
the natural killer group of T lymphocytes, surface markers show them to be a distinct
population of CD3~, CD56+ cells (Starkey et al, 1988; King et al, 1989) which
increase significantly due to cell proliferation in the late secretory phase of the cycle
(King et al, 1989) and in early pregnancy (King and Loke, 1991). Their precise
function is unknown, but they may play a role in controlling the extent of trophoblast
invasion (King and Loke, 1991).
Extracellularmatrix
The stromal extracellular matrix consists of collagens I, 111, V, VI and fibronectin
(Aplin et al, 1988). During the menstrual cycle, changes in the organisation of the
extracellular matrix occur in response to changes in plasma steroid levels. From day
21 of the cycle the matrix becomes more oedematous, with the appearance of collagen
V epitopes suggesting collagen breakdown and also a reduction in the content of
collagen VI which bridges interstitial structures of connective tissues such as collagen
fibrils, nerves and blood vessels (Aplin et al, 1988; Keeneetal, 1988; Bonaldo et al,
1990). Expression of type VI collagen mRNA is constant in whole endometrial tissue
throughout the menstrual cycle, suggesting that the reduction in collagen VI is due to
breakdown or reorganisation of fibrils rather than a reduced production (Mylona et al,
1995). This matrix reorganisation is thought to facilitate implantation.
Cellular basement membrane
Early ultrastructural studies demonstrated that decidual cells were associated with a
pericellular matrix which resembled a pericellular basement membrane (Lawn et al,
1971). Decidual cells have been demonstrated to produce a capsular basal lamina
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containing laminin, collagen type IV, heparan sulphate proteoglycan and the
glycoprotein BM-40 (Wewer et al, 1985; Faber et al, 1986; Aplin et al, 1988).
During the proliferative phase of the cycle, no production of basal lamina components
was observed (Wewer et al, 1985), but in early secretory endometrium
immunoreactive laminin was detectable before histological evidence of decidualisation
(Faber et al, 1986). Using a panel of monoclonal antibodies specific for various
laminin subunits, pregnant stromal basement membrane was demonstrated by
immunofluoresence and Western blotting to contain laminin subunits a2, (31, (32 and
yl (Church et al, 1996). During the nonpregnant cycle a2 laminin was absent from
proliferative tissue, but was present in the late secretory phase in areas of
decidualisation. RT-PCR demonstrated that a2 laminin chain mRNA was present in
decidua, with small amounts of this transcript detectable in endometrial tissue
throughout the cycle, suggesting that production of a2 laminin is under hormonal
control. The function of the decidual pericellular basement membrane is unknown, but
it may play a role in controlling the adhesion, migration, and differentiation of
invading trophoblast cells (Church et al, 1996).
Surface epithelium
The surface epithelium is the first interface between maternal and foetal tissues and
lends itself to scanning electron microscopy studies of its structure, as well as
conventional histological studies by light microscopy.
The changes occurring in the surface epithelium during the menstrual cycle have been
well documented (Johannisson and Nilsson, 1972; Ferenczy, 1976; Ludwig et al,
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1990). Twenty four hours after the onset of menses the uterine cavity shows areas of
desquamation over most of its surface, but the basal stumps of the glands remain. On
the second and third day after the onset of menses, epithelium grows out from the
basal glands over the epithelial stroma which is partly covered by fibrin mesh.
Macrophages can be identified clearing the uterine slough, with a peak of activity on
the third and fourth days. By the fifth and sixth day of the cycle the endometrium has
completely re-epithelialised, and further differentiation of the surface epithelium begins
with ciliagenesis and the formation of microvilli. Ciliated cells are predominantly
found around the gland openings, with increasing numbers of ciliated cells towards the
endocervix. Surface microvilli are also identified. By the mid-secretory phase the cilia
are showing signs of degeneration and the microvilli become adherent to each other.
In early pregnancy the surface of the uterus shows an absence of cilia and small,
irregular microvilli (Johannisson and Nilsson, 1972). In a study of 68 women
undergoing curettage, the percentage of ciliated cells in glandular and luminal
epithelium was demonstrated to rise during the proliferative phase to a maximum of
20% at the time of ovulation (Masterton et al, 1975). During the secretory phase of the
cycle, this percentage declined. It has been suggested that cilia are important for the
transport of secretory products, and their position around gland openings
(Johannisson and Nilsson, 1972) gives support to that hypothesis. The reduction in
the percentage of ciliated cells during the secretory phase of the cycle (Masterton et al,
1975), along with their degeneration (Johannisson and Nilsson, 1972) at a time when
secretions are only starting to appear in the gland lumena(Noyes et al, 1950) suggests
that they may have another purpose such as ovum or sperm transport.
Endometrial vasculature and menstruation
The endometrium is supplied by spiral arterioles arising from basal arteries in the
myometrium. These vessels regrow from the vascular stumps remaining in the
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stratum basalis following menstruation into markedly coiled end arterioles, each
supplying 4-7mm- of the endometrial surface (Markee, 1940). Vessels of the
myometrium and basal layer of the endometrium are little influenced by cyclical
hormone changes, but vessels of the functional layer do take part in the cyclical
endometrial changes.
The physiological changes that occur in the endometrium during menstruation were
first documented over 50 years ago, with work by Markee looking at endometrial
ocular explants (Markee, 1940) and histological studies by Bartelmez (Bartelmez,
1933). Other work has included histological studies by Christiaens of hysterectomy
specimens taken within 72 hours of the onset of menses (Christiaens et al, 1980),
scanning electron microscopy studies by Ludwig (Ludwig et al, 1990) and in vitro
models for the regulation of peri-implantational haemostasis and menstruation
described by Lockwood and Schatz (Lockwood and Schatz, 1996).
Decidual transformation of stromal cells begins in peri-arterial areas, before spreading
throughout the endoetrium (Noyes et al, 1950). Plasminogen activators (PAs) initiate
conversion of plasminogen to plasmin, which degrades extracellular matrix proteins as
well as fibrinogen. In a decidualisation model based on stromal cell monolayers
derived from decidualised endometrium, the decidualised stromal cells are associated
with reduced expression of urokinase PA, tissue type PA (Schatz et al, 1995) and the
extracellular matrix degrading matrix metalloproteinase (MMP-3) (Schatz et al, 1994),
and increased expression of plasminogen activator inhibitor (PA1-1) (Schatz et al,
1995) and tissue factor (TF), an initiator of coagulation (Lockwood etal, 1993). Thus
decidualised stromal cells are well placed to control bleeding from blastocyst invasion
by promoting a state of increased haemostasis and decreased fibrinolysis.
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Menstruation is preceded by regression of the endometrium. Withdrawal of steroids
from the decidualisation model resulted in reduced levels of TF and PAI-1, thus
promoting fibrinolysis and the degradation of extracellular matrix proteins by plasmin
and MMP-3, which is activated by plasmin (Lockwood et al, 1994; Lockwood et al,
1995). Degradation of the extracellular matrix leads to an increased coiling of the
uterine spiral arterioles. Immediately prior to the onset of menses, intense spiral
arteriole vasoconstriction occurs (Markee, 1940). When these vessels dilate,
menstrual bleeding occurs, with blood escaping from the ends of damaged arterioles
directly into the uterine cavity, or through the vessel walls to form endometrial
haematomata (Christiaens et al, 1980). Some bleeding also occurs from damaged
veins, and red cells may pass through the walls of vessels by diapedesis. Patchy loss
of endometrial tissue follows, with successive layers being lifted off as bleeding
continues. Haemostatic mechanisms in the endometrium are strikingly different to
vessels elsewhere in the body. Platelet activation and adhesion in endometrial vessels
is initially suppressed, but with increased blood extravasation, damaged vessel ends
are sealed by intravascular plugs of platelets and fibrin. A morphometric study of
hysterectomy specimens in the early menstrual phase of patients with proven
menorrhagia showed a positive correlation between menstrual blood loss and the
number of haemostatic plugs, the authors suggesting that these plugs are more fragile
and easily displaced in menorrhagic women than in controls (van Eijkeren et al, 1991).
By 20 hours after the onset of menses, when most of the endometrial shedding has
occurred, haemostasis is achieved by a further intense spiral arteriole vasoconstriction.
Tissue regeneration begins within 36 hours of the onset of menses, while some
endometrial shedding is still occurring, and arises from glands in the basal layer of the
endometrium (Ludwig et al, 1990). As well as changes in the endometrium, events
also occur in the uterine cavity, with coagulation and rapid anticoagulation of
menstrual blood as it passes through the uterine cavity (Sheppard et al, 1983; Rees et
al, 1985).
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The onset of menstruation
Stromal regression prior to menstruation is a consistent finding in many histological
studies of the normal menstrual cycle (Noyes etal, 1950; Johannisson et al, 1987; Li
et al, 1988) and has also been noted in an experimental mouse model (Finn and Pope,
1984). There is some debate about whether the trigger for menstruation is regression
of the decidualised stroma, with the resulting shear stresses leading to the release of
vasoactive substances, or whether spiral arteriole vasoconstriction is the primary
event, with stromal changes occurring secondary to altered blood flow. A variety of
vasoactive agents have been implicated in pre-menstrual vasoconstriction including
prostaglandin F2a (Abel and Baird, 1980) and the endothelins, which will be
discussed in more detail later in this chapter.
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The Effects of Synthetic Progestagens on the Endometrium
The effects of synthetic progestagens on the endometrium have been examined in a
number of studies, using a variety of different progestagens, administered by a variety
of methods, and with a variety of exposure times. These studies have been mainly
concerned with contraceptive regimens of progestagens and many focused on the
breakthrough bleeding associated with synthetic progestagen administration, since this
represents a common clinical problem which can limit the acceptability of the method.
The effects of systemic and local administration of synthetic progestagens on the
compartments of the endometrium are summarised below.
Systemic progestagen administration
Progestagens may be administered orally, via long-acting intramuscular injection or
more recently via delivery systems such as vaginal rings or subcutaneous implants.
Endometrial glands
Following administration of different types of oral progestagens for a minimum of two
months, endometrial glands showed a reduction in the number of mitoses and reduced
tortuosity (Ludwig, 1982). Pseudostratification was a common finding, but basal
vacuolation was reduced. Longer term use resulted in a scant endometrium with large
glands. Injection of depot medroxyprogesterone acetate resulted in a reduction in
gland cell height from the 20th day after injection (Roberts et al, 1975). Vaginal rings
releasing levonorgestrel produced a significant reduction in gland diameter after six
weeks of use and this effect was dose dependent (Johannisson etal, 1982). In a study
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using different doses of intramuscular progesterone as part of hormone replacement
therapy (HRT) in women with premature ovarian failure, low dose progesterone was
associated with an increase in glandular mitoses and in the volume fraction of gland
occupied by gland cells compared with a standard regimen, and increasing the dose of
progesterone did not change these parameters (Li et al, 1992).
Stroma
Synthetic gestagens had a marked effect on the stroma in a number of studies
(Landgren et al, 1979; Ludwig, 1982; Lietal, 1992). Stromal oedema increased in a
focal pattern and decidualisation was a common finding following oral administration
of a number of different progestagens (Ludwig, 1982). This was proportional to the
duration of progestagen use and leukocyte infiltration of the stroma was apparent. The
decidual reaction was shown to be proportional to the dose of progestagen in a study
using vaginal rings as the vehicle for norethisterone release (Landgren et al, 1979).
During a dose-finding HRT study, high dose intramuscular progesterone resulted in a
significant increase in stromal cell diameter on day 19 of the cycle, while producing no
changes in endometrial glandular morphology (Li et al, 1992).
Surface epithelium
Defective ciliagenesis was a common response to oral treatment and was observed in
all samples of endometrium following at least two months exposure to oral treatment
(Ludwig, 1982). A reduction in size and numbers of microvilli was apparent as soon
as 5 days after injection with depot medroxyprogesterone acetate (Roberts etal, 1975).
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Vasculature
Long term use of oral progestagens resulted in large venous vessels, often including
vessels in the superficial layer of the endometrium (Ludwig, 1982). This was
confirmed in the endometrium of women exposed to oral norethisterone or
medroxyprogesterone acetate for between eight days and six months when dilated
venules were observed in progestagen-exposed but not in control samples, and were
more often seen in specimens strongly suppressed by progestagen or those with
atrophic changes (Song et al, 1995). A decrease in microvascular density was
demonstrated using immunohistochemical staining for von Willebrand factor and
CD34 in progestagen-exposed biopsies. In contrast a detailed study of the endometrial
microvascular density following exposure to subcutaneous levonorgestrel for between
three and 12 months showed an increase in the endometrial microvascular density
compared with controls (Rogers et al, 1993). Subsequent work demonstrated both a
reduction in endometrial endothelial cell proliferation in endometrium exposed to
subcutaneous levonorgestrel (Goodger (MacPherson) et al, 1994) and a reduced
endothelial cell migratory response to endometrial explants from subcutaneous
levonorgestrel users compared with normal controls (Subakir, 1995). These results
suggest that the observed increase in microvascular density in endometrium exposed to
subcutaneous levonorgestrel may be due to a lower rate of regression in the vascular
compartment compared to the stromal and glandular compartments.
Intrauterine progestagen administration
Synthetic progestagens can be administered directly to the endometrium via a
hormone-impregnated intrauterine device. First developed for contraception (Pharriss
et al, 1974), such devices are now being used for therapeutic indications such as the
treatment of menorrhagia (Milsom et al, 1991), and have a potential role in the
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hormone replacement therapy and the treatment of endometrial hyperplasia. The first
report of the intrauterine administration of a progestagen in humans was by
Scommegna in 1970, who introduced a device releasing 30-40]J,g progesterone into
the uterine cavity of 13 women between 18 hours and seven days prior to
hysterectomy (Scommegna et al, 1970). The endometrium was found to have been
converted from a proliferative to a secretory pattern after as little as 18 hours exposure.
Over the next few days of exposure, Scommegna reported a discordance in maturation
of the endometrial glands and stroma, with the stroma being more advanced than the
glands. After 24 hours exposure decidualisation was noted, and by the fourth day of
exposure the glands began to undergo involutional change. It was noted that, with this
device, the functional layer was more affected than the basal layer.
In a dose-finding study using 4 different release rates of progesterone from 20-110jJ,g
/ 24 hours, biopsies were taken following two to ten months of exposure (Martinez-
Martinou et al, 1975). All biopsies showed evidence of variation in the normal
endometrial pattern, varying from a secretory appearance to a suppressed
endometrium, with the higher release rates tending to endometrial suppression.
Decidual reaction was common, particularly in the suppressed endometria. An
inflammatory infiltrate was noted in half of the biopsies. When a device releasing
65ptg progesterone in 24 hours (Progestasert®, AlzoCorp, Palo Alto, Ca., USA) was
studied, the response to the device was said to be decidual in nature, initially at its
most intense immediately adjacent to the delivery system (Pharris, 1977). Later it was
noted to spread out to the distal endometrium. Glands were described as small and
few, lined with cuboidal rather than columnar cells.
Scanning electron microscopy studies of the endometrium exposed to the
Progestasert® showed fewer shorter ciliated cells (Bonnar and Sheppard, 1979) and a
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reduction in the surface micro-villi (Gonzalez-Augulo et al, 1979). Erosion of the
surface epithelium, was noted below the inert arms of the device but to a lesser degree
than that found with inert or copper containing devices (Bonnar and Sheppard, 1979).
Studies of the vasculature following exposure to Progestasert® showed capillary
microthrombosis within the functional layer of endometrium adjacent to the inert arm
of the device (Sheppard and Bonnar, 1980). This is similar to that found with inert or
copper-containing intrauterine contraceptive devices, but was noted to be less with
progesterone releasing devices. Dilated venules were a common finding.
Studies using a more potent progestagen, D-norgestrel, showed a more profound and
uniform effect on the endometrium (Nilsson et al, 1978). Two groups of patients
were studied, those having an endometrial biopsy taken after a median of 96 days
exposure (range 74-118 days) and those undergoing hysterectomy after 29 to 36 days
exposure. The endometrial biopsies showed a pattern of scarce glands with a low
epithelium and no signs of mitotic activity, set within an oedematous decidualised
stroma. An inflammatory infiltration was noted. Hysterectomy specimens confirmed
that the changes affected all layers within the endometrium and that the whole of the
uterine cavity was affected, not just that endometrium in contact with the device,
suggesting that intrauterine D-norgestrel had a more uniform and profound effect on
the endometrium than intrauterine progesterone. Non-invasive studies of the effects of
intrauterine levonorgestrel on endometrial thickness and uterine blood flow using
transvaginal ultrasound and Doppler blood flow demonstrated a reduction in
endometrial thickness by ten weeks after insertion, but no alteration in uterine blood
flow (Pakarinen etal, 1995).
This section has reviewed the structural and functional changes occurring within the
endometrium during the normal menstrual cycle and in response to exogenous
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progestagen administration. The next section reviews the evidence supporting a role
for nitric oxide and the endothelins as mediators involved in paracrine and autocrine
interactions in the endometrium.
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Nitric Oxide and Nitric Oxide Synthase
Nitric oxide (NO), a noxious, free radical species, has long been recognised as an
atmospheric pollutant. Within the past decade however, understanding of the
biological roles of this simple molecule has mushroomed. Work investigating its
actions has been carried out in several different fields of biological research
simultaneously, such that NO was awarded the title "Molecule of the Year" by the
journal Science in 1992. In 1987 it was shown that mammalian vascular endothelial
cells could produce the molecule (Palmer et al, 1987). Since then, NO has been
shown to be an important messenger in a number of diverse mammalian systems.
Synthesis and Cellular Actions of Nitric Oxide
NO is produced from the precursor L-arginine, catalysed by the enzyme nitric oxide
synthase (NOS). This was demonstrated in studies showing that NO was released
from porcine endothelial cells in the presence of L-arginine and that the addition of
15N-labelled L-arginine produced 15NO (Palmer et al, 1988). Simultaneous work in
the field of immunology demonstrated that activated murine macrophages could
metabolise L-[guanido-15N2] labelled arginine to 15N02- and 15N03- (Stuehr and
Marietta, 1985) and that activated macrophages were able to inhibit tumour cells in the
presence of L-arginine but not D-arginine, with L-citrulline and nitrite (NO2-) being
produced as by-products (Hibbs etal, 1987).
Nitric oxide exerts its effects by the activation of soluble guanylate cyclase, leading to
an increase in the concentration of cyclic guanosine monophosphate (cGMP) in target
cells (Lowenstein and Snyder, 1992).
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Three classical areas of NO function have been described. These are concerned with
vascular effects, cell mediated immunity and neurotransmission in the brain and
peripheral nervous system. It is interesting to bear in mind that research in these three
fields was taking place simultaneously, with developments in one field opening up
lines of research in another.
Vascular functions
One of the first description of the molecule's effects was in the area of vascular
physiology. Earlier work had demonstrated that acetyl choline could produce
relaxation of blood vessels only in the presence of an intact endothelium, which
produced a diffusible substance known as endothelium derived relaxing factor (EDRF)
(Furchgott andZawadzki, 1980). Further studies suggested that NO and EDRF were
one and the same (Furchgott, 1988). This was confirmed with the observations that
both substances had the same physiological activity, the same short biological half life
(less than five seconds), and that both were inhibited by haemoglobin and enhanced by
superoxide dismutase to a similar degree (Palmer et al, 1987). In addition, both EDRF
and NO were shown to have similar effects on platelet function, inhibiting platelet
aggregation (Radomski et al, 1987a) and adhesion to the endothelium (Radomski et al,
1987b).
Cell mediated immunity
It has long been recognised that macrophages, activated by cytokines released from
sensitised lymphocytes, form the basis of cell mediated immunity and mount a non¬
specific response to bacteria, protozoa or tumour cells. The role of NO in cell
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mediated immunity was first proposed in 1987 (Hibbs et al, 1987). Since then, NO
mechanisms have been demonstrated in the cell mediated response to a number of
micro-organisms (Granger et al, 1986; Adams etal, 1990; Liewetal, 1990), with the
suggestion that the L-arginine / NO pathway may have originally evolved as a first line
defence against intracellular parasites or neoplastic cells.
Neurotransmission
A number of agents have been shown to play a part in neurotransmission in the central
nervous system, a common feature of many being an associated increase in cyclic
GMP levels. In 1977, it was reported that NO could stimulate guanylate cyclase in
homogenates of mouse cerebral cortex (Miki et al, 1977). Following the identification
of the L-arginine / NO pathway in vascular physiology, it was demonstrated that the
addition of L-arginine to rat synaptosomal cytoplasm in the presence of NADPH
resulted in the formation of NO and citrullineand was accompanied by the stimulation
of soluble guanylate cyclase (Knowles etal, 1989). This reaction was inhibited by L-
NMMA, suggesting that rat neural tissue contained NOS. Rat cerebellar cells were
also shown to produce an EDRF-like material which was associated with a rise in
cyclic GMP levels when N-methyl D aspartate (NMDA) receptors were stimulated
(Garthwaite et al, 1988). NO has also been shown to play a role in peripheral
neurotransmission via the non-adrenergic non-cholinergic (NANC) nerves, an
important component of the autonomic nervous system (Rand, 1992).
24
Nitric Oxide Synthase
NO is not stored in cells, but is synthesised on demand. Inactivation or reuptake
mechanisms have not yet been discovered and its biological activity is therefore
regulated by its production and by its rate of clearance. The production of NO is
catalysed by the enzyme nitric oxide synthase (NOS), which oxidises the guanidine
group of L-argininein the presence of NADPH. A number of cofactors are involved
in the reaction, which also requires the presence of calmodulin. The clearance of NO
is catalysed by the enzyme superoxide dismutase. The production of NO is







Figure 1.1. The production of NO.
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NO is a labile molecule and its direct measurement is difficult. Measuring the
conversion of L-arginine to L-citrulline is one method of inferring the production of
NO in tissues, while the oxygenation products of NO (nitrites and nitrates) can be
measured following reduction of nitric oxide with nitrate reductase using the Greiss
reaction. With the sequencing and purification of NOS enzymes, detection of NOS
mRNA and protein in tissues is now possible using a variety of techniques including
immunohistochemistry, Western blotting, Northern analysis, in situ hybridisation and
the reverse transcription-polymerase chain reaction (RT-PCR). Three different
isoforms of NOS have been characterised, first described in brain tissue, endothelial
cells and macrophages. They are characterised in part by their sensitivity to calcium.
Type I or neuralNOS
Rat neural NOS (nNOS) was the first form to be described. The enzyme was found to
be expressed at high levels in the brain, in particular the cerebellum, and was
dependent on calcium and calmodulin for its activity (Bredt and Snyder, 1990).
Type II or endothelialNOS
NOS from vascular endothelial cells (eNOS) was also constitutively expressed and
calcium/ calmodulin - dependent (Moncadaet al, 1991). Initially it was assumed that
the nNOs and eNOS were the same, but cloning of both bovine and human
constitutive NOS's has shown them to be two distinct gene products, sharing 57%
amino acid homology.
Type III or iNOS
NOS activity in rat macrophages was found to be different from the other two
isoforms. Under basal conditions enzyme activity was negligible, but with stimulation
by lipopolysaccharide and certain cytokines, production was massively enhanced
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within a few hours (Stuer and Marietta, 1987). This enhancement was independent of
the presence of calcium (Nathan and Hibbs, 1991).
The distinction between the three different isoforms is recognised now to be more
complex than was originally thought, with evidence of calcium-dependent inducible
enzymes (Palmer etal, 1992) and inducible constitutive forms (Salter etal, 1991).
The biological effects of the various isoforms of NOS were demonstrated with the
successful breeding of mice with the different isoforms of NOS inactivated through
gene knockout techniques. Null mutant nNOS (nNOS") mice were noted to have
dilated stomachs with constricted pyloric sphincters (Huang et al, 1993), and appeared
to be resistant to brain damage caused by vascular strokes (Huang et al, 1994). iNOS"
mice were noted to have reduced defences against intracellular pathogens such as
Listeria and Leishmania and were more susceptible to lymphoma; these mice were
more successful at resisting the hypotension associated with endotoxic shock and other
inflammatory stimuli (MacMicking et al, 1995). eNOS" mice exhibited systemic
hypertension confirming the importance of NO as a physiological vasodilator (Huang
etal, 1995).
27
Nitric Oxide and Nitric Oxide Synthase in the Uterus
A number of studies in both animal and human tissue have identified the involvement
of a nitric oxide-cGMP system in several areas of uterine physiology and are
summarised here. While animal studies offer a convenient method of studying NO
and NOS in the uterus, care should be taken when drawing comparisons between
species. Investigations into the role of NO in the uterus have concentrated on three
main areas concerned with myometrial contractility, vasodilatation and
neurotransmission.
Myometrial contractility
The effects of the molecule on smooth muscle led many workers to investigate the
possibility that NO is responsible for maintaining a quiescent uterus during pregnancy.
This theory was supported by anecdotal reports of the use of NO donors to induce
uterine relaxation for procedures such as manual removal of placenta (Peng et al,
1989) or to correct uterine inversion (Bayhi et al, 1992) and by an observational study
which suggested that glyceryl trinitrate arrested preterm labour (Lees et al, 1994).
L-arginine, NO and sodium nitroprusside (a NO donor) were shown to inhibit the
inherent contractility of rat uterine muscle strips taken during pregnancy, delivery and
post partum (Yallampalli et al, 1993). L-NAME, an inhibitor of NOS, increased
contractility while methylene blue, an inhibitor of soluble guanylate cyclase, and L-
N°-nitro-arginine, a specific blocker of NOS, prevented the relaxation effects of L-
arginine. Measurement of uterine nitrates and nitrites showed that levels were
significantly higher preterm than at term and the inhibitory effects of L-arginine were
reduced in tissues of animals at term compared with earlier in pregnancy, suggesting
that NO-induced relaxation declines towards delivery and that a NO system maintains
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uterine quiescence during pregnancy but not during delivery (Yallampalli et al, 1993).
This theory was supported by rabbit studies (Sladek et al, 1993), when it was
demonstrated that NOS activity, as measured by an L-arginine conversion assay and
by the Greiss reaction, in uterine homogenates was higher in the decidual fraction than
the myometrial fraction, and decidual NOS activity was highest on day 27, declining to
one fifth of this value by term. NOS activity was not calcium-calmodulin dependent,
the authors suggesting a role for iNOS in producing an endogenous uterine relaxant
(NO) which decreases towards term. Guinea pig studies showed that myometrial
cGMP increased abruptly half way through pregnancy to 200 times the non-pregnant
value, declining sharply again towards the end of pregnancy (Weiner et al, 1994).
However when measurements were made of both calcium-dependent and calcium-
independent NOS activity during pregnancy (using an L-arginine conversion assay),
although they found a decline in myometrial NOS activity with advancing gestation,
there was no difference in NOS activity when compared to non-pregnant animals. The
authors proposed that, in the guinea pig, the mechanism for increasing myometrial
cGMP was independent of NOS.
The effects of exogenous steroids on uterine NO production were examined when full
thickness uterine tissue from prepubertal rats treated with exogenous oestradiol or
oestradiol and progesterone showed a significant reduction in nitrite and nitrate
production, as measured by the Greiss reaction, when compared with control and
progesterone-treated rats (Yallampalli et al, 1994). The authors suggested a steroid
hormone influence on the production of NO in the rat uterus. By contrast, a study in
the sheep found that administration of oestradiol increased NOS activity in the
myometrium, as measured by the L-arginine conversion assay, and that this increased
NOS activity was calcium dependent (Figueroa and Massmann, 1995). There was no
such increase in NOS activity in the endometrium.
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The role of a nitric oxide-cGMP system in the human pregnant and non-pregnant
uterus was demonstrated when it was shown that cGMP was generated in myometrial
strips in the presence of L-arginine or diethylamine/ nitric oxide (a donor of NO), but
not L-NAME (Buhimschi et al, 1995). cGMP levels in the myometrium were reduced
in samples taken during labour. Inhibitors of NOS increased the contractility of
pregnant and non-pregnant uterine muscle strips while diethylamine/nitric oxide
inhibited uterine contractility, particularly during pregnancy when compared with non¬
pregnant and labouring strips (Izumi et al, 1993). Contractility studies of myometrial
muscle strips obtained at the time of Caesarean section demonstrated irregular
spontaneous contractility which was abolished by L-arginine (Izumi et al, 1993).
These studies (Izumi et al, 1993; Buhimschi et al, 1995) confirmed the earlier animal
studies suggesting that NO may be involved in maintaining uterine quiescence during
pregnancy and support the observational study which suggested that glyceryl trinitrate
patches arrested preterm labour on 20 occasions in 13 women (Lees et al, 1994).
However, evidence against the hypothesis that NO may be an endogenous modulator
of myometrial tone was presented in a study of 61 patients undergoing elective
Caesarean section (Jones and Poston, 1997). Strips of term or pre-term myometrial
tissue showed no change in spontaneous contractility when L-arginine, L-NAME or
D-MANE was added to the tissue bath. In vivo studies of intrauterine pressure
recordings carried out in patients undergoing mid-trimester termination of pregnancy
showed no reduction in intrauterine pressure following systemic administration of
glyceryl trinitrate, a donor of nitric oxide (Norman et al, 1995). The role of NO in
myometrial contractility has yet to be elucidated and so far NO has not been




The in vivo effects of NO on uterine blood flow were examined when measurements
of uterine artery blood flow in non-pregnant sheep were recorded in response to
oestradiol 17(3, a known vasodilator (Van Buren et al, 1992). Subsequent injection of
L-NAME produced significant dose-dependent decreases in uterine blood flow, the
authors postulating that L-NAME specifically antagonises the vasodilator effects of
oestradiol 17(3 on the uterine vasculature.
The vasodilator effects of NO on human uterine artery blood flow have been examined
in vitro studies. A direct effect of endothelial NO formation on human uterine artery
relaxation was proposed when it was shown that acetyl choline induced an
endothelium-dependent relaxation which was abolished by methylene blue and L-
NMMA and reinstated by L-arginine (Jovanovic et al, 1994a). L-arginine was also
shown to have a direct relaxant effect on uterine artery rings with or without
endothelium, the effect being suppressed by methylene blue and L-NMMA. Addition
of a calmodulin inhibitor (known to inhibit constitutive NOS) did not affect the
relaxant effects of l-arginine, suggesting that constitutive NOS was not involved
(Jovanovic et al, 1994b), while addition of dexamethasone (known to suppress
inducible NOS activity) significantly suppressed the relaxation effects of L-arginine.
The authors suggested a role for iNOS in the L-arginine-evolved relaxation of the
artery. A study using pre-constricted strips of human uterine artery demonstrated a
relaxation response when the strips were treated with nicotine (Toda et al, 1994);
removal of the endothelium did not influence the response. NOS inhibitors abolished
the response, but L-arginine reversed this. Histochemical studies using NOS
antiserum demonstrated the presence of immunoreactive fibres in the adventitia, with
the authors suggesting that human uterine arteries are innervated by vasodilator nerves
which use NO as a neurotransmitter (Toda etal, 1994).
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NO may also play a role in foeto-placental blood flow, with NO donors having been
shown to relax pre-constricted human placental cotyledons (Myatt et al, 1991).
Further studies proved that inhibition of NOS in isolated human placental cotyledons
produced increases in perfusion pressure, the authors suggesting that formation of NO
contributed to the maintenance of resting vascular tone (Myatt et al, 1992b). NO
concentrations, as measured by the Greiss reaction, have been shown to be increased
in the foeto-placental circulations of pregnancies complicated by pre-eclampsia (Lyall
et al, 1995) and intrauterine growth retardation (Lyall et al, 1996), possibly as a
compensatory response to improve placental blood flow.
Neural effects
NO's production in uterine nerves was suggested with the finding of NADPH
diaphorase-positive nerves in the uterus of rats treated with diethylstilbestrol (Shew et
al, 1993). NADPH diaphorase is a histochemical stain which reduces a dye in the
presence of NADPH but not NAD and neurones staining with NADPH diaphorase
have been demonstrated to co-localise with NOS in brain and peripheral tissues
(Dawson et al, 1991). Nerve fibres staining positive for NADPH diaphorase were
located in rat myometrium, endometrium and adjacent to vasculature, with the authors
suggesting that these nerves are capable of NO synthesis and may thus affect
myometrial activity (Shew et al, 1993). Further immunohistochemical studies in the
rat using a nNOS antibody and a method of retrograde axonal tracing demonstrated
than nNOS positive nerves in the uterus can be parasympathetic, originating from the
paracervical ganglia, or sensory, originating from thoracic, lumbar and sacral dorsal
root ganglia (Papka et al, 1995).
Studies in the human uterus using NADPH diaphorase showed positive axon staining
in some, but not all, nerves in the paracervical ganglia, as well as postganglionic
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nerves in the myometrium, walls of blood vessels in the parametrium and
myometrium, in some cells of endometrial endothelium and the endothelial cells of
spiral arterioles (Yoshida et al, 1995). The authors suggested that NO released from
the postganglionic nerves may contribute to regulation of uterine vascular resistance by
release of NO from nerve endings.
Nitric Oxide and Nitric Oxide Synthase in the Endometrium
NOS has been identified in human endometrium using NADPH diaphorase (Yoshida
et al, 1995). Subsequent cloning and purification of NOS, and the production of
isoform-specific antisera, have enabled further studies to examine the distribution of
NOS in endometrium using these more specific markers. Uterine tissue from ten
women undergoing hysterectomy for benign disease was demonstrated to contain
mRNA for NOS in endometrial glandular epithelium, stroma and myometrium across
the cycle (Telfer et al, 1995). NOS-like immunoreactivity, using a monoclonal
antibody raised against bovine endothelial NOS, localised to endometrial stroma and
blood vessels, with weak staining in glandular epithelium and none in myometrium;
this contrasted with NADPH diaphorase activity which was identified in glandular
epithelium throughout the cycle, stroma in late proliferative and early secretory
samples and in myometrial blood vessels. Subsequent work in 34 hysterectomy
specimens using a monoclonal antibody raised against human eNOS and a polyclonal
antibody raised against murine iNOS has demonstrated eNOS immunoreactivity to be
detected in vascular endothelium and in endometrial glandular cells, with iNOS
immunoreactivity localising to glandular epithelial cells (Telfer etal, 1997). Using this
antibody there was no stromal staining. There was a variation in the intensity of
glandular staining which did not relate to the stage of the cycle. Reverse transcription
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polymerase chain reaction confirmed the presence of mRNA for both eNOS and iNOS
in gland preparations from proliferative and secretory endometrium.
A study including 26 hysterectomy specimens and three specimens of decidual tissue
from early pregnancy examined NADPH diaphorase activity and eNOS and iNOS
mRNA content of endometrial glands and stroma across the cycle by Northern blot
analysis (Tseng et al, 1996). NADPH staining was localised to endometrial glands,
with faint staining in proliferative endometrium but intense staining in late secretory
endometrium, suggesting enhanced NOS activity later in the cycle. There was positive
staining in endometrial blood vessels. eNOS mRNA was detected in endometrial
glands and decidua, with enhanced expression in early and late secretory samples;
incubation of glandular cells with relaxin doubled eNOS expression, while incubation
with progesterone had no effect. In contrast, iNOS mRNA was detected only in
glands from a menstrual endometrium; negative CD45 staining excluded blood
contamination and incubation of stromal cells with relaxin or progesterone did not
enhance expression. The authors suggested that oestrogen induces eNOS but not
iNOS and that release of NO may regulate the onset of menses (Tseng et al, 1996).
These studies (Telferet al, 1995; Tseng et al, 1996; Telferetal, 1997) suggest that
NOS is expressed in the different compartments of the endometrium, although the
effects of cyclical endogenous steroids is unclear. All studies show the localisation of
NOS to endometrial blood vessels. Both iNOS and eNOS protein and mRNA are
expressed in endometrial glands, with one study showing no variation across the cycle
and another showing enhanced expression of eNOS and iNOS mRNA in the late
secretory and menstrual phases respectively. The reason for this discrepancy is
unclear. Stromal expression of eNOS and iNOS mRNA was absent in two studies
(Tseng etal, 1996; Telferetal, 1997), although the smaller study did suggest stromal
expression of NOS mRNA across the cycle (Telfer et al, 1995). Decidualised stroma
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expressed eNOS but not iNOS mRNA, although the number of samples was small
(Tseng etal, 1996).
Using NADPH diaphorase as a marker for NOS activity, mouse endometrium was
examined in early pregnancy and in an artificially induced decidualised endometrium
(Moorhead et al, 1995). Positive staining was noted in cells with a distribution
identical to macrophages in non pregnant and early pregnancy tissues. As pregnancy
progressed, NADPH diaphorase activity increased, paralleling the pattern of
decidualization. Positive staining was also present in artificially induced decidual
cells. The authors postulated that the function of decidual NO may be to assist
endothelial cells in maintenance of vascular smooth muscle relaxation and to inhibit
platelet aggregation, thus facilitating blood flow through the placenta (Moorhead et al,
1995).
A number of potential roles for NO in the endometrium may be proposed. NO may
play a part in the establishment of early pregnancy. As the developing blastocyst
embeds in the endometrium, cells of the syncytiotrophoblast erode the endothelial
lining of superficial endometrial blood vessels which have undergone vasodilatation.
Maternal blood enters lacunar spaces in the syncytiotrophoblast to establish the
uteroplacental circulation and inhibition of platelet activation and adhesion may assist
this process. NO's actions as a vasodilator and inhibitor of platelet aggregation may
also be important in menstruation, since the initial events in the process include spiral
arteriole vasodilatation following a period of vasoconstriction and exposure of
subendothelial collagen without the normal platelet adhesion seen in the general
circulation (Christiaens et al, 1980).
The precise role of nitric oxide and nitric oxide synthase in the endometrium during the
menstrual cycle and in early pregnancy is unclear. The involvement of NO in the
35
endometrium of patients with menorrhagia has not been addressed. Exogenous
steroids have been demonstrated to have an effect on NO production (Yallampaii et al,
1994; Figueroa and Massmann, 1995) in animal studies. The effects of high dose
exogenous steroids on the expression of endometrial NOS are examined further in
chapter five.
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Endothelins and their Receptors
The endothelins (ETs) comprise a family of 21 amino acid peptides, first isolated from
the supernatant of porcine endothelial cells. In 1988, Yanagisawa et al demonstrated
that this supernatant caused an endothelium-independent slow-onset contraction of
isolated porcine coronary artery (Yanagisawa et al, 1988). The vasoconstrictor,
known as endothelin, was purified and identified as a 21 amino acid peptide with free
amino- and carboxy-termini. Dose-response experiments revealed endothelin to
produce a vasoconstrictor response greater than angiotensin 11, vasopressin or
neuropeptide Y, and in vivo studies in anaesthetised rats showed that the
vasoconstrictor response was sustained for 40-60 minutes. This endothelin is now
known as endothelin-1 or ET-1.
Unusually, the gene for endothelin was cloned and sequenced before the peptide had
been fully pharmacologically characterised and analysis of the human genomic DNA
predicted two further 21 amino acid isoforms, ET-2 and ET-3 (Inoue et al, 1989). In
humans, the gene for ET-1 is located on chromosome 6, for ET-2 on chromosome 1
and for ET-3 on chromosome 20.
Synthesis
All endothelins are produced from biologically inactive intermediates. ET-1 is
synthesised as a 203 amino acid peptide, pre-proendothelin. Proteolytic cleavage
results in the 38 amino acid intermediate, proendothelin-1 (proET-1), and a further
proteolytic cleavage mediated by an endothelin converting enzyme (ECE), results in
ET-1 (Yanagisawa et al, 1988). Two ECEs have been identified (Xu et al, 1994;
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Emoto and Yanagisawa 1995). ET-2 synthesis is thought to occur through synthesis
of pre-proET-2 and ET-3 via pre-proET-3. Dense secretory granules are difficult to
detect in endothelial cells using transmission electron microscopy, suggesting that
endothelins are not stored but are produced on demand by de novo synthesis
(Cameron and Davenport, 1992).
The basic structure of the endothelin molecules is shown in figure 1.2 and bears a
strong similarity to the sarafotoxins, a group of peptide toxins from the venom of the
burrowing asp Attractaspis engaddensis, which cause severe coronary vasospasm in
snake-bite victims (Kloog and Sokolovsky, 1989).
Endothelin-1
ET-1 has a molecular weight of 2492 Daltons and its 21 amino acids are linked by two
disulphide bridges joining amino acids 1 and 15, and 3 and 11. ET-1 has
vasoconstrictor effects in almost all animal species. These effects are mediated by an
increase in cytosolic calcium, although ET-1 does not appear to act exclusively on
calcium channels (Yangisawaetal, 1989). ET-1 has also been demonstrated to release
eicosanoids and endothelium derived relaxing factor (nitric oxide) from perfused
vascular beds (de Nucci etal, 1988).
In addition to vasoconstrictor and vasopressor properties, a number of non-vascular
pharmacological effects have also been identified. ET-1 has been demonstrated to
exert a powerful contractile effect on isolated human myometrium taken from the non¬
pregnant and term pregnant uterus (Word et al, 1992; Wolff et al, 1993) and
potentiates the in vitro contractile response of pregnant, but not non-pregnant,
myometrial strips to oxytocin (Valenzuelaet al, 1995). ET-1 exerts a constrictor effect
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Human Endothelin - 1
Human Endothelin - 2
Human Endothelin - 3
Figure 1.2. The amino acid structures of the mature endothelin isoforms, ET -1, ET -
2 and ET -3. The dark circles indicate differences in amino acid structure of ET -2 and
ET -3 compared with ET -1.
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on smooth muscle in airway and intestine (de Nucci et al, 1988), and has mitogenic
and neuroendocrine properties (Haynes and Webb, 1993).
Endothelin-2
ET-2 has a molecularweight of 2548 Daltons and differs from ET-1 in only two amino
acids at positions 6 and 7. In contrast to the body of work on ET-1, there is very little
known about the actions of ET-2, however it has been demonstrated to have a more
powerful vasoconstrictor action than either ET-1 or ET-3 (Inoue et al, 1989).
Endothelin-3
ET-3 has a molecularweight of 2644 Daltons and differs from ET-1 in positions 2, 4,
5, 6, 7 and 14. ET-3-likeimmunoreactivity was initially demonstrated in porcine brain
homogenate, suggesting that ET-3 may function as a neuropeptide (Shinmi et al,
1989.). As well as its actions on vascular smooth muscle, it exhibits fibrinolytic
activity (Korbut 1989) and acts as an anti-aggregatory peptide (Lidbury et al, 1989).
Endothelin Receptors
The identification of the three different isoforms of endothelin led to comparative
studies of their efficacy. In vivo studies suggested that, while ET-3 may have only
25-50% of the vasoconstrictor activity of ET-1, it produced a significantly more
pronounced transient pressor response than ET-1 (Inoue et al, 1989). This was
thought to be due to the different receptors involved, a receptor with a high affinity for
ET-1 being responsible for the vasoconstrictor effects and a receptor with a high
affinity for ET-3 leading to a transient vasodilatation. Cloning of cDNA for the two
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receptor subtypes demonstrated a receptor with a higher affinity for ET-1 than ET-3
localised to vascular smooth muscle and designated ETA (Arai et al, 1990), and a
receptor with an equal specificity for all 3 subtypes which localised to endothelial cells
and designated ETb (Sakurai etal, 1990).
Molecular biology studies in rat aortic smooth muscle demonstrated mRNA encoding
ETa but not ETg receptors, and predicted that ETa receptors were expressed in
vascular smooth muscle (Sakurai et al, 1992). The ETA receptor antagonist BQ123
causes a parallel shift to the right of ET-1 induced vasoconstriction in human blood
vessels, suggesting that the vasoconstriction response in humans is mediated
predominantly via ETA receptors (Davenport et al, 1993; Maguire and Davenport,
1993). By contrast, RT-PCR in cultured endothelial cells detected mRNA for ETg but
not ETa (Molenaar et al, 1993), suggesting that ET binding to ETg receptors was
responsible for the initial transient vasodilatation seen on infusion on ET-1 into
animals and humans, possibly via the release of endothelium-derived relaxing factors
such as prostacyclin and nitric oxide. This was confirmed in studies of isolated human
vessels which show no vasoconstrictor response to infusion of selective antagonists
for the ETg receptor (Davenport et al, 1993; Maguire and Davenport, 1993).
ET receptor subtypes have also been examined in human myometrium. Subtype
selective ligands identified ETA as the predominant receptor in the non-pregnant
myometrium with a smaller population of ETg receptors, and tissue bath experiments
demonstrated that ETA and not ETg mediated myometrial contractility (Bacon et al,
1995; Heluy et al, 1995). Expression of mRNA for ETA was increased in the
myometrium of pregnant compared with non-pregnant women, and this study also
suggested that ETg had a role in producing relaxation of the lower uterine segment
during pregnancy (Wolff et al, 1996).
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Inactivation
Endothelin is inactivated by the enzyme neutral endopeptidase, a membrane-bound
zinc-containing enzyme which degrades several bioactive peptides (Sokolovsky et al,
1990; Vijataraghavan et al, 1990). The enzyme has a widespread distribution in the
body (Roques et al, 1993), including the uterus where it has been shown to localise
predominantly to endometrial stromal cells (Casey et al, 1991). Enzyme activity
correlates with progesterone concentration, increasing early in the luteal phase of the
cycle and falling during the pre-menstrual phase (Casey et al, 1991; Headetal, 1993).
The net biological action of ET in a particular cell type probably depends on the
balance between peptide synthesis, interaction with receptors and degradation. The
metabolism of ET and ET receptors in the endometrium is considered in more detail
below.
Endothelins in the Endometrium
Animal studies
Initial work in rabbits provided evidence of ET expression in the endometrium. ET-
like immunoreactivity (ET-1R) was demonstrated in endometrial, but not myometrial
cells and the addition of oxytocin and vasopressin increased ET-IR from the
endometrial cells, the authors speculating that oxytocin and vasopressin were able to
potentiate their actions on the myometrium by production of endometrial ET (Orlando
et al, 1990). Subsequent studies localised ET-IR to the endometrial surface epithelium
in immature rabbit endometrium (Maggi etal, 1991). The addition of oestradiol, with
or without progesterone, resulted in decreased staining in the epithelium and increased
staining in the endometrial stromal cells suggesting that ET-IR is under ovarian steroid
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control. Binding studies performed on the myometrium of oestrogen-treated rabbits
using labelled ET-1 and ET-3 indicated two populations of binding sites present in the
myometrium, one selectively binding ET-1 (ETA receptors), the other showing an
equal affinity for ET-1 and ET-3 (ETB receptors) (Maggi et al, 1991). These studies
suggest that rabbit endometrium not only produces ET-1 but also contains receptors
for ET-1, the distribution of which might be under ovarian steroid control. In addition
endometrial ET acts on the myometrium in a paracrine fashion through two different
ET receptor subtypes to produce myometrial contractility.
A study in the rat uterus using an antiserum to ET-1 demonstrated binding in the
endometrial glandular cells, but none in the stromal cells or in the myometrium
(Kajihara et al, 1996). In pregnant, and particularly in post partum tissue, staining
was observed in glandular cells and in the myometrium. In situ hybridisation
confirmed the presence of prepro ET-1 mRNA in the cytoplasm of postpartum
glandular and myometrial cells and Northern blot analysis of myometrial tissue
demonstrated the presence of a hybridisation band corresponding to prepro-ET-1 in
pregnant but not non-pregnant tissue. The authors proposed both a paracrine and an
autocrine role for ET-1 in causing myometrial contractions.
Human studies: differentialdistribution ofET binding sites
The first study to identify a role for endothelin in the human uterus was published by
Davenport et al in 1991. The authors used quantitative in-vitro receptor
autoradiography to localise and compare the anatomical distribution of binding sites for
iodinatedendothelins(ET-l, ET-2 and ET-3) (Davenport et al, 1991). No difference
in binding between the three isoforms was identified. There was a significantly higher
density of binding sites in the endometrium compared to myometrium. Within the
endometrium, the greatest density of binding was to epithelial glandular cells and
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blood vessels, with the greatest density at the endometrial-myometrial junction. There
was no significant stromal binding. Because of the small number of tissue samples,
changes across the cycle were not examined. It was suggested from this distribution
that ET could play a role in the haemostatic control of menstruation as well as in
endometrial regeneration. Subsequent immunocytochemical studies (Cameron et al,
1992), using antibodies to the carboxy-terminal heptapeptide of ET-1 which cross-
reacts with all three isoforms, supported the autoradiography findings showing ET-IR
to be localised to the vascular endothelium in both endometrium and myometrium and
to endometrial glandular epithelium. The greatest intensity of staining was at the
endometrial-myometrial junction.
Changes in the distribution of ET binding sites across the cycle.
Cameron et al also examined changes occurring across the cycle (Cameron et al,
1992). In the eight hysterectomy specimens studied there was some variation in the
pattern of ET-IR staining according to the time of the cycle. All glands stained positive
in secretory phase tissue but a more heterogeneous pattern of glandular staining was
apparent in proliferative endometrium. This suggested that the distribution of ET
receptors in human endometrium is under ovarian steroid control. Stromal staining
was detected in the basal layer in only one specimen from day seven.
Variation in ET-IR across the cycle was assessed in a larger study using tissue
obtained by curettage from 41 women and a polyclonal antibody raised against ET-1
with cross-reactivity against both ET-2 and ET-3 (Salamonsen et al, 1992). In
contrast to the other studies (Davenport et al, 1991; Cameron et al, 1992), alow level
of stromal staining was noted across the cycle in all specimens. In the proliferative
phase of the cycle there was little staining in luminal epithelium and no staining in
glandular epithelium, but in secretory phase specimens, staining was strong for both
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luminal and glandular epithelium. Because of the nature of the specimens, it was not
possible to comment on distribution of ET-IR within the layers of the endometrium.
A more recent study examined endometrial biopsies of 59 normally cycling women
taken as controls for patients receiving high doses of exogenous steroids, and used the
same antibody to ET-1 on paraffin-wax embedded sections of tissue (Marsh et al,
1995). This study showed a low level of stromal staining across the cycle, with a
cyclical variation of ET-IR in luminal and glandular epithelium. Maximal staining
occurred during the mid-to late secretory phase and this was followed by a decline in
glandular staining during the menstrual phase. The results of these studies suggest
that endometrial epithelial ET binding is under the influence of endogenous ovarian
steroids, increasing in the secretory phase of the cycle at a time when the endometrium
is preparing for implantation or menstruation. This study also examined the
distribution of ET-IR in the endometrium of patients with menorrhagia (measured
menstrual blood loss > 80ml) and showed a different ET-IR to that of the normal
menstrual cycle. ET-IR was less intense in glandular and luminal epithelium than that
observed at the same stage of the normal cycle, and less intense than stromal
immunostaining, which was of similar intensity to the normal menstrual cycle (Marsh
etal, 1996).
Synthesis of endometrial endothelin
The synthesis of ET in the endometrium was studied using RT-PCR on endometrium
obtained from hysterectomy specimens (O'Reilly et al, 1992). Messenger RNA for
ET-1, ET-2andET-3 was demonstrated in all specimens with no variation across the
cycle. Northern blot analysis of mRNA for pre-proET across the cycle in 21
hysterectomy specimens demonstrated that the highest levels were found in tissues
obtained during the pre-menstrual (defined as day 26-28) and menstrual (day 1-5)
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phases (Economos etal, 1992). This was thought to originate from both endometrial
glands and stroma since purified preparations of both cell types secreted
immunoreactive ET into the culture medium. The study also demonstrated that
treatment of stromal cell preparations with TGF|3 or IL-la increased levels of prepro-
ET-1 mRNA. Northern blot analysis of pre-proET in a preparation of endometrial
tissue demonstrated that levels were higher in the menstrual and proliferative phases
than in the ovulatory and secretory phases, and ET-IR was detected in a stromal cell
preparation (Kubota et al, 1995). Immunocytochemistry using a polyclonal antibody
raised against ET-1 and big ET-1 in 33 hysterectomy specimens demonstrated an
increase in expression of both these antibodies in the pre-menstrual and menstrual
phases (Ohbuchi et al, 1995).
These studies (Economos et al, 1992; Kubota et al, 1995; Ohbuchi et al, 1995)
suggest that synthesis of ET is under endogenous ovarian steroid control. Maximal
synthetic activity was consistently noted during menstruation in all the studies. There
was some variation in activity immediately before and after the menstrual phase
between studies, but in general it was increased during the peri-menstrual period
compared with at other times of the cycle.
Endothelin receptor subtypes
Endometrial synthesis of endothelin is one method of exerting control on its actions.
Another control mechanism may operate via the different subtypes of endothelin
receptors. RT-PCR was used to identify endothelin receptor subtypes in the
endometrium across the cycle (O'Reilly etal, 1992). In menstrual endometrium, ETB
receptor mRNA was increased relative to ETA receptor mRNA. In the proliferative
phase, the level of ETA receptor mRNA was much greater than that of ETB receptor
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mRNA, with no detectable ETB receptor mRNA in the mid proliferative and early
secretory phases. By the mid- to late secretory phases, an increase in ETB receptor
mRNA was observed. These findings were confirmed using Northern blot analysis
when mRNA for both ET receptors was detected in endometrial tissue, with a higher
level of ETA receptor mRNA in the proliferative phase of the cycle compared to the
secretory phase (Kubota et al, 1995). ETg receptor mRNA expression increased in the
menstrual phase.
More recently, quantitative autoradiography has demonstrated the presence of ETA and
ETg receptors in both endometrium and myometrium across the cycle, and also
allowed for localisation of ET receptor subtypes within the endometrium (Collett et al,
1996). Both ETa and ETg receptors were detected in the myometrium with no
demonstrable change in the distribution of receptors in myometrium across the cycle.
ETa receptors were expressed in stroma throughout the endometrium and showed an
increase in density within proliferative endometrium compared with secretory and
menstrual endometrium. Endometrial ETg receptors were expressed at low density in
the proliferative phase with an increased expression in the glands of the basal, but not
the functional, endometrium in the secretory phase. The highest density of ETg
receptors was seen in menstrual phase endometrium where they were present in
stromal as well as epithelial cells.
In summary, the results of these studies (O'Reilly et al, 1992; Kubota et al, 1995;
Collett etal, 1996) are consistent in the distribution of ET receptors across the cycle.
ETg has been demonstrated to be the receptor which predominates in the menstrual
phase of the cycle, with ETA showing a widespread distribution during the
proliferative phase. A number of potential roles for endometrial ET in the menstrual
and proliferative phases of the cycle may be proposed. ET may exert a mitogenic
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effect as part of the endometrial repair process (Kubotaetal, 1995; Collettetal, 1996).
Endometrial ET may also have an effect on endometrial vasculature producing direct
vasoconstriction (Yanagisawa, 1988) or vasodilatation, via release of other vasoactive
substances such as prostacyclin or nitric oxide (de Nucci et al, 1988). ET may also be
involved in the fibrinolytic activity seen in the uterine cavity during menstruation
(Korbut et al, 1989), and in the anti-platelet aggregation seen in endometrial blood
vessels at the onset of menses (Lidbury et al, 1989).
Endothelin and endothelin receptors in decidua
A body of work exists to suggest the involvement of endothelin in human pregnancy.
ET-IR has been demonstrated in amniotic fluid in a number of studies. Most studies
suggest that levels of ET-IR are increased at term compared with mid-trimester,
although there appears to be no further increase with the onset of labour (Nisell et al,
1990; Rabonietal, 1991). Increased ET-IR levels have been shown in the amniotic
fluid of women in pre-term labour associated with intra-amniotic infection (Romero et
al, 1992).
Endothelin-like immunoreactivity has been demonstrated in vessels of the umbilical
cord, with an increase in the level of ET-IR with the onset of breathing following
delivery suggesting a role in closure of the umbilical vessels (Nisell et al, 1990;
Salamonsen et al, 1992). Increased levels of ET-IR have been demonstrated with
intrauterine growth retardation associated with abnormal umbilical artery flow and pre-
eclampsia(Ihara et al, 1991; McQueen et al, 1993). All three isoforms of endothelin
have been shown to produce vasoconstriction of the foeto-placental circulation (Myatt
et al, 1992a). Differential localisation of ETA and ETB receptors has been
demonstrated in normal third trimester placentae as well as placentae from pregnancies
complicated by pre-eclampsia and intrauterine growth retardation (Rutherford et al,
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1993; Kohnen et al, 1997), suggesting a role for endothelin in the modulation of
placental blood flow. ETA receptor expression was predominantly localised to smooth
muscle cells in the proximal regions of the villous tree, with ETB receptor abundant in
the periphery and decidua. No differences in the distribution of ET receptors were
noted between placentae from normal pregnancies and placentae from pregnancies
complicated by pre-eclampsia (Rutherford et al, 1993) or intrauterine growth
retardation (Kohnen et al, 1997).
While much of the work summarised above has concentrated on the role of endothelin
from the mid-trimester onwards, little work has been carried out investigating the role
of endometrial endothelin and endothelin receptors in early pregnancy.
One study examined the synthesis and release of endothelin by human decidual cells
by reverse-phase high-pressure liquid chromatography (HPLC) and Northern blot
analysis in cultured pregnant decidual tissue from 6-8 weeks gestation (Kubota et al,
1992). ET-IR was detected in the medium of the cultured decidual cells. Reverse-
phase HPLC showed that the major component of the ET-IR corresponded to ET-1.
Northern blot analysis using human pre-proET-1 as a probe showed the presence of
pre-proET-1 in decidual cells. This study also examined the likely ET receptor
subtype in decidual cells by competitive binding studies and showed the presence of
binding sites with a high affinity for ET-1 and ET-2, the authors suggesting a
predominance of ETA receptors on human decidual cells.
The effects of decidualisationhave also been examined in studies where high levels of
exogenous steroids have been given to induce decidual change in the stroma (Kubota
etal, 1995; Marsh etal, 1995). Treatment with 0.5mg norgestrel and 0.05mg ethinyl
oestradiol was administered to three women who were to undergo hysterectomy
(Kubota et al, 1995). Northern blot analysis demonstrated an increased expression of
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pre-proET mRNA in post-treatment specimens compared to proliferative and secretory
phases of the cycle, and expression of mRNA for both ETA and ETB was observed in
the decidualised endometrium. The localisation of endometrial ET-IR following
treatment with high dose progestagens was examined in a study of 107 endometrial
biopsies from women receiving subcutaneous levonorgestrel (Norplant®) for between
three and 12 months (Marsh et al, 1995). ET-IR was assessed using a polyclonal
antibody which cross-reacts with all three ET isoforms. Strongest staining was
observed in the stroma, with a low intensity of staining in both glands and luminal
epithelium.
These studies (Kubota et al, 1992; Kubota et al, 1995; Marsh et al, 1995) suggest
that decidualisation of endometrial stroma is associated with an increase in ET binding,
and decidualised stromal cells have been demonstrated to express both ETA and ETB
receptors (Kubota et al, 1995). A number of potential roles for endothelin in early
pregnancy may be proposed. Endothelin has a potential role in regulating uterine
blood flow. In vitro contractility studies of human uterine arteries and veins
demonstrated that endothelin gave a slow and long-lasting contraction at concentrations
where conventional vasoconstrictors such as noradrenaline had almost no effect (Fried
and Samuelson, 1991) and endothelin may also induce vasodilatation via the release of
nitric oxide and prostacyclin (de Nucci et al, 1988). ET is known to be mitogenicfor a
number of tissues (Hirataetal, 1989; Takuwa et al, 1989; Shichiri et al, 1991) and
by its paracrine / autocrine actions may play a role in implantation and the
establishment of early pregnancy. In vitro studies have demonstrated that ET-1
modulates the release of renin and prolactin from decidual cells (Chao et al, 1994) and
that ET stimulates the production of PGF2a from decidual cells (Schrey and Hare,
1992). Using the ETA receptor antagonist, BQ610, the ETA receptor was shown to be
coupled to the increased prostaglandin production from first trimester decidual cells
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(Seki et al, 1995) and ET has been shown to stimulate DNA synthesis in cultured
human endometrial stromal cells (Kubota et al, 1995).
The precise role of endothelin in the endometrium during the menstrual cycle and in
early pregnancy is unclear. Endothelin has a potential role in the initiation and control
of menstruation, endometrial repair and regeneration and in the establishment of an
early pregnancy. Regulation of endothelin may be by alterations in endothelin
synthesis or by alterations in receptor expression, both of which have been
demonstrated across the cycle and in decidualised stromal cells.
Endothelin may have a role in the pathophysiology of menorrhagia, with reduced ET-
IR being demonstrated in the glandular and luminal epithelium of patients with proven
menorrhagia (Marsh et al, 1996). Endothelin receptor expression is known to be
under ovarian steroid control. The effects of high dose exogenous steroids on the
expression of endothelin receptors in the endometrium of patients with proven
menorrhagia are examined further in chapter six.
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Clinical Aspects of Menorrhagia
Introduction
Earlier menarche and fewer pregnancies mean that women in the late 20th century
experience more episodes of cyclical bleeding during their lifetime than ever before. A
community survey of 521 women showed that 30% rated their menstrual losses as
"heavy" or "very heavy" with 22% stating that heavy periods interfered with their life
(Gath etal, 1987). Complaints of excessive menstrual loss have a substantial impact
on gynaecological services and the number of women consulting their general
practitioners for menstrual dysfunction is rising. General practitioners participating in
the National Morbidity Survey showed that 31 per 1000 female patients consult their
general practitioners each year because of irregular or excessive menstruation, a rise in
consultations of 73% over 10 years (RCGP 1986). Abnormal uterine bleeding is one
of the commonest reasons for which women are referred to hospital by their general
practitioners, with almost three quarters of these referrals due to excessive menstrual
blood loss (Coulteretal, 1991).
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"But nothing could easily be found that is more remarkable than the monthly flux of
women. Contact with it turns new wine sour, crops touched by it become barren,
grafts die, seeds in gardens are dried up, the fruit of trees falls off, the bright surface
of mirrors in which it is merely reflected is dimmed, the edge of steel and the gleam of
ivory are dulled, hives of bees die, even bronze and iron are at once seized by rust,
and a horrible smell fills the air; to taste it drives dogs mad and infects their bites with
an incurable poison." Pliny.
In the 1990's, society's attitude to menstruation may have softened compared to that of
Ancient Greece, but many women still find heavy monthly menstrual bleeding an
intolerable burden. In very few areas of medicine is a patient's complaint of a
symptom enough to put in motion a sequence of investigations and treatments which
may culminate in major surgery, but this is the case for patients complaining of
menorrhagia and objective corroboration of the complaint is seldom sought.
The Objective Assessment of Menstrual Blood Loss
Menstrual blood loss has been quantified by a variety of means. The earliest was by
weight estimates of soiled sanitary material, first described in a thesis by Prussag in
1912. This technique is simple to perform, but carries with it several disadvantages.
The sanitary material may be soiled with other substances such as urine, care must be
taken to avoid evaporation and, since the technique gives an estimation of menstrual
fluid rather than menstrual blood loss, it may not be an accurate predictor of anaemia.
The blood content of menstrual fluid is recognised to vary considerably. In a study of
28 regularly menstruating volunteers, the contribution of blood varied from 1.6% to
82% of total menstrual discharge (Fraser et al, 1985).
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Radioisotope methods use 59Fe or 51Cr to label red blood cells premenstrually and
measure radioisotope activity in the circulation before and after menses. Soiled
sanitary material is collected and radioisotope activity in the collection is calculated.
Menstrual blood loss can be calculated from this in conjunction with the known
isotope activity in the peripheral circulation. One source of inaccuracy is the need to
make a complete collection of all menstrual blood lost. Whole body radioactivity has
been used to try to avoid the need for collection of soiled sanitary protection, but this
method does not allow for blood lost from other sources such as gastrointestinal
bleeding and has been shown to be associated with errors when menstrual blood
losses lie within the normal range (Price et al, 1964).
Measurement of the iron content of soiled sanitary protection has been used as a
measure of menstrual blood loss (Cole et al, 1971), with rapid measurement possible
using atomic absorption spectrophotometry. Again, this method relies on the accurate
collection of all menstrual blood lost.
Perhaps the best known method of assessment of menstrual blood loss is the alkaline
haematin method, first described by Hallberg and Nilsson in 1964 (Hallberg and
Nilsson, 1964). Again, this method relies on a full collection of all used sanitary
materials. These are soaked in a known volume of 5% sodium hydroxide solution
until all coloured spots on the pads or tampons have disappeared. Haemoglobin is
converted to alkaline haematin and the reaction takes place irrespective of the age of the
blood or the presence of any other proteins or mucins. After 20 hours, an aliquot is
removed, filtered, and the optical density is measured at 546nm. This is compared
with the optical density of a known volume of the patient's own venous blood diluted
in 5% sodium hydroxide using the formula:
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Menstrual blood = Optical density menstrual fluid x volume of menstrual solution
loss Optical density venous blood x volume of venous solution
This method has the advantage of being cheap and simple to perform, and does not
require exposure of the patient to radioactive materials. A recovery of 96.3% ± 0.5
(mean ± SEM) was calculated using this technique (Hallberg and Nilsson, 1964). The
importance of a full collection of menstrual blood loss must be emphasised and many
studies have recommended that the patient wear a tampon during bathing, urination or
defecation to avoid loss of any clots.
A similar technique has been recently described in which a non-ionic detergent replaces
sodium hydroxide as the diluent (Gannon et al, 1996). One drawback of all these
methods is the need for women to collect their menstrual losses, a task which many
women find distasteful. The study by Gannon et al achieved a collection in 89% of
women invited to participate, although the authors admit that this level of co-operation
may not be achievable outwith a research setting. A pictorial blood loss assessment
chart has been devised to avoid the collection of used sanitary material (Higham et al,
1990), but this method may be associated with a high rate of false positive results
leading to an over diagnosis of menorrhagia (Deeny and Davis, 1994).
The measurement of menstrual blood loss is time-consuming and requires a high
degree of motivation from patients. Without such measurements however, the efficacy
of surgical and medical treatments cannot be objectively assessed.
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The Definition of Menorrhagia
Menorrhagia is defined as a menstrual blood loss in excess of 80ml. This definition is
derived from two large population studies. The first was carried out in Sweden in
1966 on 476 women aged between 15 and 50 years, who were selected at random as
part of a health screening programme and invited to measure their menstrual blood loss
by the alkaline haematin method (Hallberg et al, 1966). The second study was in
Northumbria in 1971 and measured iron in used sanitary materials from 348 women
using atomic absorption spectrophotometry (Cole et al, 1971). Menstrual blood loss
in these two studies was shown to have a positive skew distribution with a mean
menstrual blood loss of 37.5 - 43.4ml, median of 27.5 - 30ml and losses in excess of
80ml lying above the 95th centile. Hallberg's study also demonstrated that when
losses exceeded 80ml, 67% of patients were anaemic, confirming that losses in excess
of 80ml should be considered as pathological rather than physiological.
Objective measurement of menstrual blood loss is rarely undertaken outwith a research
setting. However patients' perception of menorrhagia has been shown to be inaccurate
in several studies. In Hallberg's original population survey, women were asked to
rate their menstrual blood loss as heavy, moderate or scanty. 45% of women rating
their loss as 'heavy' had a measured menstrual blood loss of less than 40ml and 13%
had a loss of less than 20ml (Hallberg et al, 1966). A study of 69 women with a
convincing complaint of menorrhagia showed that 62% had measured menstrual blood
losses of less than 80ml (Fraser et al, 1984). This suggests that other factors, social
and psychological, may lead women to seek treatment for their perceived menorrhagia
and these factors may also influence the results of treatment.
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The Aetiology of Menorrhagia
Menorrhagia may occasionally be due to systemic disease such as bleeding diatheses
or endocrinopathies. Local causes of heavy menstrual blood loss include uterine
fibroids, endometrial polyps, complications of undiagnosed pregnancy, intrauterine or
pelvic infection, adenomyosis or endometriosis, copper-containing or inert intrauterine
contraceptive devices (IUCDs), and cervical or endometrial malignancy (Cameron,
1989). However in the majority of patients undergoing dilatation and curettage
because of menstrual disturbance, no significant intrauterine pathology was identified
(MacKenzie and Bibby, 1978). Menorrhagia may be secondary to a disturbance of the
hypothalamo-pituitary-ovarian axis. This has been demonstrated in patients
complaining of menorrhagia at extremes of reproductive age (Fraser and Baird, 1972;
van Look et al, 1977) but for the majority of patients with heavy regular periods, no
such disturbance has been demonstrated (Haynes et al, 1977).
Investigation of the patient complaining of menorrhagia is aimed at identifying organic
pathology, in particular endometrial malignancy. Such investigation is generally
unrewarding, the vast majority of patients having no obvious underlying cause for
their menorrhagia, so-called 'dysfunctional uterine bleeding' (DUB), and attention has
focused on local factors within the endometrium as a cause of excessive blood loss.
The Pathophysiology of Dysfunctional Uterine Bleeding
A variety of mechanisms have been proposed in the pathogenesis of DUB. There is
extensive evidence that endometrial prostaglandins (PGs) play a role. Endometrial
prostaglandin levels increase in the secretory phase of the cycle (Maathuis and Kelly,
1978) and overall levels of PGE2 and PGF20: have been shown to be elevated in
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women with proven menorrhagia (Cameron et al, 1987). Furthermore, the ratio of
PGE2 (a vasodilator) to PGF2« (a vasoconstrictor) is increased in patients with
increased menstrual blood loss (Smith et al, 1981). Endometrial fibrinolysis is also
thought to play a role in the aetiology of menorrhagia, with excessive fibrinolytic
activity being demonstrated in the endometrium of women with increased menstrual
blood losses compared with normal controls (Bonnar et al, 1983). Platelet activating
factor has actions as a vasoconstrictor and stimulates platelet aggregation, and may
play a role in the paracrine control of the uterine vascular bed. There is evidence that it
is synthesised in stromal cells (Alecozay et al, 1991). In addition, a variety of
cytokines have been implicated in the process of endometrial repair and angiogenesis,
and these may be important in the eventual cessation of menstrual bleeding (for
review, see Cameron etal, 1996). The potential roles of endothelin, a 21 amino acid
peptide with potent vasoconstrictor properties, and nitric oxide, a readily diffusible
free radical species with vasodilator properties, have been discussed earlier in this
chapter.
The Investigation of the Patient Complaining of Menorrhagia
For years, dilation and curettage (D&C) has been the mainstay investigation for
abnormal vaginal bleeding, often with the misconception that the procedure is curative
and will lead to the resumption of a normal menstrual cycle. In a study of 22 women
with menstrual blood losses in excess of 80ml, the effects of D&C were examined by
measuring menstrual blood loss using the alkaline haematin method for several months
following the procedure (Haynes et al, 1977). In most patients, there was a reduction
in menstrual blood loss in the first month after curettage, but by the second month after
the procedure the majority of patients had losses at least equal, if not greater than their
pre-curettage menstrual blood loss. The technique is not without complications. The
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procedure is usually performed under general anaesthesia, and operative complications
include uterine perforation and cervical trauma. In a review of 1029 procedures, the
overall complication rate was reported as 1.7%, with four patients requiring
laparoscopy or laparotomy and one requiring hysterectomy (MacKenzie and Bibby,
1978). D&C is a blind technique and focal endometrial lesions may be missed. When
hysterectomy was performed following dilatation and curettage, it was demonstrated
that less than half of the uterine cavity was sampled in more than half of cases (Stock
and Kanbour, 1975).
With the development of devices for taking an endometrial biopsy through an undilated
cervix, there has been a move away from in-patient D&C towards an out-patient
approach (RCOG, 1994). In addition, the realisation that young women with regular
menstrual cycles are at low risk of developing endometrial hyperplasia and neoplasia
has questioned the need for the use of any invasive endometrial biopsy in such cases
(Lewis, 1993). Whilst this has led to a dramatic fall in D&C rates in North America,
major changes in practice have not been seen in the England (Coulter et al, 1993) or
Scotland (Common Service Agency for the Scottish Health Service, 1994). One
reason for this may be that in women for whom sampling of the uterine cavity is
indicated, there has been some reluctance to abandon traditional D&C in favour of a
less invasive, but similarly blind, biopsy technique which may only sample a small
proportion of the endometrium. In a study of 25 patients scheduled for hysterectomy
who underwent pre-operative endometrial sampling by a Pipelle device or Vabra
aspirator, the percentage of endometrium sampled by the Pipelle device was 4.2% ±
0.92% (mean ± SEM) and by Vabra aspirator was 41.6% ± 5.7% (Rodriguez et al,
1993).
The development of fibre optic hysteroscopy to provide a panoramic view of the
endometrial cavity and facilitate directed biopsy provides a valid alternative to D&C,
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with recommendations that it be more widely used in clinical practice (Lewis, 1993).
The availability of narrower gauge instruments increases the scope for more cost-
effective assessment as an out patient. In a series of 638 outpatient hysteroscopies
only 3% of patients required a general anaesthetic because of cervical stenosis
(Mencaglia et al, 1987). The diagnostic accuracy of hysteroscopy compares
favourably with both hysterosalpingography and D&C. Hysterosalpingography was
able to detect only 62% of the endometrial polyps, 74% of the submucous fibroids and
58% of intrauterine adhesion that were detected with hysteroscopy (Hamou et al,
1985). In a review of 276 cases undergoing both hysteroscopy with directed
endometrial biopsies and D&C , 81% of cases had hysteroscopic findings agreeing
with those of curettage, 16% had hysteroscopic findings more revealing than curettage
and 3% had hysteroscopic findings less revealing than curettage (Gimpleson and
Rappold, 1988).
With the increasing use of investigations such as hysteroscopy, the percentage of
women diagnosed as having dysfunctional uterine bleeding may fall as more organic
pathology is detected; it is important to bear in mind however that findings such as
small fibroids and endometrial polyps may be incidental to, and not the cause of,
excessive menstrual blood loss. A review of 400 patients presenting for out patient
assessment of abnormal uterine bleeding, including 253 referrals due to menorrhagia,
is presented in chapter two.
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The Medical Management of Menorrhagia
Introduction
The traditional surgical treatment for menorrhagia is hysterectomy. 60% of women
referred to hospital with menorrhagia had a hysterectomy within five years (Coulter et
al, 1991) and menorrhagia makes a significant contribution to the 20% lifetime risk of
women in the United Kingdom undergoing the procedure (Vessey et al, 1992). While
hysterectomy offers a very effective cure for menorrhagia, it is only suitable for those
women who have no further wish to conceive and the procedure represents major
surgery with post-operative morbidity rates of 25-47% (Dicker et al, 1982; Dwyer et
al, 1993). Conservative endometrial ablation techniques offer an alternative surgical
treatment option with significantly reduced post-operative morbidity (Dwyer et al,
1993; Pinion et al, 1994). Long term follow up of these techniques is ongoing
(Sculpher et al, 1996) but again they are unsuitable for women wishing to retain their
reproductive function.
A number of different medical modes of treatment of dysfunctional uterine bleeding are
available, with varying degrees of success. Treatments fall into four main groups as
summarised in table 1.1.
Randomised controlled trials which measure menstrual blood loss before and after
treatment should be the gold standard to assess the treatment of menorrhagia, since it is
only when the objective efficacy of treatment is known that patient satisfaction with
treatment can be put into its proper context. There are several points to bear in mind




-combined oral contraceptive pill (COCP)
-danazol
-gonadotrophin releasing hormone (GnRH) analogues
Prostaglandin synthetase inhibitors
Inhibitors of fibrinolysis
Reducers of platelet fragility
Table 1.1. Drugs used in the medical management of menorrhagia.
on perceived menstrual blood loss and the potential side effects of treatments, effective
reduction in MBL may not equate with patient satisfaction with treatment. Another
problem with many clinical trials is that patients are only included in the study if their
MBL is in excess of 80ml, thus giving no information on the efficacy of treatment for
those patients with perceived menorrhagia but normal blood losses. Finally, while
many authors publish results showing the percentage reduction in MBL, patients may
still be losing in excess of 80ml, so the treatment may hardly be classed as curative.
Hormonal treatments
The use of synthetic progestagens in the treatment of dysfunctional uterine bleeding
will be reviewed in more detail later in this chapter.
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Combined oral contraceptivepill
The combined oral contraceptive pill (COCP) is used infrequently for the treatment of
menorrhagia, being prescribed by only 11% of a national sample of 518 general
practitioners (Coulter et al, 1995). Anecdotally, it has long been recognised that
women using the COCP for contraception report reduced menstrual blood loss. This
observation has been confirmed objectively in both menorrhagic women and normal
controls (Nilsson and Solvell, 1967). The results of a large trial comparing ovulation
inhibitors with antifibrinolytic therapy or curettage in patients with proven menorrhagia
(Nilsson and Rybo, 1970) showed an overall reduction in MBLfrom a mean of 158ml
to 75ml in the 164 patients randomised to receive the COCP, a reduction of 53%. The
influence of organic pathology in the form of uterine fibroids was also examined in
this study. The reduction in MBL was significantly lower in patients with fibroids
(n=35) who had a percentage reduction of only 25% compared with 59% and 66% for
women with 'slightly enlarged' (n=65) and 'normal-sized' (n=62) uteri respectively.
Side effects were mild with no thromboembolic complications noted. The age range of
patients included in the study was 17-51 years.
Part of the unpopularity of this form of treatment, despite its effectiveness, is the fear
of thromboembolic disease in the older age group of women who present with
menorrhagia. The appreciation that age alone, in the absence of smoking or other
predisposing factors such as previous thromboembolic disease or family history, is not
an absolute contraindication to its use should widen its availability to women in the
over 35 year age group. The mode of action of inhibitors of ovulation is mainly local,
with production of an inactive endometrium, and there may also be a reduction in
endometrial prostaglandin synthesis and impaired uterine fibrinolysis.
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Danazol
Danazol is a synthetic androgen with antioestrogenic and antiprogestogenic activity; it
acts by inhibition of pituitary gonadotrophins. Danazol was first used in the treatment
of DUB in 1979 (Chimbira et al, 1979). Eighteen patients with proven menorrhagia
received danazol 400mg daily for 12 weeks. MBL fell from 231 ± 39ml (mean ±
SEM) to 135 ± 33ml at one month. By three months of treatment, ten out of 18
patients were amenorrhoeic and the remainder had a mean MBL of only 3ml, a
reduction in MBL of 96%. Two patients withdrew from the study because of side
effects. This danazol regimen had some short term "carry over" effect after
discontinuing treatment, with MBL three months following discontinuation still
significantly less than pre-treatment values, however the authors accepted that the
expense of treatment and side effects limited its use in some patients. Later work by
the same author looked at reductions in dosage regimes in an effort to balance efficacy
against patient acceptability and found that a regimen of 200mg daily in 16 patients
with MBL >60ml gave reductions in MBL of 78% with no withdrawals because of
side effects (Chimbira et al, 1980).
The main limitation of treatment with danazol is the incidence of androgenic side
effects such as weight gain (a statistically significant increase of 4.5kg above pre-
treatment values with a regime of 400mg daily), muscle cramp and skin rashes
(Chimbira et al, 1980). An attempt to improve patient acceptability by comparing a
regimen of decreasing doses of danazol (200 mg daily for the first cycle, reducing to
100 mg daily for the second and 50 mg daily for the third) to a continuous regimen of
200 mg danazol daily or a gestagen (norethindrone 5 mg tds from day 19 to 26 of the
cycle) in 57 patients with MBL>80ml (Higham and Shaw, 1993) showed that, while
both danazol regimens were more effective than the gestagen at reducing MBL, the
reducing dose regimen did not improve the incidence of adverse side effects. Over
half of the danazol treated patients in this study had MBL >80ml after treatment.
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In a study comparing danazol 200 mg daily to mefenamic acid, the danazol group of
20 patients with objective menorrhagia showed an overall reduction of 60% in MBL,
but three quarters of the patients experienced side effects with 40% of the group
declining to continue with treatment because of this (Dockeray et al, 1989). This
compared to a reduction in MBL of 20% in the mefenamic acid group but with only
one third of patients reporting side effects and 10% refusing to continue with treatment
because of side effects. Given these limitations, the main use of danazol therapy has
been as second line therapy in patients with previous treatmentfailures or as short term
treatment prior to surgery.
Gonadotrophin releasing hormone analogues
Gonadotrophin releasing hormone analogues act on receptors in the anterior pituitary
gland. When administered continuously, an initial surge in production of the anterior
pituitary hormones is followed by down-regulation, resulting in a hypo-oestrogenic
state and endometrial atrophy. Bleeding patterns in ovulatory patients who did not
complain of menorrhagia showed a reduction in the number of days bleeding and
amenorrhoea resulted in about one third of patients (Berqvist et al, 1982). The use of
luteinising hormone releasing hormone (LHRH) analogue in a small study of
menorrhagic patients demonstrated a reduction in MBL from a mean of 131ml pre
treatment to a mean of 11ml after three treatment cycles (Shaw and Fraser, 1984)).
Long term treatment is limited by unwanted hypo-oestrogenic effects, in particular
bone loss, and its use is mainly confined to short term treatment pre-surgery. The use
of LHRH agonist in combination with hormone replacement therapy in 20 patients
complaining of menorrhagia showed a reduction in menstrual blood loss from a pre
treatment median of 68ml (range 23-397ml) to a median of 17ml at three months with
80% of patients expressing satisfaction with their treatment (Thomas et al, 1991).
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Prostaglandin synthetase inhibitors
In terms of randomised controlled trials, more has been published on non-steroidal
anti-inflammatory drugs (NSAIDs) than any other medical treatment of menorrhagia.
The first uncontrolled report was published in 1976 (Anderson et al, 1976). This
report highlighted the convenience of a regimen to be taken only during menses and
which would also treat dysmenorrhoea. Non-steroidal anti-inflammatory drugs remain
a popular choice, being prescribed by a quarter of general practitioners for the
treatment of menorrhagia (Coulter et al, 1995). Most studies use mefenamic acid
500mg tds for five days during menses, although reductions in MBL have also been
documented using other PG synthetase inhibitors including diclofenac sodium,
flurbiprofen, ibuprofen and meclofenamate sodium.
Reductions in MBL in patients with proven menorrhagia ranged from 22-46% (Fraser
et al, 1981; Muggeridge and Elder, 1983; Hall et al, 1987; Dockeray et al, 1989;
Cameron etal, 1990; Chamberlain etal, 1991; van Eijkeren et al, 1992; Bonnar and
Sheppard, 1996). A proportion of patients did not respond to treatment, with post
treatment blood losses still in the menorrhagic range. Some studies included women
with MBL <80ml, and still showed reductions in MBL, although of a smaller order
(19%) for these patients (Fraser et al, 1981). Reductions of 9-38% were also noted in
women using IUCDs; again the larger reductions were seen in patients with MBLs in
excess of 80ml (Guillebaud et al, 1978; Rybo et al, 1981). The incidence of side
effects reported was generally low, suggesting the treatment would be suitable for long
term use. This has been borne out in one long term study which used mefenamic acid
500mg tds during menses for more than one year in 38 women with a subjective
complaint of menorrhagia (Fraser, 1983). The study showed that measured MBL was
reduced from pre-treatment values of 66 ± 5ml (mean± SEM) to 49 ± 10ml at six to
nine months and 43 ± 5ml at 12 to 15 months of treatment, an overall reduction of
24% which was sustained during long term treatment. In addition to measured MBL,
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subjective symptoms such as the duration of menses, number of days of pain, number
of sanitary towels used and the number of capsules ingested also reduced significantly
with time, with only two patients having to discontinue because of gastrointestinal
symptoms.
Non-steroidal anti-inflammatory drugs are thought to reduce menstrual blood loss by
their action as a prostaglandin synthetase inhibitor, although in vivo studies examining
endometrial tissue levels of PGE2 and PGF2a in response to NSA1D administration
have proved inconclusive (Fraser, 1983; Shapiro and Haning, 1983). Plasma levels
of mefenamic acid have been shown to correlate with improvements in MBL
(Dockeray et al, 1986). The variable results from tissue studies and from some
patients in clinical trials may thus be due to inadequate tissue levels in the uterus.
Inhibitors offibrinolysis
Tranexamicacid, an inhibitor of fibrinolysis, is used infrequently as first line therapy
in the United Kingdom (Coulter et al, 1995) despite a number of trials which show a
reduction in MBL of around 50% in patients with DUB (Milsom et al, 1991; Preston
et al, 1995; Bonnar and Sheppard, 1996). In a crossover study with flurbiprofen
(Milsom et al, 1991), 15 women with proven menorrhagia showed a reduction in
MBL from a mean of 295ml (range 81-701ml) to 155ml (range 36-51 lml) after
treatment with tranexamic acid 1.5gm tds for three days, then lgm bd for another four
days. This compared to a post treatment MBL of 223ml (range 50-636ml) when
treated with flurbiprofen lOOmg bd for five days, a reduction in MBL of 44% with
tranexamic acid and 21% with flurbiprofen. Reported side effects were minor with no
discontinuations because of adverse drug effects. Similar efficacy was reported in a
comparative trial with norethisterone, involving 46 women with proven ovulatory
menorrhagia (Preston et al, 1995). Twenty five received tranexamic acid lgm qds for
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four days and measured MBL was reduced from 175ml (SD 84ml) to 97ml (SD
89ml), an overall reduction of 45%. This compared to a increase with norethisterone
5mg bd from day 19 to 26 of the cycle of 20%, from 173ml (SD 85ml) to 208ml (SD
135ml). The effect of tranexamic acid is dose dependent, with lower doses of 2gm
daily producing reductions in MBL of 36% in anaemic women complaining of
menorrhagia (Callender et al, 1970). Tranexamic acid produced subjective
improvements of 35-51% in patients with perceived menorrhagia, suggesting that it is
also effective in patients with MBL<80ml (Vermylen etal 1968; Nilsson and Solved,
1967). Patients with menorrhagia in association with 1UCD use have also benefited
from treatment with antifibrinolytic therapy, with a 56% reduction in MBL
demonstrated in 19 women after taking tranexamic acid 1.5gm tds for five days during
menses (Ylikorkala and Viinikka, 1983).
Side effects are reported in about one third of patients. These are mainly
gastrointestinal and again are dose dependent. One factor limiting the widespread
acceptance of antifibrinolytic therapy has been the fear of increased thrombotic activity,
highlighted by isolated case reports of intracranial thrombosis and central venous stasis
retinopathy (Rydin and Lundberg, 1976; Agnelli et al, 1982). Histochemical studies
have shown no evidence of reduced fibrinolysis in superficial vein walls following
treatment with tranexamic acid 3-4gm daily on a continuous basis for three weeks
(Astedt, 1978) and in Scandinavia, where antifibrinolytics have been used as first line
therapy for over 20 years, there has been no increase in the incidence of
thromboembolic disease during this time (Rybo, 1991).
Reducers ofplateletfragility
Ethamsylate, which has effects on prostaglandin synthesis as well as direct effects on
plateletfragility, has been used in the treatment of menorrhagia for a number of years,
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but results from the few clinical trials reported are variable. In a small crossover trial
with placebo, ethamsylate 500mg qds from five days before the onset of menses and
for ten days thereafter produced a 50% reduction in MBL in nine women complaining
of menorrhagia, compared with no change in the placebo group (Harrison and
Campbell, 1976). A smaller reduction of 19% was noted when 13 IUCD users
complaining of menorrhagia were examined. Side effects were reported in 18 out of
53 ethamsylate cycles, and 17 out of 50 placebo cycles. Another study of IUCD users
showed only a 7% reduction in MBL after treatment with ethamsylate 500mg qds
during menses (Kasonde and Bonnar, 1975). More recent work examined 44 women
with MBL >80ml and showed that ethamsylate 500mg qds during menses reduced
MBL by 20% after three months of treatment, although actual values of MBL are not
reported and over one fifth of patients originally randomised did not complete
treatment(Chamberlainetal, 1991). In a randomised controlled trial with mefenamic
acid and tranexamic acid, ethamsylate 500mg qds during menses showed no reduction
in menstrual blood loss (Bonnar and Sheppard, 1996).
Synthetic Progestagens for the Treatment of Menorrhagia
Synthetic progestagens have been used in the treatment of menorrhagia for over 30
years and are the most popular drug prescribed in general practice for the treatment of
menorrhagia (Coulter et al, 1995). Their use in the past has been largely empirical and
illustrates the importance of objective randomised controlled trials. A further problem
with the interpretation of trials using synthetic progestagens is the variety of types,
dosages and treatment regimens of progestagens used.
The first report of the use of progestagens in the treatment of menorrhagia was in 13
women with subjective menorrhagia, and used norethisterone in varying doses from
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day 15 to 26 of the menstrual cycle (Bishop and de Almeida, 1960). The authors
reported a subjective improvement in menstrual blood loss in 34 of 52 cycles treated,
and this regimen was universally adopted. It was not until 1987 that short term
progestagen therapy was examined objectively, when a non-significant reduction in
MBLfrom 131 to 110ml in six women with ovulatory menorrhagia was observed after
treatmentwith norethisterone 5mg bd from day 16 to 26 of the cycle (Cameron et al,
1987). Further work on a regimen using the same dosage from day 19 to 26 of the
cycle in 15 women with ovulatory menorrhagia showed a 20% reduction in MBL from
109 to 92ml, but two thirds of patients thus treated had post treatment MBL >80ml
(Cameron et al, 1990). A more recent study using norethisterone 5mg bd from day 19
to 26 of the cycle in 21 women with confirmed ovulatory menorrhagia demonstrated a
20% increase in MBL (Preston et al, 1995).
Increasing the length of treatment to 21 days each cycle has given improved results in
one small study involving ten patients with proven ovulatory menorrhagia (Fraser,
1990). Following treatment either with norethisterone 5mg tds or
medroxyprogesterone acetate lOmg tds, both from day 5 to 26 of the cycle, MBL fell
by 35% from 112 to 73ml. Half of the patients thus treated were still losing >80ml
after treatment. Proposed modes of action are the down-regulation of endometrial
oestrogen receptors when progestagens are added early in the cycle, or inhibition of
ovulation.
Where a shorter duration of progestagen dose has proven to be effective is in that
minority of patients with anovulatory menorrhagia, when use of norethisterone 5mg
tds or medroxyprogesterone acetate lOmg tds, in a regimen from day 12 to 26 of the
cycle gave a 50% reduction in MBL in six patients with confirmed anovulatory
menorrhagia, with all but one post treatment MBL being below 80ml (Fraser, 1990).
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For the majority of patients who present with ovulatory menorrhagia however, short
duration progestagens are ineffective.
While the results of systemic progestagens for the treatment of ovulatory dysfunctional
uterine bleeding are variable, the results of use of local intrauterine progestagens are
more consistent. Inert or copper-containing intrauterine devices have been shown in
clinical trials to increase menstrual blood loss (Guillebaud et al, 1976). Intrauterine
devices releasing progesterone or a synthetic progesterone, levonorgestrel, were
introduced to improve contraceptive efficacy and reduce side effects. The first such
device released 65/<g of progesterone in 24 hours over one year (Progestasert® IUCD:
AlzaCorp., Palo Alto, USA.) and reduced MBL in 12 menorrhagic women from a
median of 138 to 49ml at 12 months use (Bergqvist and Rybo, 1983). This
represented a reduction of 65%, with all women having MBL within the normal range
after treatment, however the device was withdrawn from general use because of an
excess risk of ectopic pregnancies. The more recent levonorgestrel intrauterine system
(LNG IUS) (Mirena®: Leiras Oy, Turku, Finland) releases 20/<gm of levonorgestrel
in 24 hours over five years (figure 1.3). Initial studies in 20 patients with MBL>80ml
(range 80-381ml) demonstrated a reduction in MBL from a median of 176ml before
treatment to 24ml at three months (range 0-145ml) and 5ml at 12 months (range 0-
33ml) (Andersson and Rybo, 1990). This represented reductions in MBL of 86% at
three months use and 97% at 12 months use. Seven out of the 20 patients were
amenorrhoeic at the end of one years use. In a comparative study with flurbiprofen
and tranexamic acid, LNG IUS again produced reductions of 82% at three months,
88% at six months and 96% at 12 months of use (Milsom et al, 1991). One feature of
local progestagen use is the increase in breakthrough bleeding, which was reported in
most women during the first three cycles of treatment (Andersson and Rybo, 1990).
Although tolerated by most of the women in the study, two requested removal of the
device because of this. One further patient expelled the device. The importance of
71
counselling patients with regard to abnormal bleeding patterns or amenorrhoea was
stressed. The LNG IUS is currently only licensed in the UK for contraception.
Possible modes of action of progestagen-releasing devices are a reduction in
endometrial prostaglandin synthesis (Cameron et al, 1987), the production of an
inactive endometrium (Silverberg et al, 1986) and a reduction in endometrial
fibrinolytic activity (Bonnar and Sheppard, 1979).
An additional feature of progestagen-releasing devices is their effect on MBL in
patients with normal losses. Both devices have also been shown to reduce MBL,
Progestasert® by 50% (Rybo and Bergqvist 1977), Mirena® by 63% (Nilsson, 1977)
in patients who did not complain of menorrhagia.
The results of a randomised comparative parallel group study comparing the efficacy
and patient acceptability of the levonorgestrel intrauterine system and oral
norethisterone for the treatment of idiopathic menorrhagia are presented in chapter
three.
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Figure 1.3. The levonorgestrel intrauterine system (LNG IUS). The system consists
of a plastic T-shaped frame with a steroid reservoir around its vertical stem. The
reservoir contains 52mg levonorgestrel and is covered by a membrane which regulates
the release of LNG. The total length of the system is 32mm.
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Chapter Two
Out Patient Hysteroscopy and Endometrial Biopsy in the Investigation of
Abnormal Uterine Bleeding
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Abnormal uterine bleeding is one of the most common reasons for which women are
referred to hospital by their general practitioners (RCGP, 1986). Women in the late
twentieth century experience more episodes of cyclical bleeding during their lifetime
than ever before, an average of over 470 in their reproductive lifetime. Furthermore
the widespread use of exogenous steroids for contraception and hormone replacement
therapy (HRT) has led to both an increase in the number of women presenting with
irregular vaginal bleeding and a prolongation of bleeding cycles beyond the natural
menopause.
The development of fibre optic hysteroscopy to visualise the endometrial cavity and
facilitate biopsy has altered the approach to the investigation of abnormal uterine
bleeding, with a move away from in patient dilatation and curettage (D&C) towards a
more cost effective assessment as an out patient.
An out patient hysteroscopy service was established at Glasgow Royal Infirmary in
1989. This chapter comprises an analysis of 400 consecutive patients who attended
the clinic between February 1992 and August 1993. Referrals due to menorrhagia
accounted for 63%, with a further 17% referred with postmenopausal bleeding and
15% due to abnormal bleeding on HRT. Factors influencing success at accessing the
uterine cavity were examined, and the intrauterine pathology identified was reviewed.
Subjects and methods
Patients were referred from general gynaecology clinics or, in a few cases, direct from
their general practitioner. The hysteroscopy clinic was staffed by four gynaecologists,
with two nurses and secretarial support. Three of the operators had a minimum of
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three years hysteroscopy experience; the fourth had been attending the clinic in a
training capacity for six months.
The procedure of hysteroscopy was explained both in a hand-out which patients
received before their appointment and verbally by nursing staff at the clinic itself. Pre¬
medication was offered routinely in the form of 4mg oral diazepam and 75mg
intramuscular diclofenac. In the final months of the study period, some women
underwent hysteroscopy after an interstitial cervical block using Citanest 3% with
Octapressin® (Astra Pharmaceuticals Ltd., Kings Langley, UK) as an alternative to the
pre-medication.
The examination was conducted with patients in a modified lithotomy position using a
rigid 4mm diagnostic hysteroscope (Olympus Optical Co. Europe, Hamburg,
Germany) and carbon dioxide as the distending medium via an automatic hysteroflator
(Olympus, Germany). Samples of endometrial tissue were taken using a Pipelle
aspirator (Laboratoire CCD, Paris, France) or a Vabra system (Berkeley Medevices
Inc., Berkeley, US) and were submitted for pathological assessment and dating using
the method described by Noyes et al (Noyes et al, 1950).
Statistical analysis





Of the 400 referrals, 253 (63%) were referred because of a clinical diagnosis of
menorrhagia, that is a subjective complaint of heavy periods. Sixty six (16%)
complained of postmenopausal bleeding (PMB), 42 (10%) of unscheduled bleeding on
HRT and 17 (4%) of heavy withdrawal bleeds on HRT. Other indications included
assessment prior to transcervical endometrial resection (TORE) (n=5), a history of
unopposed oestrogen therapy (n=4), surveillance of a previous endometrial
abnormality (n=4), infertility (n=2) and recurrent abortion (n=l).
Of the 253 patients with menorrhagia, 117 complained of heavy menstrual loss with a
regular cycle (menstrual interval of 28±7days), while 136 complained of heavy
periods with menstrual irregularity. 84 patients presented with intermenstrual or
postcoital bleeding and 85 complained of dysmenorrhoea. Seven patients had of a
cycle length of less than 21 days and 16 had a cycle length longer than 35 days.
Age distribution
The youngest patient referred for investigation was 21 years, the oldest 72 years; the
median age of referral was 46 years. Looking specifically at the group referred with a
complaint of menorrhagia, the youngest was 21 years, the oldest 56 years and the
median age of referral was 43 years. Twenty six percent of the women referred with
menorrhagia were under 40 years, an age group where the incidence of significant
intra-uterine pathology is low (Lewis, 1993). Of the patients referred with
postmenopausal bleeding, the age range was 44-72 years, median 54 years. Patients
referred because of heavy or unscheduled bleeding on HRT ranged in age from 32-65
years, median 50 years.
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Factors influencing access to the uterine cavity
Hysteroscopy was indicated in 332 of the 400 referrals, being omitted at the operator's
discretion if he or she felt the procedure would cause unnecessary discomfort while
yielding no additional information. The procedure was successful in 260 (78%)
patients. In the group under investigation for menorrhagia, the procedure was
successful in 185 (84%) of 220 cases.
Endometrial biopsy was attempted in 398 patients, from whom a tissue sample was
obtained in 384 (96%) cases. The 14 women from whom endometrial biopsy was not
successful were referred for D&C under general anaesthesia, when biopsies were
obtained in ten cases.
Factors thought to influence success in accessing the uterine cavity for both
hysteroscopy and endometrial biopsy were analysed and are summarised in table 2.1.
Of the 400 patients in the study, 30 were nulliparous; a further 29 were parous but
had never achieved a vaginal delivery. Twelve gave a history of previous cervical
surgery and 66 were postmenopausal with an increased likelihood of cervical stenosis.
Some patients had more than one risk factor and were included in more than one
group. Operator experience was also analysed, as 116 (29%) of the procedures were
carried out by the trainee.
Hysteroscopic appearances
Hysteroscopy was possible in 185 (72%) of the patients referred due to menorrhagia,
29 (44%) of patients presenting with post menopausal bleeding and 32 (70%) of
patients complaining of heavy or unscheduled bleeding on HRT. The results are
shown in table 2.2. The commonest intrauterine pathologies documented were
submucous fibroids and endometrial polyps.
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In the group complaining of menorrhagia, the patient's age, cycle and associated
symptoms of intermenstrual bleeding were noted to determine whether there was any
correlation between such factors and the presence of intra-uterine pathology. The
results are shown in table 2.3. There was no statistically significant difference in the
presence of intra-uterine pathology between groups.
Endometrial histology
Histological assessment of endometrial biopsies obtained from 366 women in the three
main referral groups is shown in table 2.4. In the groups referred because of
menorrhagia or abnormal bleeding on HRT, the commonest histological finding was
of normal proliferative or secretory endometrium. In the group referred because of
PMB, the commonest report was that there was no tissue or that the tissue obtained
was insufficient to make a tissue diagnosis.
Over 75% of patients presenting with menorrhagia had no histological abnormality of
the endometrium. The endometrial appearances were related to the time in the cycle
where known. Eighty three patients were sampled in the first half of the cycle; 78
(94%) showed proliferative endometrium. One hundred patients were sampled in the
second half of the cycle; 86 (86%) had secretory changes in the endometrium and 14
(14%) had a proliferative pattern suggestive of anovulatory cycles.
There were two cases of adenocarcinoma detected, both in patients presenting with
post menopausal bleeding. Of the four patients with a report of severe atypical
hyperplasia, one presented with menorrhagia and three with postmenopausal bleeding;
all four patients were over the age of 45. In 68% of patients presenting with




There was one known case of uterine perforation during the series in a patient
undergoing investigation for menorrhagia . There were no cases of cervical trauma,
excessive bleeding or infection.
Discussion
Despite the inherent problems of a retrospective analysis, this study does promote an
insight into the out patient management of women presenting with abnormal uterine
bleeding.
Of the 400 patients studied, menorrhagia was the commonest indication for referral,
accounting for almost two thirds of the total. The remaining one third was split almost
equally between women presenting with postmenopausal bleeding and those with
abnormal bleeding patterns on hormone replacement therapy, a distribution which
reflects the increasing numbers of women experiencing artificial bleeding cycles.
About half of the group complaining of menorrhagia had an irregular cycle, with 36%
also experiencing abnormal bleeding outwith menses.
Where hysteroscopy was attempted, it was successful in 78% of the patients overall
and in 84% in the group of the women referred with menorrhagia. As expected, it was
significantly more difficult to access the uterine cavity in nulliparous patients compared
with patients who had had previous vaginal deliveries. By contrast, parous patients
delivered by Caesarean section appeared to present no significant increased difficulty
compared to patients with a previous vaginal delivery. Seven patients in whom
hysteroscopy was attempted had a past history which might be expected to make
investigation more difficult, five of a previous cone biopsy and two of repair
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operations with amputation of the cervix. Such a history made hysteroscopy
impossible in just over half of cases but the numbers of patients in the cervical surgery
group was small. Postmenopausal patients presented significant increased difficulty in
passing the hysteroscope, however even then hysteroscopy was achieved in 58% of
these patients. The use of local anaesthesia in the form of interstitial or paracervical
blocks may have altered success rates but numbers were too small to be analysed
separately. This review does not suggest that patients with a history of previous
cervical surgery, postmenopausal or nulliparous patients constitute an inappropriate
referral for out patient assessment, but that some consideration should be given to
more effective local analgesia before attempting the procedure. Operator experience
did not appear to make a significant difference to success rates of hysteroscopy in this
review. The figures were taken over an eighteen month period during which time a
reasonable level of skill had been acquired, emphasising the need for formal
supervised training since the skills required for out patient hysteroscopy are very
different from those required to do the same procedure under general anaesthesia.
The figures for obtaining an endometrial biopsy show that a biopsy was easier to
achieve than hysteroscopy, with access to the uterine cavity or a tissue sample being
obtained in 96% of cases. Seventy two patients in the group overall had a failed
hysteroscopy and in a further 68 hysteroscopy was not attempted, usually due to
patient anxiety; an endometrial biopsy was obtained in 83% and 97% of these patients
respectively, suggesting that an initial out patient approach is still valid in most cases.
However the limitations of biopsy alone, with regard to blind sampling and area of
endometrium sampled should be borne in mind in these groups, particularly when
trying to exclude endometrial carcinoma or hyperplasia (Ferry et al, 1993). This is
particularly illustrated in the group presenting with postmenopausal bleeding, when
68% of patients had insufficient or no tissue obtained on biopsy to make a tissue
diagnosis. While this is suggestive of an atrophic endometrium, there is no way to
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ensure that a focal lesion has not missed the sampler unless hysteroscopy is performed
in conjunction with endometrial biopsy.
A normal uterine cavity and endometrium was significantly more likely to be reported
in patients undergoing investigation for menorrhagia than in the other groups. The
hysteroscopic appearances of the uterine cavity showed no abnormality in 73%
(135/185) of patients having hysteroscopy for investigation of menorrhagia; this is in
keeping with figures generally quoted for the incidence of dysfunctional uterine
bleeding. Submucous fibroids were the commonest abnormality, noted in 13% of the
menorrhagia group, with endometrial polyps in a further 7.5%, however it is
important to bear in mind that such findings may be incidental to rather than the cause
of menorrhagia. Fibroids and endometrial polyps were also found in patients
complaining of postmenopausal bleeding and abnormal bleeding on HRT, with no
significant difference in incidence across the three referral groups. There was one case
of endometrial adenocarcinoma observed in a patient presenting with postmenopausal
bleeding.
A normal uterine cavity was as likely to be found in a patient with a regular menstrual
cycle as an irregular one and in a menorrhagic patient over the age of 40 as under.
Fifty seven of the 185 patients having hysteroscopy for investigation of menorrhagia
gave a history of intermenstrual bleeding, but this symptom was a poor predictor of
intrauterine pathology, with a sensitivity of 42.2% and specificity of 57.8%. There
was no significant difference in the finding of intrauterine pathology in patients
complaining of abnormal bleeding compared with patients who had no such complaint.
It is often thought that patients complaining of intermenstrual bleeding are more likely
to have intrauterine pathology. These figures do not support that view.
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Endometrial biopsy is performed to exclude endometrial carcinoma or atypical
hyperplasia with its potential for malignancy. Seventy three (18%) of the 400 patients
referred for endometrial biopsy were under the age of 40 years, rising to 26% in the
group referred for investigation of menorrhagia. While this compares favourably to
other quoted figures of 45% and 39% (MacKenzie et al, 1978; Coulter et al, 1993), it
still represents potential over-investigation, since such patients are at low risk of
significant intrauterine pathology (Lewis, 1993). During the study period there were
two cases of adenocarcinoma (an overall incidence of 0.5%), both in patients
presenting with post menopausal bleeding. There were four cases of atypical
endometrial hyperplasia (an overall incidence of 1%). Three of these patients
presented with postmenopausal bleeding, one with menorrhagia and an irregular
bleeding pattern. All these patients were over the age of 40. These figures confirm the
view that endometrial biopsy is an invasive procedure which is unnecessary as a first
line investigation in women under the age of 40 complaining of heavy regular periods,
and should not be performed unless other risk factors are present (RCOG, 1994).
There was only one known case of uterine perforation during the series in a patient
undergoing investigation for menorrhagia . There were no cases of cervical trauma,
excessive bleeding or infection. This represents an overall complication rate of
0.25%, which compares favourably to D&C with complication rates as high as 1.7%
(MacKenzie and Bibby, 1978).
In conclusion, the results of this study suggest that an out patient approach in the
investigation of abnormal vaginal bleeding is valid. There was no sinister intrauterine
pathology in any patient under the age of 40 years. In the absence of any other risk
factors such as anovulatory cycles, invasive investigation of this group is unnecessary
and should not be a first line approach. As expected, the majority of patients
presenting with menorrhagia were shown to have dysfunctional uterine bleeding.
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Symptoms of intermenstrual bleeding were not predictive of intrauterine pathology in
the patients studied. Based on this study these symptoms do not merit first line
invasive investigation unless other risk factors are present.
There is an increasing tendency towards day case surgery in the investigation of
menorrhagia or other abnormal vaginal bleeding. These figures suggest that for the
younger age group of women, no invasive procedure, whether under general or local
anaesthetic, is necessary as a first line investigation. Where hysteroscopy and biopsy
are required, an out patient approach should be considered, using local anaesthetic
techniques to improve hysteroscopic access to the uterine cavity if required since blind
out patient biopsy techniques may not adequately sample the endometrium of women
at increased risk of hyperplasia or malignancy.
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Patient group Successful hysteroscopy Successful endometrial
biopsy ;
Previous vaginal delivery 231 / 283 (82%) a 331/341 (97%) b
Nulliparous 12 / 25 (48%) a 25 / 29 (86%) b
Previous Caesarean section 17/24(71%) 27 / 29 (93%)
Previous cervical surgery 3 / 7 (43%) 7/12 (58%) c
No previous cervical
surgery
257 / 325 (79%) 375 / 388 (97%) c
Post menopausal status 29 / 50 (58%) d 62 / 66 (94%)
Pre menopausal status 184 / 219 (84%) d 247 / 253 (98%)
Trainee hysteroscopist 71/98(72%) 108/ 116(93%)
Experienced hysteroscopist 187 / 230 (81%) 270 / 276 (98%)
Table 2.1. Success in accessing the uterine cavity.
Factors influencing success in accessing the uterine cavity for hysteroscopy and
endometrial biopsy in the different groups. The results are shown as number of
patients and the percentage of patients in which hysteroscopy was successfully










135 (73%) a>b 7 (24%) a 16 (50%) b
Uterine fibroids 24(13%) 1 (3%) 6(19%)
Endometrial polyp 14 (7.5%) 2 (7%) 3 (9%)
Endocervical polyp 2(1%) 3 (10%) 0
Atrophic endometrium 3 (2%) c>d 15 (51%) c 7 (22%) d
Menstrual endometrium 1 (0.5%) 0 0
Endometrial hyperplasia 0 1 (3%) 1 (3%)
Endometrial
adenocarcinoma
0 1 (3%) 0 ;
Other* 8 (4%) 0 1 (3%)
*Other includes three patients with an IUCD, one with a subseptate uterus, one with
adenomyosis, one with a sterile pyometra and two patients in whom the view obtained
was inadequate to comment.
Table 2.2. Hysteroscopic appearances.
Hysteroscopic appearance of each of the three main referral groups.
PMB=postmenopausal bleeding, HRT= heavy or unscheduled bleeding on hormone
replacement therapy. The results are shown as number of patients and the percentage
of patients in that referral group. Statistical significance (x2 test) is as follows: a'b>c>d
p<0.05. Some patients had more than one intrauterine pathology noted.
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71 (76%) 23 (24%)
Irregular menstrual cycle
(n=91)






89 (77%) 26 (23%)
Age under 40 years
(n=46)
38 (83%) 8(17%)
Age 40 years or over
(n=139)
97 (70%) 42 (30%)
Table 2.3. Patient characteristics.
The presence of intrauterine pathology according to cycle regularity, presence of
intermenstrual bleeding and patient age. The results are shown as number of patients
and the percentage of patients in that group. There was no statistically significant
difference in the presence of intra-uterine pathology between groups.
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189 (76%) a-b 4 (6%) a-c 30 (52%) b>c
Simple hyperplasia 8 (3%) 1 (2%) 5 (9%)
Atypical hyperplasia 1 (0.5%) 3 (5%) 0
Endometrial adenocarcinoma 0 2 (3%) 0
Atrophic endometrium 2(l%)d 10 (16%) d 7(12%)
Menstrual endometrium 17(7%) 0 2 (3%)
Endometrial polyp 6 (2%) 0 1 (2%)
Exogenous hormone effects 11 (4%) 0 1 (2%)
Endometrial metaplasia 1 (0.5%) 0 0
Insufficient / no sample 14(6%) e-8 42 (68%) f.g 12 (20%) e'r
Table 2.4. Endometrial histology.
Endometrial histology obtained in each of the three main referral groups.
PMB=postmenopausal bleeding, HRT=heavy or unscheduled bleeding on hormone
replacement therapy. Percentage figures show the proportion of cases within the
referral group. Statistical significance (x2 test) is as follows: a>b>c,d,e,l p<o.05. Some
patients had more than one type of histology noted.
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ChapterThree
Randomised Comparative Study of the Levonorgestrel Intrauterine
System and Norethisterone for the Treatment of Idiopathic Menorrhagia.
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This study was designed to compare the effectiveness of the levonorgestrel
intrauterine system (LNG IUS) with norethisterone for the treatment of idiopathic
menorrhagia. The norethisterone regimen chosen was not the dose recommended in
the British National Formulary, but an increased dose and duration of administration
which has been demonstrated to be effective in one small study (Fraser, 1990).
Subjects and Methods
The study was a randomised comparative parallel group study with patients acting as
their own controls in a pre-treatment cycle. For the study to have an 80% power to
detect a difference of 45ml between treatments, it was calculated that 22 patients would
be required for each treatment arm.
Women complaining of heavy regular periods were recruited into the study from
gynaecology outpatient clinics. The study was granted ethical approval from the
relevant local ethics committees and patients received a full verbal and written
explanation of the study. Entry criteria are shown in table 3.1. Patients were excluded
from the study if they had been treated with steroid hormones or anticoagulation agents
during the previous three months, or had used injectable hormones for contraception
during the previous 12 months.
Patients were asked to collect their menstrual loss over one cycle. The importance of a
complete collection was emphasised and verbal and written instructions were given on
how to achieve this. Patients were issued with menstrual diaries to complete
prospectively, documenting bleeding patterns and menstrual pain during the study.
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The degree of menstrual blood loss (MBL) was measured objectively using the
alkaline haematin method (Hallberg and Nilsson, 1964) as described in chapter one.
The type of sanitary protection used was assessed to make allowances for colour
changes caused by dyes in the pads.
Patients with a menstrual blood loss in excess of 80ml proceeded to randomisation by
computer generated numbers, the results being sealed in opaque, consecutively
numbered envelopes which were opened at the entry visit. The levonorgestrel
intrauterine system (Mirena®: Leiras Oy, Turk, Finland) was fitted into the uterus
within seven days of the onset of menses. Norethisterone tablets were prescribed at a
dose of 5mg three times daily from day 5 to 26 of the cycle over three cycles. A
symptom questionnaire was completed and blood was taken to measure haemoglobin
and serum ferritin concentrations. Patients were asked to collect their menstrual loss
after their first and third treatment cycles. They were reviewed at these times to
complete a symptom questionnaire. At the third cycle visit, or at premature
termination, haemoglobin and ferritin concentrations were measured again, patients'
satisfaction with their treatment was assessed and patients were given the option of
continuing with the treatment.
StatisticalAnalysis
Statistical analyses were carried out both on the per protocol and the intention-to-treat
populations. The non-parametric Wilcoxon rank sum test was used to compare the
differences between the treatment groups for the primary and secondary outcome
measures. If the data were normally distributed the two-sample t-test was used. The
time effect within the treatment group was tested by Friedman's two-way ANOVA or
by Wilcoxon signed rank test (paired t-test for normally distributed data). Side-effects
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were tested with the CATMOD for categorical repeated measures. Calculations were
made using SAS® (version 6.07, SAS Institute Inc., Cary, NC, USA).
Results
One hundred and fifty one patients with a complaint of heavy regular menses were
referred by their general practitioner and were asked to collect for an objective
measurement of their menstrual blood loss. Of these, 89 completed a collection.
Forty eight (54%) had losses within the menorrhagic range (> 80ml), and of these, 44
were willing to proceed to randomisation (figure 3.1).
The characteristics of the 44 patients enrolled in the randomised study are as shown in
table3.2. There was no significant difference between the two groups at baseline.
Of the 44 patients entered in the study, eight withdrew before the end of the three
month follow up period, three because of unacceptable drug-related side effects (two
in the norethisterone group), two because of perceived treatment failure (both in the
norethisterone group), one because of prolonged amenorrhoea (norethisterone group)
and one for undefined personal reasons (norethisterone group) (figure 3.1). One
patient expelled the levonorgestrel system in the third cycle of treatment. In addition,
two patients did not make a final collection of their menstrual loss (both in the
norethisterone group). There were no serious adverse events related to either
medication.
Table 3.3 shows the effects of treatment on menstrual blood loss. Menstrual blood
loss was significantly reduced following treatment compared with baseline for both the
levonorgestrel group (p<0.0001) and the norethisterone group (p<0.0001). There
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was no difference between the median menstrual blood loss between treatment groups
at baseline, but there was a difference between treatment groups at one month and
three months (p<0.05). Median menstrual blood loss was reduced to normal in both
groups (< 80ml) by the first cycle of treatment.
Individual blood loss changes and individual percentage changes in menstrual blood
loss after three months treatment are shown in figure 3.4. Intention-to-treat analysis
showed that the levonorgestrel intrauterine device reduced menstrual blood loss by
94% when menstrual blood loss at three months was expressed as a percentage of the
control (median reduction 104ml, range -108 to 733ml). When the patient who did not
retain the levonorgestrel intrauterine system was excluded from analysis, the group
still showed a 94% reduction in menstrual blood loss (median reduction 103ml, range
70 to 733ml). Oral norethisterone reduced menstrual blood loss by 87% (median
reduction 94ml, range 56 to 212ml). Six out of nineteen (32%) of patients in the
levonorgestrel intrauterine system group and no patients in the norethisterone group
were amenorrhoeic following three cycles of treatment.
Haematologicalparameters
Ten patients (seven in the LNG group and three in the norethisterone group) who
received prophylactic iron treatment during the course of the study were excluded from
the assessment of haemoglobin and ferritin concentrations. At baseline, median
haemoglobin concentrations were 12.8g/dl (range 11.7-13.8g/dl) in the levonorgestrel
group and 13. lg/dl (range 11.1-15.5g/dl) in the norethisterone group. Median ferritin
concentrations were 19 ng/1 (range 4-49ng/l) in the levonorgestrel group, and 14ng/l
(range <1-53/1) in the norethisterone group. There was no significant difference in
median haemoglobin or ferritin concentrations between treatment groups at baseline.
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Following treatment median haemoglobin and ferritin concentrations did not change
significantly in either group.
Side effects
Symptoms of intermenstrual bleeding had been reported by 11/22 of the levonorgestrel
group and 8/22 of the norethisterone group at baseline, with no significant difference
between groups. Following three cycles of treatment as per protocol, 10/19 of the
levonorgestrel intrauterine system group reported experiencing intermenstrual bleeding
compared with only 2/12 of the norethisterone group. This represents a significant
difference in favour of norethisterone (p=0.005). Of the 11 patients reporting
intermenstrual bleeding prior to treatmentwith levonorgestrel, five continued to report
this symptom following three cycles of treatment. Of the eight patients reporting
intermenstrual bleeding prior to treatment with norethisterone, none reported this
symptom following three cycles of treatment.
Of the 36 patients who completed treatment, full menstrual diaries were returned by 29
(15 in the levonorgestrel group and 14 in the norethisterone group). There was no
significant difference in the median number of days on which mild or moderate-to-
severe pain were experienced between treatment groups at three months. When asked
about subjective symptoms (headaches, acne, abdominal or back pain, nausea,
oedema, weight gain, decreased libido, sweating, hair loss or greasy hair, and increase
in body hair), there was no difference in the occurrence of such symptoms between
baseline and three months of treatment in either group, and no difference in the
occurrence of such symptoms between the norethisterone- and levonorgestrel-treated
groups. A small but significant (p<0.05) measured weight gain was observed in both
groups, 0.6 kg in the norethisterone group and 1.1 kg in the levonorgestrel group, but
this was not perceived by the patients. There was a significant decrease in the reported
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incidence of mood swings (p<0.05) in both groups from baseline to cycle three, but
no difference in the incidence between norethisterone- and levonorgestrel-treated
groups. There was a significant decrease in the reported incidence of breast tenderness
(p<0.0005) in both groups from baseline to cycle three, with patients receiving
levonorgestrel more likely to be reporting this symptom at three months of treatment
(pcO.OOl) than patients receiving norethisterone. In both groups menstruation
interfered with the patients' daily life less after three cycles of treatment than at baseline
(p=0.001).
Patientsatisfaction
In the levonorgestrel group, 14/22 (64%) women said they liked the treatment 'well or
'very well' and 17/22 (77%) elected to continue with the treatment at the end of the
three months study. In the norethisterone group, 8/18 (44%) reported that they liked




This study has demonstrated that both the levonorgestrel intrauterine system, and oral
norethisterone at a dose of 5mg three times daily for 21 days of the cycle were highly
effective in reducing menstrual blood loss at three months of use (94% and 87% mean
reductions in menstrual blood loss respectively). Menstrual blood loss was within
normal limits (<80ml) after one month in all patients receiving treatment with the
levonorgestrel intrauterine system, and by the end of three months in all but one patient
receiving norethisterone. Intermenstrual bleeding was more commonly reported in the
levonorgestrel intrauterine system group than in the norethisterone group. Despite this
more patients wished to continue with treatment in the levonorgestrel intrauterine
system group than the norethisterone group, suggesting that the benefits of reduced
menstrual blood loss outweighed the inconvenience of intermenstrual bleeding. Other
studies have demonstrated that intermenstrual bleeding decreases with prolonged use
of the levonorgestrel intrauterine system (Luukkainen, 1991).
The reductions in menstrual blood loss achieved in this study compare favourably to
other studies using first line treatments such as tranexamic acid (Preston et al, 1995;
Bonnar and Sheppard, 1996), prostaglandin synthetase inhibitors (Anderson et al,
1976) and the combined oral contraceptive pill (Nilsson and Rybo, 1970), and also to
studies using treatments generally considered as short-term options because of side
effects such as danazol (Chimbira et al, 1979) and gonadotrophin-releasing hormone
analogue (Thomas et al. 1991). The reduction in menstrual blood loss achieved with
norethisterone was particularly impressive when compared with previous studies using
the drug at different doses and for different durations. Norethisterone is most
commonly prescribed for 6 to 10 days in the late luteal phase of the cycle. Such a
regimen is effective in regulating an irregular cycle, leading to a predictable withdrawal
bleed, but is ineffective for the treatment of ovulatory dysfunctional uterine bleeding.
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One report showed a non-significant reduction in menstrual blood loss in six women
with objectively proven menorrhagia (Cameron et al, 1987). Another study showed a
20% decrease in menstrual blood loss, but two thirds of patients still had menstrual
blood losses in excess of 80ml at the end of treatment (Cameron et al, 1990), while a
more recent study demonstrated a 20% increase in menstrual blood loss following
treatment with norethisterone (Preston et al, 1995). Such disappointing results have
led to suggestions that norethisterone has little or no effect in reducing ovulatory
dysfunctional uterine bleeding (Bonnar and Sheppard, 1996). When the dosage and
duration of treatment were increased, reductions in menstrual blood loss were
improved in a study using norethisterone or medroxyprogesterone acetate from day 5
to 26 in ten women with ovulatory menorrhagia, resulting in a 37% reduction in
menstrual blood loss following two cycles of treatment (Fraser, 1990). The present
study has shown that, given in high enough doses from early in the cycle,
norethisterone is effective at reducing menstrual blood loss, with only one patient still
having losses in excess of 80ml after three months treatment. In addition, this regimen
has led to a significant reduction in symptoms of intermenstrual bleeding.
The complaint of heavy periods is subjective and this study supports previous
observations that half of women who complain of heavy periods have menstrual blood
losses within the normal range (Cameron et al, 1990). This has implications for over-
treatment, particularly for surgical over-treatment since many perceived 'treatment
failures' of medical therapy may represent women whose losses are within the normal
range. These women may ultimately seek a permanent surgical cure for their
menstrual upset, with the associated morbidity risks.
Both the levonorgestrel intrauterine system and oral norethisterone in this regimen
offer an efficacy comparable to the best medical treatment currently available. The
levonorgestrel intrauterine system in particular offers a reliable treatment which makes
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menstrual blood loss normal in all patients and is well tolerated, with over three
quarters of patients wishing to continue with the treatment long term. It has the added
advantage of a low incidence of systemic side effects and other studies have
demonstrated that it offers highly effective contraceptive cover (Andersson et al,
1994), which is quickly reversible on removal (Andersson et al, 1992). Once fitted,
the system frees the patient from the need to take oral medication and it therefore offers
an alternative to surgery which until now has been the only real option for long term
treatment.
Conclusions
Both the levonorgestrel intrauterine system and oral norethisterone offer an effective
treatment for menorrhagia, but if norethisterone is to be prescribed for women with
ovulatory menorrhagia it should be given at a dose of 5mg three times daily from day 5
to 26 of the cycle. The levonorgestrel intrauterine system is associated with higher
rates of patient satisfaction and continuation with treatment long-term and offers an
alternative to both existing medical and surgical treatments for menorrhagia.
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Inclusion Criteria
• Parous women aged between 18 and 45 years in good general health with a regular
menstrual cycle.
• Normal pelvic examination with a sound measurement of the uterus less than 10
cm and negative cervical cytology.
• Measured menstrual blood loss in excess of 80 ml.
• Willingness to accept randomisation to either levonorgestrel intrauterine system or
oral norethisterone.
Table 3.1. Entry criteria.
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Figure 3.1. Flow chart showing patient progress through the study. * patient
withdrew because of intermenstrual bleeding. ** one patient withdrew because of




Age (years) 38.5 (31-45) 39 (30-45)
Height (cm) 158.5 (152-170) 159.5 (147-178)
Weight (kg) 69.9 (52.1-116.0) 71.4 (46.4-96.6)
BP systolic (mm Hg) 121 (100-155) 119(100-150)
diastolic (mm Hg) 80 (65-95) 79(64-108)
Parity 2(1-5) 2(1-5)
MBL pre treatment (ml) 105 (82-780) 120 (82-336)
Table 3.2. Characteristics of the 44 women enrolled to the study. Data are presented




Median (range) 105 (82-780) 120 (82-336)
1st treatmentcvcle (ml)
Median (range) 16a (0-62); 46a (0-213);
Mean difference (ml) 149 64
95% confidence intervals (ml) -159 to 458 -85 to 214
3rd treatment cvcle (ml)
Median (range) 6b (0-284); 20b (4-137);
Mean difference (ml) 133 108
95% confidence intervals (ml) -163 to 429 13 to 203
Table 3.3. Menstrual blood loss measurements in the two groups of women in control
and treatment cycles, analysed in the intention to treat population. a> b p<0.05. LNG




Figure 3.4. Individual blood loss reductions for norethisterone and LNG IUS. The
upper two figures show the menstrual blood loss before and after three cycles of
treatment. The lower two figures show percentage change in MBL in cycle three




Epithelial Cell Morphometry, Scanning Electron Microscopy Assessment,
and a2 laminin and Dolichos Biflorus Immunohistochemistry of the
Endometrium of Patients with Proven Menorrhagia, Before and After
Treatment with Exogenous Progestagens
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The endometrium undergoes profound structural changes during the normal menstrual
cycle and following exposure to exogenous progestagens (chapter one). High dose
exogenous progestagens have been demonstrated to reduce menstrual blood loss
(chapter three). This chapter investigates some of the changes occurring in the
endometrium of patients with proven menorrhagia in response to systemic
norethisterone and intrauterine levonorgestrel and examines four aspects, changes in
epithelial cell height, epithelial surface morphology, epithelial secretory activity and
stromal decidualisation.
Epithelial cell height was assessed by morphometry measurements (part one).
Epithelial surface morphometry was assessed by scanning electron microscopy (part
two).
Epithelial secretory activity was assessed using Dolichos biflorus agglutinin
immunohistochemistry (part three).
Stromal decidualisation was assessed using a2 laminin immunohistochemistry (part
four).
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Part One. Endometrial Epithelial Cell Morphometry in the Endometrium of Patients
with Proven Menorrhagia, Before and After Treatment with Oral and Intrauterine
Progestagens
Materials and Methods
Collection of endometrial biopsies
Endometrial tissue was obtained from 23 healthy parous women taking part in the
clinical trial described in chapter three. The tissue was collected using a Z-sampler
(ZS1, Chatsworth, USA.) in the mid luteal phase of the cycle (median day 21, range
day 16-25), was snap-frozen in liquid nitrogen and stored at -70°C until required. The
timing of biopsy collection is shown in table 4.1.
Twelve women received intrauterine progestagens via a levonorgestrel intrauterine
system (LNG 1US) releasing 20 pg levonorgestrel in 24 hours (Mirena®: Leiras Oy,
Turku, Finland), fitted within seven days of the onset of menses. Eleven women
received oral progestagens in the form of norethisterone 5mg three times daily from
day 5-26 of their cycle.
A second endometrial biopsy was taken in the mid-luteal phase of the first treatment
cycle and was snap-frozen and stored as before. The median exposure time of the
tissue to intrauterine levonorgestrel was 18 days (range 14-22 days), and to oral
norethisterone was 18 days (range 14-20 days). The timing of biopsy collection is
shown in table 4.1.
106
10pm cryostat sections of tissue were cut, mounted onto 3-aminopropyltriethoxy-
silane coated slides (Sigma, Poole, UK) and air dried. Tissue sections were stained
with Harris's haemotoxylin (Sigma, UK) and eosin (BDH, Glasgow, UK),
dehydrated in a graduated ethanol-xylene series (70%, 90%, 100% ethanol, xylene
twice) and mounted in DPX-mounting medium (BDH, UK).
Morphometric analysis of cell height was carried out on endometrial glandular and
surface epithelial cells by one observer. Nine arbitrarily chosen sites were measured in
areas of biopsy with good epithelial preservation and no stromal disruption, and the
median calculated. A bright light field microscope (Orthoplan, Leitz: Leica Ltd.,
Milton Keynes, UK) with objectives x 63 and wide-angle eyepiece x 12.5 was used
with an eyepiece graticule (Leica Ltd., UK). Perpendicular measurements of cell
height were made from the apical surface to the basement membrane of the cell (figures
4.1 and 4.2). All measurements were made by one observer.
Statistical analysis
An unpaired t-test was used to compare exposure time to treatment in the two groups,
and epithelial cell height pre- and post-treatment in the two groups. A Wilcoxon
signed rank test was used to compare measurements following treatment in the two
groups.
Results
There was no significant difference in exposure time of the tissue to treatment in the
two groups.
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One patient who had been randomised to receive levonorgestrel was noted to have a
proliferative pattern of endometrium in her pre-treatment biopsy. This was assumed to
be secondary to anovulation and epithelial cell height measurements were omitted from
analysis. Because of tissue disruption, measurements of glandular epithelial cell height
were not possible in a further two pre-treatment biopsies and in three post treatment
biopsies (one LNG IUS, two norethisterone). Likewise, measurements of surface
epithelial cell height were not made in two pre-treatment biopsies and in nine post
treatment biopsies (five LNG 1US, four norethisterone).
There was no correlation between glandular or surface epithelial cell height and the
timing of the pre-treatment endometrial biopsy (coefficient of correlation 0.16 and 0.10
respectively).
Epithelial cell height measurements are summarised in tables 4.2 and 4.3. There was
no difference in glandular (p=0.266) and surface (p=0.894) epithelial cell height
between the two groups before treatment. There was no difference in glandular
(p=0.294) and surface (p=0.054) epithelial cell height between the two groups
following treatment.
Following treatment with levonorgestrel, there was a significant reduction in both
glandular (p<0.001) and surface (pcO.Ol) epithelial cell height.
Following treatment with norethisterone, there was a significant reduction in both
glandular (pcO.OOl) and surface (p<0.05) epithelial cell height.
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Figure 4.1. Photomicrograph of haemotoxylin and eosin staining in a pre-treatment
biopsy taken of day 24 of the cycle. Two glands (G) can be seen amid stromal cells
(S). A perpendicular measurement of epithelial cell height is taken from the apical
surface to the basement membrane as shown. Scale bar represents 50/zm.
Figure 4.2. Photomicrograph of haemotoxylin and eosin staining in a post-treatment
biopsy taken after 18 days exposure to norethisterone. Three glands (G) can be seen
amid stromal cells (S). In contrast to figure 4.1, the glands are lined with a more
cuboidal epithelium and the perpendicular measurement of epithelial cell height is much
reduced. Scale bar represents 50/*m.
Figure 4.1.
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day 15 - 13 -
day 16 X 14 XX
day 17 X 15 XX
day 18 X 16 XX
day 19 XXX 17 xxxx
day 20 X 18 xxxx
day 21 xxxxx 19 XX
day 22 xxxx 20 xxxx
day 23 XXX 21 XX
day 24 XX 22 X
day 25 XX 23 -
day 26 - 24 -
Total 23 Total 23
Pre-treatment biopsies Treatment biopsies
Table 4.1. Timing of endometrial biopsies in pre-treatment and treatment cycles. Pre-
treatment biopsies are expressed as number of days from last menstrual period.
Treatment biopsies are expressed as number of days exposure to exogenous
progestagens. x=one patient.
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1 31 (27-33) 15(12-16) 23 (19-25) 16(15-17)
2 35 (31-39) 16(12-17) 23 (21-29) 16(14-19)
3 P.M 19(17-21) 14(13-15) P.M
4 33 (29-35) P.M 23 (21-29) P.M
5 29 (25-35) 16(14-17) 27 (25-27) 12(10-14)
6 Prolif 17(12-21) Prolif 12(10-15)
7 31 (29-33) 14(8-16) 29 (23-29) 19(19-21)
8 27(23-31) 16(16-19) 31 (29-33) P.M
9 31 (29-33) 27 (27-29) 23 (19-25) 17(17-19)
10 33 (33-37) 16(16-17) 29 (27-29) P.M
11 27 (23-29) 25 (23-27) 14(7-17) P.M
12 27 (25-33) 19(17-21) 29 (25-29) 19(17-21)
Table 4.2. Epithelial cell height measurements pre- and post treatment with the
levonorgestrel intrauterine system, expressed as median (range). Prolif = proliferative
phase endometrium suggestive of anovulatory cycle. P.M = poor morphology. There
is a marked difference in median cell height measurements pre- and post-treatment,
with little overlap of the ranges.
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1 31 (29-37) 19(16-21) 21 (17-21) 17(15-19)
2 31 (29-35) 13 (12-13) 19(17-21) P.M
3 25 (21-27) 19(19-21) 33 (29-35) P.M j
4 37 (31-41) 19(15-19) 33 (33-39) 25(21-25)
5 35 (31-37) 16(13-17) 29 (27-31) 12(9-13)
6 25 (25-31) 21 (19-21) 23 (21-25) 19(17-23) j
7 17(15-21) P.M 14(13-16) P.M
8 16(10-19) 14(12-16) 16(14-21) 14(12-14)
9 P.M P.M P.M P.M
10 39 (35-41) 17(16-21) P.M 19(16-19)
11 16(13-17) 17(14-19) 17(13-27) 14(12-19) :
Table 4.3. Epithelial cell height measurements pre- and post treatment with
norethisterone, expressed as median (range). P.M = poor morphology. In contrast to
the levonorgestrel-treated group there is a less marked difference in median cell height
measurements pre- and post-treatment, particularly with regard to surface epithelial cell
height, and the ranges are not so distinctly separate.
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Part Two. A Scanning Electron Microscopy Assessment of Endometrial Surface
Epithelium of Patients with Proven Menorrhagia, Before and After Treatment with Oral
and Intrauterine Progestagens.
Materials and Methods
Collection of endometrial biopsies
Seventeen endometrial biopsies were obtained from 15 healthy parous women with
proven menorrhagia taking part in the clinical trial described in chapter three. The
tissue was collected as described in part one of this chapter in the mid luteal phase of a
control cycle (median day 21, range day 19-24) (n=8), and in the mid-luteal phase of
the first cycle of treatment with either oral norethisterone (n=3) or with intrauterine
levonorgestrel (n- 6). Two patients had both a control and a treatment biopsy taken.
The median exposure time of the endometrium to the treatment was 16 days in the
norethisterone group (range 15-20 days) and 20 days in the levonorgestrel group
(range 14-21 days).
The samples were rinsed briefly in 0.9% saline solution, fixed in gluteraldehyde 2.5%
in cacodylate buffer 0.1M for at least 24 hours and then were processed according to
the scanning electron microscopy protocol of the Tennent Institute of Opthalmology,
Western Infirmary, Glasgow. Briefly the tissue was rinsed four times in cacodylate
buffer (BDH, UK) over 60 minutes at room temperature, fixed in 1% osmium
tetroxide (Oxkem Ltd., Holton, UK) for 60 minutes, rinsed again four times in
cacodylate buffer over 60 minutes and dehydrated in a graduated ethanol series ( 25%,
50%, 75%, 100% x four), each step in the series taking 15 minutes. The samples
were then subjected to critical point drying with carbon dioxide followed by sputter
coating with gold in a high-vacuum evaporator to achieve a coating thickness of 4 nm.
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The specimens were stored in a dessicator containing silica gel until required. The
microscope used was a JSM 6400 scanning electron microscope (JEOL, Tokyo,
Japan) and a blind assessment of the specimens was made by one observer. The
specimens were studied at different angles and tilts at an accelerating voltage of 10 kV.
Photographs were taken using Kodak TMAX 100 film 120 format or Ilford FP4 plus,
120 format.
Preliminary studies on random endometrial biopsies showed that the processing
resulted in 'worms' of tissue 10-20mm long and l-2mm diameter. Much of the
external surface of some specimens consisted of interlocking fibres with occasional
enmeshed red blood cells, presumably a reflection of tissue disruption during the
sampling. Detailed surface anatomy could be visualised in gaps in this fibrin network.
To expose the internal detail, the specimens were mechanically disrupted by gentle
pressure after critical point drying but before gold sputter coating.
Results
Control biopsies
The surface epithelium was slightly folded and interrupted only by the openings of the
endometrial glands at distances of approximately 150jJ.m from each other (figure 4.3).
At higher magnifications (figures 4.4), the surface epithelium was observed to consist
of polygonal cells of about 2.5jo.m diameter, some bearing dense tufts of microvilli on
their apical surface, others with cilia projecting from the surface.
Treatment biopsies
While most biopsies exhibited the features described below, others were of a more
heterogeneous appearance. Within the same sample, some areas were similar to that
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seen in the control biopsies, with cilia and microvilli on the apical surface of the cells,
but other areas of the same biopsy showed the features described below.
1. Defective ciliagenesis.
Cilia were absent and the tufts of microvilli appeared shorter and sparser. This was a
consistent finding in all the levonorgestrel-treated biopsies and in all but one of the
norethisterone-treated biopsies (figures 4.5 and 4.6).
2. Collapsed cells.
In some of the post treatment biopsies, the apical surface of the cells had a collapsed
appearance (figure 4.7). This feature was associated with the levonorgestrel-treated
biopsies.
3. Flattened cobblestone epithelium.
The surface epithelium was devoid of any features with the cell margins showing
clearly (figures 4.8, 4.9 and 4.10) . This feature was more pronounced with the
levonorgestrel-treated biopsies.
On the basis of these three features, the control biopsies and the post-treatment
biopsies could be differentiated with a sensitivity of 0.84, specificity of 0.96 and
positive predictive value of 0.91.
On the basis of the appearances of collapsed cells and a pronounced cobblestone
epithelial pattern, the levonorgestrel-treated biopsies could be differentiated from the
norethisterone-treated biopsies with a sensitivity of 0.76, specificity of 0.83 and a
positive predictive value of 0.91.
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Figure 4.3 (xlOOO). Control biopsy.
View over surface epithelium between two gland openings at day 19. The ciliated (C)
and microvillous (V) cells typical of this stage of the cycle are visible. Scale bar
represents lOjxm.
Figure 4.4 (x6000). Control biopsy.
Same specimen at higher magnification showing the two different apical cell
appearances. Two ciliated cells (C) can be seen amid the microvilli (V) cells. Scale
bar represents lptm.
 
Figure 4.5 (x950). Norethisterone-treated biopsy.
Genera] view over the surface epithelium following 16 days exposure to
norethisterone. The opening of the gland (G) is visible on the left. In contrast to the
control biopsies, fewer ciliated cells are apparent and the cilia are less well defined.
Scale bar represents 10pm.
Figure 4.6 (x2200). Norethisterone-treated biopsy.
Same specimen at higher magnification showing the surface epithelium between two




Figure 4.7 (x600). Levonorgestrel-treated biopsy.
General view over the surface epithelium following 19 days exposure to
levonorgestrel. To the right is an area disrupted by the sampling and covered by a
mesh of fibrin (F). The opening of a gland (G) can be seen at the bottom of the
picture, with a second at the top left of the picture. The epithelium between the glands
shows a gradation between an area of defective ciliagenesis (D) to an area with a
flattened cobblestone (C) appearance to the epithelium. Scale bar represents 10pm.
Figure 4.8 (x2200). Levonorgestrel-treated biopsy.
Surface epithelium between two glands following 20 days exposure to levonorgestrel,
showing an absence of ciliated cells and a sparse microvillous pattern. The cells are
variable in size and have a collapsed appearance. Scale bar represents 10pm.
Figure 4.8.
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Figure 4.9 (x330). Levonorgestrel-treated biopsy.
General view of the surface epithelium following 21 days exposure to levonorgestrel.
Cilia are almost absent, microvilli are markedly reduced and the cell margins can be
seen, giving a flattened cobblestone appearance to the epithelium. A gland opening
(G) can be seen to the left of the picture. Scale bar represents 100pm
Figure 4.10 (xl800). Levonorgestrel-treated biopsy.
Different area of the same specimen at a higher magnification, demonstrating the
variability in surface topography after treatment with levonorgestrel. The surface
epithelium is devoid of surface features and demonstrates a flattened cobblestone
appearance with prominent epithelial cell margins (M). A red blood cell (RBC) is seen




Part Three. Dolichos Biflorus Agglutinin (DBA) Histochemistry of the Endometrium
of Patients with Proven Menorrhagia, Before and After Treatment with Oral and
Intrauterine Progestagens.
Materials and Methods
Collection of endometrial biopsies
Endometrial tissue was obtained from 18 healthy parous women with proven
menorrhagia taking part in the clinical trial described in chapter three. The tissue was
collected as described in part one of this chapter in the mid luteal phase of the cycle
(median day 21, range day 15-26 days). The timing of biopsy collection is shown in
table 4.4.
Eleven women received intrauterine levonorgestrel via a LNG IUS. Seven women
received oral norethisterone. A second endometrial biopsy was taken in the mid-luteal
phase of the first treatment cycle. The median exposure time of the tissue to
intrauterine levonorgestrel was 19 days (range 15-24 days) and to oral norethisterone
was 18 days (range 13-19 days). The timing of biopsy collection is shown in table
4.4.
10 pm cryostat sections of tissue were cut, mounted onto 3-aminopropyltriethoxy-
silane coated slides (Sigma, UK) and air dried. Sections were fixed in acetone (BDH,
UK) for ten minutes, then incubated in 0.5% hydrogen peroxide (Sigma, UK) in
methanol (BDH, UK) for 30 minutes at room temperature to inactivate endogenous
peroxidase and washed twice for five minutes in phosphate buffered saline (PBS)
containing lOmM sodium phosphate, 120 mM sodium chloride (pH 7.5). Sections
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were than incubated for 45 minutes at room temperature in a 10 pg / ml solution of
DBA-biotin (Vector Laboratories, Peterbrough, UK) diluted in PBS + 3% bovine
serum albumin. Afterfurther rinsing in PBS for five minutes, sections were incubated
for 30 minutes at room temperature with a commercially available avidin / biotin /
peroxidase complex (Vectastain Elite ABC reagent: Vector Laboratories, UK), rinsed
again in PBS for five minutes and DBA binding was localised using 1 mg / ml
diaminobenzidine tetrahydrochloride (Sigma, UK) and 0.02% hydrogen peroxide in
50mM Tris CI, pH7.6. Sections were washed in tap water to stop the reaction,
carefully wiped dry and mounted in Immu-mount medium (Shandon, Pittsburgh,
USA).
Negative control sections were treated in an identical fashion without DBA-biotin
solution in PBS + 3% BSA.
Sections were examined and photographed using the appropriate condenser and a
conventional bright light field microscope (Orthoplan, Leitz: Leica Ltd., UK).
Staining was assessed independently by two observers and graded subjectively
according to the extent of staining within individual epithelial cells and the number of
cells stained within the glands or surface epithelium.
Statistical analysis




There was no significant difference in the exposure time of the tissue to treatment in the
two groups.
In general there was an unexpectedly high level of background staining in all the
specimens examined, including the controls. Preliminary studies using paraffin
sections had not shown this degree of background staining.
Pre-treatmentbiopsies
DBA was expressed in glandular and luminal epithelium, although the pattern of
staining was heterogeneous, with some glands and areas of surface epithelium
showing little or no staining. The pattern of subcellular localisation was also
heterogeneous, with some cells showing staining confined to the apical surface, while
others exhibited staining within the cytoplasm as well. There was little or no staining
of secretions within the glandular lumen (figure 4.11).
Post-treatment biopsies
Following treatment with either levonorgestrel or norethisterone, there was a reduction
in epithelial cell height of both glands and surface epithelium, with columnar cells
showing a more cuboidal pattern (see part one). The pattern of staining was similar to
the pre-treatment biopsies, with heterogeneous expression of DBA between glands and
between cells within the glands (figure 4.12). In general the pattern of DBA staining
within glands was increased, with more cells within the gland exhibiting staining
throughout the cytoplasm. As with the pre-treatment biopsies, there was little or no
staining of secretions within the gland lumena. There was no obvious difference in the
pattern of DBA expression between the levonorgestrel- and norethisterone-treated
groups.
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Figure 4.11. Photomicrograph of DBA immunostaining of a pre-treatment biopsy
taken on day 21 of the cycle. Four glands (G) are seen, two with almost all glandular
epithelial cells exhibiting staining throughout the cytoplasm, one with a more
heterogeneous pattern of epithelial staining and one with negative staining. Scanty
luminal secretions are apparent (S). Scale bar represents 25/rm.
Figure 4.12. Photomicrograph of DBA immunostaining of a post-treatment biopsy
taken following 18 days exposure to norethisterone. The tissue is less well preserved
than the pre-treatment biopsy. Three glands (G) and an area of surface epithelium (S)
are seen, with a flattened epithelium compared with the pre-treatment biopsy.
Cytoplasmic staining is observed in all the cells within the glands and surface










day 15 - 13
day 16 X 14 \ \
day 17 15 X
day 18 \ 16 XX
day 19 XXX 17 XX
day 20 18 XX
day 21 WW 19 XX
day 22 XXX 20 xxxx
day 23 XX 21 XX
day 24 XX 22 X
day 25 XX 23 -
day 26 - 24 -
Total 18 Total 18
Pre-treatment biopsies Treatment biopsies
Table 4.4. Timing of endometrial biopsies in pre-treatment and treatment cycles. Pre-
treatment biopsies are expressed as number of days from last menstrual period.
Treatment biopsies are expressed as number of days exposure to exogenous
progestagens. x=one patient.
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Part Four, a 2 Laminin Immunocytochemistry in the Endometrium of Patients with
Proven Menorrhagia, Before and After Treatment with Oral and Intrauterine
Progestagens.
Materials and Methods
Collection of endometrial biopsies
Endometrial tissue was obtained from 19 healthy parous women with proven
menorrhagia taking part in the clinical trial in chapter three. The tissue was collected as
described in part one of this chapter in the mid luteal phase of the cycle (median day
21, range day 16-25). The timing of biopsy collectionis shown in table4.5.
Ten women received intrauterine levonorgestrel via a LNG IUS. Nine women
received oral norethisterone. A second endometrial biopsy was taken in the mid-luteal
phase of the first treatment cycle. The median exposure time of the tissue to
intrauterine levonorgestrel was 19 days (range 15-22 days) and to oral norethisterone
was 18 days (range 14-20 days). The timing of biopsy collection is shown in table
4.5.
10 pm cryostat sections of tissue were cut, mounted onto 3-aminopropyltriethoxy-
silane coated slides (Sigma, UK) and air dried. Tissue sections were fixed in acetone
for ten minutes at room temperature and washed for five minutes in phosphate buffered
saline (PBS) containing lOmM sodium phosphate, 120 mM sodium chloride (pH 7.5).
A commercially available kit, mouse Vectastain® Elite ABC Kit (Vector Laboratories,
UK) was used for the immunohistochemical staining. Sections were first incubated in
a humidified box with horse serum for 30 minutes at room temperature to remove any
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non-specific binding. The blocking buffer was blotted off and the sections were
incubated in a humidified box for one hour at room temperature with the primary
antibody, a monoclonal antibody raised in mouse against a2 laminin (Life
Technologies, Paisley, UK), diluted 1:900 with the blocking serum. This
concentration had been established by previous work to be the optimal dilution for this
type of tissue. The sections were rinsed twice in PBS for five minutes and the
secondary antibody of biotinylated anti-mouse, diluted 1:200 with blocking buffer and
1.5% human serum, was added from the Vectastain® kit (Vector Laboratories, UK).
The sections were incubated in a humidified box for 30 minutes at room temperature,
then rinsed twice in PBS for five minutes. Endogenous peroxidase activity was
removed by incubating the sections for 30 minutes at room temperature in 0.5%
hydrogen peroxide in methanol and the tissue was rinsed twice for ten minutes in PBS.
The sections were incubated for 30 minutes at room temperature with the Vectastain®
reagent containing a preformed avidin and biotinylated horseradish peroxidase
complex. The sections were rinsed twice in PBS for five minutes and a2 laminin
binding was localised using 1 mg / ml diaminobenzidine tetrahydrochloride (Sigma,
UK) and 0.02% hydrogen peroxide in 50mM Tris CI, pH7.6 until a brown end
product developed. Sections were rinsed in tap water to stop the reaction,
counterstained with 0.2% Toluidine Blue in 30% ethanol and mounted in DPX
mounting medium (BDH, UK).
Negative control sections were incubated without the primary antibody.
Sections were examined and photographed using the appropriate condenser and a
conventional bright light field microscope (Orthoplan, Leitz: Leica Ltd., UK).
Staining was assessed by two observers and graded subjectively according to the site
and extent of staining within the specimen.
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Statistical analysis
An unpaired t-test was used to compare exposure time of the tissue to treatment in the
two groups.
Results
There was no significant difference in exposure time to treatment in the two groups.
There was no ct2 laminin immunostaining in the negative control biopsies. Four
biopsies demonstrated poor morphological preservation and were excluded from
analysis. Two were pre-treatment and two post-treatment, one following
norethisterone, the other levonorgestrel administration.
Endometrial blood vessels expressed tx2 laminin in all biopsies examined. tx2 laminin
was expressed in the basement membrane of endometrial glands and surface epithelium
in some but not all biopsies (figure 4.13). There was no difference in basement
membrane tx2 laminin expression pre- and post-treatment. Expression of k.2 laminin
in the stromal compartment was not uniform in the pre-treatment biopsies, with eight
of the 17 biopsies examined exhibiting no stromal expression of ol2 laminin. In the
remaining nine biopsies, tx2 laminin expression was mainly confined to sub-epithelial
and peri-vascular areas. Following treatment, cx2 laminin expression was detected in
the stroma of all of the biopsies examined. In 11 of the 17 post-treatment biopsies
(seven levonorgestrel-treated, four norethisterone-treated), staining was no longer
restricted to sub-epithelial and peri-vascular stroma, but demonstrated a more
widespread distribution (figure 4.14). However even in these biopsies, the pattern of
stromal staining was not uniform throughout the stromal compartment.
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Figure 4.13. Photomicrograph of ct2 laminin immunostaining of a pre-treatment
biopsy taken on day 22 of the cycle. The section is counterstained with toluidine blue.
Several glands (G) are seen, with positive staining in the basement membrane.
Endometrial blood vessels (BV) are also stained positive for &2 iaminin. Scale bar
represents 1 OO/rm.
Figure 4.14. Photomicrograph of c£2 laminin immunostaining of a post-treatment
biopsy following 20 days exposure to intrauterine levonorgestrel. The section is
counterstained with toluidine blue. Beneath the surface epithelium (SE) is an area of












day 16 \ 14 \
day 17 X 15 X
day 18 X 16 XX
day 19 XXX 17 XXX
day 20 - 18 XXX
day 21 xxxx 19 XX
day 22 xxxx 20 xxxx
day 23 X 21 XX
day 24 XX 22 X
day 25 XX 23 -
day 26 - 24 -
Total 19 Total 19
Pre-treatment biopsies Treatment biopsies
Table 4.5. Timing of endometrial biopsies in pre-treatment and treatment cycles. Pre-
treatment biopsies are expressed as number of days from last menstrual period.




This chapter has demonstrated marked structural and functional changes occurring
within the glandular and stromal compartments of the endometrium within as little as
one cycle of treatment with exogenous progestagens. Glandular and surface epithelial
cell height was reduced and surface morphology was altered with a reduction in the
size and number of cilia and microvilli. Expression of Dolichos biflorus agglutinin
(DBA) was maintained following treatment, suggesting that epithelial cells retain their
secretory function despite the dramatic alterations to their morphology, but there was
little or no evidence of intraluminal secretions. Looking at the stromal compartment,
exogenous progestagens were associated with an increased expression of tx2 laminin.
Epithelial cell height is known to alter during the menstrual cycle (Johannisson et al,
1987; Li et al, 1988), decreasing during the luteal phase. No such correlation was
apparent between epithelial cell height and day of cycle for glandular (correlation
coefficient 0.16) or surface (correlation coefficient 0.10) epithelial cell height in the
pre-treatment biopsies in this study. One possible explanation for this is that the
biopsies were restricted to the mid luteal phase, with no reduction in epithelial cell
height apparent within this small window. Another explanation may lie with the timing
of the biopsies, which were timed from the first day of the last menstrual period, a
method known to be more inaccurate than timing from the day of the LH surge (Li et
al, 1988). The magnitude of the reduction in epithelial cell height seen following
treatment with both systemic norethisterone and intrauterine levonorgestrel was greater
than the variation in cell height measured prior to treatment, suggesting this was a real
effect of exogenous progestagens on epithelial cells.
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The scanning electron microscopy appearances of the pre-treatment biopsies were
similar to those reported in another study using hysterectomy specimens (Johannisson
and Nilsson, 1972), confirming the sampling technique used in this study to be a valid
method of collecting biopsies for study. Following as little as three weeks exposure to
exogenous progestagens, the surface morphology demonstrated defective ciliagenesis
and microvilli formation, both of which have been reported following exposure to
exogenous progestagens (Roberts etal, 1975; Ludwig, 1982) and in early pregnancy
(Johannisson and Nilsson, 1972). Taken to its extreme, these changes could result in
the flattened cobblestone epithelium noted in biopsies exposed to intrauterine
levonorgestrel. This may reflect the more potent progestagen, or the direct application
of the hormone to the surface endometrium, bringing about more pronounced changes
than systemic administration. The collapsed appearance of the apical surface of
epithelial cells has not been discussed in previous studies, although it is apparent in
one study examining the effects of exogenous progestagens on baboon endometrium
(Wilborn et al, 1983). The effect is unlikely to have been artefact since it was noted
only in the levonorgestrel-treated biopsies, and may represent a transition between the
state of defective ciliagenesis and the flattened cobblestone endometrium.
Epithelial cell secretory activity, as measured by DBA staining, was apparent in
glandular and surface epithelial cells in both pre-and post-treatment biopsies. The high
level of background staining noted in all the biopsies may have been a function of the
cryopreservation or tissue preparation, since it was not apparent in preliminary studies
using paraffin sections of endometrial tissue. Tissue preparation in the various lectin
binding studies has varied and can give rise to conflicting results (Aplin, 1991). All
the biopsies in this study were processed in the same way and the
immunohistochemistry was performed in a single batch, so comparisons before and
after treatment are valid.
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In all the biopsies studied there was a heterogeneous pattern of expression, with some
cells expressing DBA while neighbouring cells in the same gland did not.
Heterogeneity within and between glands is a consistent feature of the endometrium
revealed by lectin histochemistry (Aplin, 1991). This study examined endometrial
samples taken only in the mid-luteal phase and detected little or no change in the pattern
of DBA expression before and after treatment. This may suggest that DBA is already
maximally expressed in the mid-luteal phase and increasing the exposure of the
endometrium to progestagen does not increase expression. It is interesting to note that
intracellular DBA staining accumulated in post-treatment biopsies largely in the absence
of intraluminal secretions. High doses of exogenous progestagens seem thus to
interrupt the mobilisation and secretion of intracellular glycoproteins from endometrial
glandular cells.
Stromal expression of a.2 laminin was increased following exposure of the
endometrium to both norethisterone and levonorgestrel. This was particularly apparent
in biopsies from patients treated with intrauterine levonorgestrel, when tissue exposed
to intrauterine levonorgestrel for a median of only 19 days showed a very similar
pattern of a.2 laminin expression to that seen in first trimester pregnant decidual tissue
(Gaby Kohnen, personal communication).
One feature of endometrial exposure to exogenous progestagens in this study has been
the heterogeneous response of the different compartments. This was notable in the
surface morphology changes, and alterations in glandular DBA and stromal a2 laminin
expression, and was evident whether the steroid was administered locally or
systemically. This suggests that the effects of exogenous progestagens are mediated




Expression of Endothelial and Inducible Nitric Oxide Synthase in the
Endometrium of Patients with Proven Menorrhagia, Before and After
Treatment with Exogenous Progestagens.
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The role of nitric oxide (NO) in the pathophysiology of dysfunctional uterine bleeding
is unknown. High dose exogenous progestagens have been demonstrated to reduce
menstrual blood loss in patients with idiopathic menorrhagia (chapter three). The
hypothesis constructed was that high dose exogenous steroids exert their effects on
menstrual blood loss by altering the expression of endometrial nitric oxide synthase
(NOS).
Materials and methods
Collection of endometrial biopsies
Endometrial tissue was obtained from 12 healthy parous women taking part in the
clinical trial described in chapter three. The tissue was collected using a Z-sampler
(ZSI, Chatsworth, US) in the mid-luteal phase of the cycle (median day 21, range day
19-25), was snap-frozen in liquid nitrogen and stored at -70°C until required. The
timing of biopsy collection is shown in table 5.1.
Six women received intrauterine progestagen via a levonorgestrel intrauterine system
(Mirena®: LeirasOy, Turku, Finland). Six women received oral progestagens in the
form of norethisterone 5mg three times daily from day 5 to 26 of their cycle.
A second endometrial biopsy was taken in the mid-luteal phase of the first treatment
cycle and was snap-frozen and stored as before. The median exposure time of the
tissue to intrauterine levonorgestrel was 18 days (range 13-24 days) and to oral
norethisterone was 17 days (range 13-20 days). The timing of biopsy collection is
shown in table 5.1.
135
10pm cryostat sections of tissue were cut, mounted onto 3-aminopropyltriethoxy-
silane coated slides (Sigma, Poole, UK) and air-dried overnight before being stored at
-70°C until further use.
Immunocytochemistry for eNOS
Tissue sections were allowed to come to room temperature, fixed in acetone for 15
minutes, air dried and rehydrated with phosphate buffered saline (PBS) containing
lOmM sodium phosphate, 120mM sodium chloride (pH 7.5) for five minutes. A
commercially available kit, mouse Vectastain® Elite ABC Kit (Vector Laboratories,
Peterborough, UK) was used for the immunohistochemical staining. Sections were
first incubated in a humidified box with 3% (w/v) immunoglobulin-free bovine serum
albumin (Sigma, Poole, UK) in PBS for 20 minutes at room temperature to remove
any non-specific binding. The blocking serum was blotted off and the sections were
incubated in a humidified box for one hour at room temperature with the primary
antibody, a monoclonal antibody raised in mouse against human endothelial NOS
(Affiniti, Nottingham, UK), diluted 1:500 with the blocking serum. This
concentration had been established by previous work to be the optimal dilution for this
type of tissue. The sections were rinsed twice in PBS for five minutes and the
secondary antibody of biotinylated anti-mouse was added from the Vectastain® kit.
The tissue was incubated in a humidified box for 30 minutes at room temperature, then
rinsed twice for five minutes in PBS. Endogenous peroxidase activity was removed
by incubating the sections for 30 minutes in 0.3% hydrogen peroxide (Sigma, UK) in
methanol. The sections were rinsed twice for ten minutes in PBS and incubated for 30
minutes at room temperature with the Vectastain® reagent containing a preformed
avidin and biotinylated horseradish peroxidase complex. The sections were rinsed
twice for five minutes in PBS, and eNOS binding was localised using lmg/ml 3,3'-
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diaminobenzidine tetrahydrochloride (Sigma, UK) and 0.02% hydrogen peroxide in
50mMTris CI, pH7.6. The sections were rinsed in tap water for five minutes to stop
the reaction and counterstained with Harris haemotoxylin and eosin and mounted in
DPX medium (BDH, Glasgow, UK).
Negative control slides were incubated without the primary antibody. Previous work
on endometrial tissue in this laboratory had also used an irrelevant IgG] mouse
monoclonal antibody against glucose oxidase from Aspergillus niger (Dako Ltd, High
Wycombe, UK), an enzyme which is not present in mammalian tissue as a control.
Immunocytochemlstry for iNOS
Immunocytochemistry for iNOS was performed as described above, using the rabbit
Vectastain® Elite ABC Kit (Vector Laboratories, UK) and a polyclonal antibody to
amino acids 1131-1144 of murine iNOS (Cambridge Biosciences, Cambridge, UK) as
the primary antibody. Previous work had shown the optimal dilution for this type of
tissue to be 1:400, diluted in blocking serum as before.
Control slides were incubated without the primary antibody.
The sections were examined and photographed using the appropriate condenser and a
conventional bright light field microscope (Orthoplan Leitz: Leica Ltd., Milton
Keynes, UK). Staining was assessed independently by two observers and graded
subjectively according to the site and extent of staining within the specimen.
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Statistical analysis
An unpaired t-test was used to compare days of exposure to treatment between the two
groups.
Results
There was no difference in the exposure time of the tissues to treatment between the
levonorgestrel and the norethisterone groups.
eNOS immunocytochemistry
There was no eNOS immunoreactivity in the control slides.
All biopsies, pre- and post-treatment, showed localisation of eNOS to endometrial
blood vessels. All of the pre-treatment biopsies showed positive glandular staining for
eNOS, although there was some variation in the intensity of staining between
specimens (figures 5.1 and 5.2). Following treatment, glandular eNOS
immunoreactivity was abolished in all of the patients treated with levonorgestrel, and in
three out of six of the patients treated with norethisterone. eNOS immunoreactivity
was not detected in endometrial stroma pre- or post-treatment.
iNOS immunocytochemistry
There was no iNOS immunoreactivity in the control slides.
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iNOS immunoreactivity localised to glandular epithelium and some vascular smooth
muscle cells. Again, there was some variation in the intensity of staining between
specimens. Following treatment with norethisterone or levonorgestrel, glandular
iNOS immunoreactivity was attenuated or absent in all of the specimens examined.
Administration of norethisterone resulted in the appearance of small areas of
decidualisation in tissues from two of the six patients, whereas a pronounced decidual
reaction was seen in all the biopsies taken from the six women treated with intrauterine
levonorgestrel. iNOS immunoreactivity was weakly expressed in decidualised stroma
in all biopsies examined (figure 5.3 and 5.4)
The tissue sections were further compared with sections stained with cx2 laminin, a
marker for stromal cells which have undergone decidualisation (see chapter two). The
areas of iNOS expression in the post-treatment biopsies corresponded to areas of
stromal decidualisation.
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Figure 5.1. Photomicrograph of eNOS immunostaining in a pre-treatment endometrial
biopsy taken of day 16 of the cycle. There is weak staining in the glandular epithelium
(G) and in an endometrial vessel (BY). Scale bar represents 25//m.
Figure 5.2. Photomicrograph of eNOS immunostaining in a pre-treatment endometrial
biopsy taken of day 22 of the cycle. In contrast to the previous specimen, there is no
staining in glandular epithelium (G), illustrating the variation in staining between
specimens. Vascular endothelial cells (BV) stain strongly positive in this specimen.
Scale bar represents 50//m.
Figure 5.1.
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Figure 5.3. Photomicrograph of a post-treatment biopsy following 20 days exposure
to intrauterine levonorgestrel. The section is stained with haemotoxylin and eosin and
demonstrates the characteristic appearance of decidualised stroma immediately beneath
the surface epithelium (S), with large stromal cells and a wide zone of deeply staining
cytoplasm surrounding the nucleus. Scale bar represents 25//m.
Figure 5.4. Photomicrograph of iNOS immunostaining in parallel section to figure
5.3. There is weak staining in the decidualised stroma (D) beneath the surface
epithelium (S). Scale bar represents 25/^m.
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day 15 - 13 -
day 16 X 14 X
day 17 X 15 X
day 18 - 16 XX
day 19 X 17 XXX
day 20 - 18 X
day 21 XXX 19 -
day 22 XXX 20 XXX
day 23 - 21 -
day 24 XX 22 X
day 25 X 23 -
day 26 - 24 -
Total 12 Total 12
Pre-treatment biopsies Treatment biopsies
Table5.1. Timingof endometrial biopsies in pre-treatment and treatment cycles. Pre-
treatment biopsies are expressed as number of days from last menstrual period.




This study has demonstrated the differential expression of eNOS and iNOS proteins in
the endometrium of patients with proven menorrhagia. eNOS protein was expressed
in endometrial glandular epithelium and vascular endothelium, and iNOS protein in
endometrial glandular epithelium and vascular smooth muscle cells. There was a
variation in the intensity of staining for both eNOS and iNOS. Prior to treatment with
both intrauterine levonorgestrel and oral norethisterone, there was no stromal
expression of either eNOS or iNOS protein. Following treatment, stromal
decidualisation was apparent and iNOS protein was expressed in the decidualised
stroma.
There are some limitations imposed by the sampling technique. By nature of the
device used to obtain the,biopsies in this study, tissue specimens were a random
distribution of layers of endometrium, with the deeper zona compacta being
undersampled, thus there may be changes in protein expression in deeper layers
compared to the more superficial ones which may not be appreciated by this sampling
technique. Another potential disadvantage of this method of endometrial sampling is
that the morphological structure is less well preserved. These disadvantages must be
set against the major advantage of this technique which allows for repeated sampling of
the same individual thus detecting any changes in protein expression following
treatment.
This work confirms previous studies which have detected NOS-like immunoreactivity
in human endometrium. Telfer et al detected NOS mRNA in endometrial glands,
stroma and myometrial blood vessels across the cycle (Telfer et al, 1995). eNOS
immunoreactivity was assessed using a monoclonal antibody raised against bovine
endothelial NOS, and localised to endometrial glands and stroma in secretory phase
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samples. NADPH diaphorase activity in secretory phase samples was detected
predominantly in endometrial glands. This present study used a different eNOS
antibody, a monoclonal antibody raised against human eNOS which detected eNOS
immunoreactivity only in glandular epithelium in this type of tissue, and may thus
explain the discrepancy in results. Work examining the presence of mRNA and
protein for both eNOS and iNOS in 34 hysterectomy specimens using the same
antibodies as in this study demonstrated no eNOS or iNOS mRNA or protein in
endometrial stroma (Telfer et al, 1997) and supports the work of Tseng et al, who
demonstrated intense staining in blood vessels and in endometrial glands in late
secretory endometrium using NADPH diaphorase (Tseng et al, 1996). This was
thought to be due to expression of eNOS, since eNOS mRNA was detected in a
preparation of endometrial glands and expression was maximal in late secretory
samples; eNOS mRNA was not detected in endometrial stromal preparations, in
keeping with present findings. Tseng et al detected iNOS mRNA only in epithelial
glands from a menstrual endometrium, with iNOS mRNA undetectable in stromal
cells.
Animal studies which have demonstrated NOS activity in decidua using NADPH
diaphorase activity (Moorhead et al, 1995), citrulline conversion and nitrite/nitrate
production (Sladek et al, 1993). Northern blot analysis of human decidua
demonstrated expression of eNOS but not iNOS mRNA (Tseng et al, 1996) and in
vitro incubation of endometrial stromal cells with medroxyprogesterone acetate also
failed to demonstrate expression of iNOS. This current study demonstrated expression
of iNOS but not eNOS in decidualised stromal cells. One explanation for this
discrepancy may be that decidual cells associated with early pregnancy express
different proteins compared with the decidual cells induced by supraphysiological
doses of exogenous gestagens seen in this study. Another possibility is that Northern
blot analysis may not have been sensitive enough to detect decidual NOS activity. A
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study on human decidua using both murine and human iNOS antibodies has confirmed
the current study's results, demonstrating weak immunoreactivity on decidual cells
from first trimester pregnancies (Telferetal, 1997).
NO may play a role in the onset of menses, producing the vasodilatation which follows
intense vasoconstriction of the spiral arterioles (Markee, 1940). In the study by Telfer
etal in 1997, nine patients had had menstrual blood loss measured objectively prior to
hysterectomy and the authors found no correlation between the intensity of eNOS
immunostaining and the degree of menstrual blood loss (Telfer et al, 1997). Menstrual
blood loss measurements following the first cycle of treatment of the 12 patients in this
current study showed a significant reduction in all six patients receiving intrauterine
levonorgestrel, and in five out of the six patients receiving oral norethisterone,
correlating with reduced expression of glandular eNOS, although the number of
patients was small. It is possible that the reduction in endometrial glandular eNOS
expression overcame the weak expression of iNOS in decidualised stroma to produce
an overall menstrual blood loss. Alternatively, changes in NOS expression and NO
production may have paracrine effects on neighbouring cells, leading to an overall
reduction in menstrual blood loss (Franchi et al, 1994). Six of the patients studied,
one in the norethisterone group and five in the levonorgestrel group complained of
frequent or continuous intermenstrual bleeding during the first cycle of treatment.
These symptoms correlated with increased stromal iNOS expression, but the number
of patients was small.
Although this study examined the endometrium of patients with proven menorrhagia, it
should be remembered that menstruation represents a failure of fertilisation and
implantation, and that the most important role of the endometrium is to facilitate the
establishment of a successful pregnancy. An increase in NOS activity in decidualised
stroma would be of benefit at the site of implantation in early pregnancy, catalysing the
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production of NO, a potent vasodilator (Furchgott, 1988) and inhibitor of platelet
aggregation and adhesion (Radomski et al, 1987 a,b) to maximise endometrial blood
flow, and endometrially-derived NO may also reduce myometrial contractility (Izumi et
al, 1993).
In summary, this work has demonstrated the presence of both eNOS and iNOS
immunoreactivity in endometrial glands of patients with objective menorrhagia.
Following treatment with exogenous progestagens, glandular eNOS and iNOS
immunoreactivity was reduced or absent, but there was weak expression of iNOS in
areas of decidualised stroma. The precise relationship between NO and other locally-
produced mediators of endometrial function remains to be elucidated.
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Chapter Six
Autoradiography for Endothelin A and B Receptors in the Endometrium of
Patients with Proven Menorrhagia, Before and After Treatment with
Exogenous Progestagens.
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Endothelin is a potent vasoconstrictor which acts via endothelin A and B receptors.
Little is known about the role of endothelin in the pathophysiology of dysfunctional
uterine bleeding (DUB). Endothelin-like immunoreactivity (ET-1R) has been
demonstrated in the human uterus, at sites which may have an effect on spiral arteriole
vasoconstriction (Davenport et al, 1991), andET-IR is reduced in the endometrium of
patients with menorrhagia (Marsh et al, 1996). High dose exogenous progestagens
have been demonstrated to reduce menstrual blood loss in patients with DUB (chapter
three). The hypothesis constructed was that high dose exogenous progestagens reduce
menstrual blood loss by altering the expression of endothelin A and B receptors in the
endometrium.
Materials and Methods
Collection of endometrial biopsies
Endometrial tissue was obtained from 18 healthy parous women taking part in the
clinical trial described in chapter three. The tissue was collected using a Z-sampler
(ZSI, Chatsworth, USA.) in the mid luteal phase of the cycle (median day 21, range
day 16-25), was snap-frozen in liquid nitrogen and stored at -70°C until required. The
timing of biopsy collection is shown in table 6.1.
Eight women received intrauterine progestagens via a levonorgestrel intrauterine
system (Mirena®: Leiras Oy, Turku, Finland). Ten women received oral
norethisterone 5mg three times daily from day 5 to 26 of their cycle.
A second endometrial biopsy was taken in the mid-luteal phase of the first treatment
cycle and was snap-frozen and stored as before. The median exposure time of the
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tissue to intrauterine levonorgestrel was 17 days (range 15-21 days) and to oral
norethisterone was 15 days (range 13 - 21 days). The timing of biopsy collection is
shown in table 6.1.
Binding to ETa receptors was determined using [ 125I]-PD151242, an endothelin ETA
antagonist with a specific activity of 74Tbq/mM, 2000 Ci/mM at the activity reference
date (Amersham International, Amersham, UK).
Binding to ETB receptors was determined using 1125I]BQ3020, an endothelin ETB
specific receptor ligand with a specific activity of approximately 74 Tbq/mM, 2000
Ci/mM at the activity reference date (Amersham International, UK).
Non-specific binding was assessed using unlabelled ETA and ETB ligands, gifted by




10 pm cryostat sections of tissue were cut, mounted onto 3-aminopropyltriethoxy-
silane coated slides (Sigma, Poole, UK) and air-dried overnight before being stored at
-70°C until further use. The tissue was allowed to come to room temperature and
preincubated for 15 minutes in buffer containing 5QmM HEPES, 5mM MgCU and
0.3% bovine serum albumin (pH 7.4) (Sigma, Poole, UK) to rehydrate the tissue.
Sections were then incubated in HEPES buffer containing 0.1 pM [125I]PD 151242 or
[125I]BQ3020 (Amersham, UK) for two hours at room temperature. This
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concentration had been established by previous work to be the optimal dilution for this
type of tissue. Non-specific binding was assessed by incubating sections in HEPES
buffer containing O.lpM 1125I]-PD151242 or [125I|BQ3020 with an excess of the
corresponding unlabelled ligand (1/<M). Sections were washed three times for ten
minutes each time in ice-cold 50mM Tris-HCL (pH 7.4), briefly rinsed in deionized
water at4°C, fixed in ice-cold formalin for ten minutes, washed again three times for
five minutes each time in deionized water at 4°C and air dried.
The slides were loaded into an autoradiography cassette along with standard [ 125I]
microscales (Amersham, UK) and exposed to Hyperfilm-(3max (Amersham, UK) for
four days. The film was developed in Kodak D-19 developer (Sigma, UK) for six
minutes, rinsed in tap water for 90 seconds and fixed with Kodak rapid fixer (Sigma,
UK) for 12 minutes. The film was then rinsed in running tap water for 15 minutes.
The autoradiographic film was examined by two independent observers and
photographed using a wide field condenser and a xl degree objective lens in a
conventional bright field microscope (Orthoplan, Leitz: Leica UK Ltd., Milton
Keynes, UK).
Microautoradiography
The slides were coated in Hypercoat EM-1 emulsion (Amersham, UK) at42°C using a
wire loop to achieve as thin and uniform a coating as possible, and stored in a light-
tight box containing silica gel at 4°C for six days. Slides were developed in Kodak D-
19 developer for five minutes, rinsed for 30 seconds in 0.5% acetic acid, fixed for ten
minutes in GBX fixer (Sigma, UK) and rinsed in running tap water for 15 minutes.
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Tissue sections were counterstained with 0.2% Toluidine Blue in 30% ethanol, and
mounted in DPX-mounting medium (BDH, Glasgow, UK). The sections were
examined and photographed under epipolarisation with a xlO objective lens in a
conventional bright light field microscope (Orthoplan Leitz: Leica Ltd., UK), and
binding assessed by two independent observers as the pattern of developed silver
grains in the nuclear emulsion above the tissue section.
Statistical analysis
An unpaired t-test was used to compare days of exposure to treatment between the two
treatment groups.
Results
There was no difference in the exposure time of the tissues to treatment between the
norethisterone and the levonorgestrel groups.
Interpretation of the macroautoradiographic images was limited by the sampling
technique. Tissue was obtained mostly from the stratum functionalis, without the
orientation seen in blocks of tissue obtained at hysterectomy. Two specimens obtained
following treatment with norethisterone were fragments only and it was impossible to
comment on patterns of binding in these specimens. Binding of ETA and ET3 was
apparent in all of the other macroautoradiographs, but the resolution of the
macroautoradiographic images did not allow for an accurate discrimination between
glands and stroma.
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The specificity of binding of both [ 125I|PD151242 and 1125I]BQ3020 was confirmed
by the absence of binding of the labelled ligand in the presence of an excess of the
unlabelledligand.
The distribution of ETA and ETg receptors in the endometrium was assessed by
microautoradiography. When the pre-treatment biopsies were examined, ETA
receptors were expressed in the stroma in all specimens. There was no expression of
ETA receptors in endometrial glands or surface epithelium. It was not possible to
confidently localise ETA receptors to blood vessels because of the high level of stromal
expression and the limited resolution of microautoradiography. ETg receptors were
localised to endometrial glands in some but not all pre-treatment specimens. Surface
epithelium was consistently negative. In specimens where the deeper layers had been
sampled, there was positive staining for ETg in the deeper layers and negative staining
in the superficial layers. There was positive stromal staining in only three of the
control biopsies taken on days 21, 22 and 25 of the cycle.
Following treatment with either intrauterine levonorgestrel or oral norethisterone, there
was no consistent change in the pattern of ETA receptor expression. When ETg
receptors were assessed, there was expression of ETg receptors in the stroma of eight
out of eight specimens treated with intrauterine levonorgestrel (figures 6.1 and 6.3)
and in seven out of eight specimens treated with norethisterone. The endometrial
glands showed reduced expression of ETg receptors following treatment.
The macroautoradiographic film and microautoradiographic slides were further
compared with tissue sections stained with a2 laminin, a marker for stromal cells
which have undergone decidualisation (chapter four) (figures 6.2 and 6.4). The areas
of stromal ETg expression in the post treatment biopsies corresponded to areas of
stromal decidualisation.
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Figure 6.1. Microautoradiograph of a post-treatment biopsy following 20 days
exposure to intrauterine levonorgestrel, probed with | '-5I ]BQ3020 ligand. Tangential
fibre optic illumination of the section revealed areas of high intensity binding (B)
which corresponded to areas of stromal decidualisation. Scale bar represents 100/mn.
Figure 6.2. Photomicrograph of a parallel section to figure 6.1. The section is stained
with a.2 laminin, and demonstrates areas of stromal decidualisation (D). Scale bar
represents 100/<m.
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Figure 6.3. Higher magnification microautoradiograph of figure 6.1, probed with
|125I|BQ3020 ligand. The section demonstrates the junction between an area of
decidualised(D) and non-decidualised stroma (S). Tangential fibre optic illumination
revealed areas of high intensity binding which corresponded to areas of stromal
decidualisation. Scale bar represents 80/jm.
Figure 6.4. Photomicrograph of a parallel section to figure 6.3. The section is stained









day 15 - 13 -
day 16 X 14 X
day 17 X 15 XX
day 18 X 16 XX
day 19 XXX 17 XX
day 20 X 18 XXXX
day 21 xxxx 19 XX
day 22 XXX 20 XXX
day 23 X 21 X
day 24 X 22 X
day 25 XX 23 -
day 26 - 24 -
Total 18 Total 18
Pre-treatment biopsies Treatment biopsies
Table 6.1. Timing of endometrial biopsies in pre-ireatment and treatment cycles. Pre-
treatment biopsies are expressed as number of days from last menstrual period.




This study demonstrates the expression of receptors for ETA and ETB in secretory
phase endometrium, and following treatment with high doses of exogenous
progestagens. Prior to treatment, ETA receptors localised to the stromal compartment
while ETB receptors were heterogeneously expressed in the endometrial glands of
secretory phase endometrium. Following treatment, ETA expression persisted in the
stroma, but ETB receptor expression was apparent in areas of decidualised stroma with
reduced expression in endometrial glands.
Previous studies of the expression of ET receptors across the normal cycle have shown
changes in the relative levels of ETA and ETB receptor mRNA using RT-PCR and
Northern blot analysis (O'Reilly et al, 1992; Kubota et al, 1995). Quantitative
autoradiography confirmed these findings, and also allowed for the localisation of ET
receptor subtypes, with ETA receptors localising to the endometrial stroma and ETB
receptors to the endometrial glands (Collett et al, 1996). The current study examines
receptor subtype localisation during the mid-luteal phase only and the findings correlate
with the changing pattern of receptor subtypes across the cycle (O'Reilly et al, 1992;
Kubota etal, 1995; Collett etal, 1996).
The heterogeneous pattern of glandular ETB receptor binding in this study may be
explained by the sampling technique. Aspiration biopsy of the endometrium
preferentially samples the superficial layers of the endometrium, with the basal layers
being undersampled. In the few samples where the deeper layers were sampled, a
gradient was noted with deeper layers showing an increase in glandular ETB receptor
binding. This finding is in keeping with previous autoradiographic studies which have
demonstrated the pattern of ETB receptor glandular binding in the mid-luteal phase to
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be predominantly in the basal layers, with the superficial layers only expressing
receptors from the late-luteal phase onwards (Collettet al, 1996).
High doses of exogenous progestagens induce stromal decidualisation. Work carried
out on endometrium exposed to high doses of subcutaneous levonorgestrel
(Norplant®) demonstrated a decrease in ET-IR in glands and luminal epithelium, and
an increase in stromal ET-IR (Marsh et al, 1995) and would support the findings of the
current study. In endometrium exposed to high doses of oral exogenous steroids,
Northern blot analysis revealed mRNA for both ETA and ETg receptor subtypes in
decidualised stroma, and decidualised stroma also expressed high levels of prepro-ET
mRNA, suggesting an increase in the synthesis of receptors and endothelin (Kubota et
al, 1995). The lack of an effect of treatment on the pattern of ETA receptor subtype
expression in this present study may reflect the different sensitivities of
autoradiography and Northern blotting techniques.
ET has been implicated as a modulator of endometrial blood flow (Davenport et al,
1991; Cameron et al, 1992), where it may play a role in the spiral arteriole
vasoconstriction which precedes menstruation (Markee, 1940). Levels of prepro-ET-1
mRNA (Economos et al, 1992; Kubota et al, 1995) and big ET-IR (Ohbuchi et al,
1995) are maximal during the menstrual phase of the cycle when intense spiral arteriole
vasoconstriction is required to limit menstrual blood loss (Christiaens et al, 1980) and
ET has been demonstrated to be a potent vasopressor agent on uterine arteries and
veins in vitro (Fried and Samuelson, 1991).
The distribution of endothelin immunoreactivity has been examined across the cycle in
the endometrium of patients with menorrhagia (Marsh et al, 1996), and showed a
reduction in ET-IR in glandular and luminal epithelium in patients with menorrhagia
when compared to patients with a normal cycle. There was no difference in the
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intensity of stromal staining. In the current study, menstrual blood loss was markedly
reduced after the first cycle of treatment in 16 out of the 18 patients studied. The
endometrial sampling technique used in this study did not give any information about
the distribution of ETA or ETg receptors in the basal endometrium, at a site which
might be expected to contribute to the action of controlling bleeding from basal arteries
(Davenport et al, 1991; Cameron et al, 1992) and it may be that full-thickness
specimens of endometrium would be required to investigate this effect. ETg is known
to be found at high concentrations in menstrual endometrium where it is thought to
play a role in the control of menstruation (Collett et al, 1996). Upregulation of ETg
receptor earlier in the cycle by the administration of exogenous progestagens may have
contributed to the reduced menstrual blood losses seen in this study. Nine out of the
18 patients studied complained of intermenstrual bleeding during the first cycle of
treatment. There was no correlation between this symptom and a change in ETA or
ETg receptor binding in the post-treatment biopsies.
The second major role for ET in decidualised endometrium may be at implantation. ET
is thought to induce vasodilatation via the release of nitric oxide (NO) and prostacyclin
(de Nucci et al, 1988), thus providing a mechanism for fine control of endometrial
blood flow. NO can be released from vascular endothelium by a range of stimuli,
including ET binding to the ETB receptor (Takayanagai et al, 1991). This current
study has demonstrated an increase in the expression of ETg receptors in decidualised
stroma, the same cell type which has been demonstrated to express iNOS (chapter
five). ET is also known to be mitogenicfor a number of tissues including rat vascular
smooth muscle (Hirata et al, 1988), fibroblasts (Takuwa et al, 1989), glomerular
mesangial cells (Simonsen etal, 1989) and certain types of tumour cells (Shichiri et al,
1991) and by these paracrine / autocrine actions may play a role in implantation and the
establishment of early pregnancy. In vitro studies have demonstrated that ET-1
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modulates the release of renin and prolactin from decidual cells (Chao et al, 1994) and
thatET stimulates the production of PGF2a from decidual cells (Schrey et al, 1992).
ET has been shown to stimulate DNA synthesis in cultured human endometrial stromal
cells (Kubota et al, 1995).
In conclusion, this study has demonstrated that high doses of exogenous progestagen
increase the expression of ETg receptors in areas of stroma which have undergone
decidualisation. There was no consistent change in the pattern of ETA receptors.
Endothelins may thus be involved in the regulation of endometrial blood flow at the
time of implantation and menstruation, and may also play a paracrine role in the
regulation of decidualised stromal cells.
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Conclusions
The complaint of excessively heavy periods is one commonly encountered in
gynaecological practice and, while rarely life-threatening, is a cause of much social and
psychological morbidity. The majority of patients presenting with menorrhagia have
no demonstrable organic pathology and this is underlined in chapter two. Synthetic
progestagens such as norethisterone are the most commonly prescribed drug for the
treatment of menorrhagia in the United Kingdom (Coulter et al, 1995), yet several
trials have shown them to be ineffective in their currently prescribed dosage. The
effectiveness of an increased dose of progestagen is demonstrated in chapter three,
with a regimen of norethisterone 5mg tds from day 5 to 26 of the cycle producing an
87% reduction in menstrual blood loss at three months. This compares to a 94%
reduction in menstrual blood loss at three months achieved with a levonorgestrel
intrauterine system (LNG IUS).
Exposure of the endometrium to both systemic norethisterone and intrauterine
levonorgestrel for two to three weeks resulted in dramatic alterations to the epithelial
and stromal compartments (chapter four). This was accompanied by reductions in
MBL of 64% and 87% after one cycle of treatment for norethisterone- and
levonorgestrel-treated patients respectively. Glandular and surface epithelial cell height
was reduced, surface epithelial ciliagenesis was defective and the normal mobilisation
and secretion of intracellular glycoproteins from endometrial glandular cells was
interrupted. These findings suggest retarded development within the glandular
compartment, and would be in keeping with studies which demonstrate endometrial
atrophy following long term exogenous progestagen administration (Nilsson et al,
1978; Ludwig, 1982; Johannisson et al, 1982; Song et al, 1995; Pakarinen et al,
1995). In contrast, the stromal compartment showed evidence of accelerated
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development, with an increase in areas of stromal decidualisation. This was
particularly pronounced in endometrium exposed to intrauterine levonorgestrel.
Decidualisation is a key component of menstruation, with regression of decidualised
endometrium occurring prior to the onset of menses, possibly resulting in the release
of vasoactive substances which start the cycle of spiral arteriole vasoconstriction-
vasodilatation-vasoconstriction. Prolongation of decidualisation in areas of
endometrium may thus have reduced the area of menstrual breakdown, resulting in the
reduction in MBL observed following the first cycle of treatment.
Nitric oxide synthase (NOS) expression was altered in endometrium exposed to
norethisterone and levonorgestrel (chapter five). These alterations were more
pronounced in levonorgestrel-treated patients. Glandular eNOS and iNOS activity was
attenuated or abolished, while iNOS was expressed in areas of decidualised stroma.
The role of nitric oxide and NOS in the pathophysiology of dysfunctional uterine
bleeding is unclear, and these observations do not readily explain the reductions in
MBL. The alterations in NOS expression may be of more relevance if we consider the
role of the endometrium in early pregnancy. Animal studies have demonstrated NOS
activity in decidua (Moorhead et al, 1995) and decidual iNOS immunoreactivity has
also been demonstrated in human decidual cells from first trimester pregnancies (Telfer
et al, 1997), where it may play a role in optimising blood supply to the implanting
blastocyst. By delivering high concentrations of a potent progestagen direct to the
endometrium the LNG IUS appears to act as a model for the endometrial response to
early pregnancy.
A role for the endothelins (ETs) in spiral arteriole vasoconstriction has been proposed
(Davenport et al, 1991), and they may play a role in the pathophysiology of
menorrhagia (Marsh et al, 1996). Chapter six examined the distribution of ETA and
ETq binding sites in the endometrium before and after treatment with norethisterone
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and levonorgestrel. No alteration in the expression of ETA was apparent following
treatment, but an increase in the expression of ETB which was observed in association
with decidualised stroma. ETB is known to undergo more complex changes during the
menstrual cycle than ETA and is found in high concentrations at menstruation, when it
is thought to play a role in the control of menstruation (Collett et al, 1996).
Upregulating the expression of this receptor subtype earlier in the cycle by the
administration of exogenous progestagens may thus have contributed to the reduction
in MBL observed in the study patients. The appearance of ETB receptors paralleled the
expression of iNOS in decidualised stroma. ETB is known to stimulate the release of
nitric oxide (Takayanagai et al, 1991) and may act as a mechanism for improving
endometrial blood flow at the time of implantation.
One feature of the LNG IUS is the high incidence of breakthrough bleeding (BTB)
associated with the first few months of use. All 22 patients reported BTB after one
cycle of treatment, with ten out of 19 still reporting the symptom at the end of three
months. The increased incidence of BTB observed in LNG IUS-treated patients cannot
readily be explained by these studies. There was a correlation between BTB and
increased expression of iNOS, but the numbers of samples were small. Endometrial
blood vessels were not examined separately in these studies and it may be that BTB is
more likely to be associated with changes in the structure of blood vessels rather than
alterations to their function. Alterations in microvascular density have been reported
following exposure to exogenous progestagens (Rogers et al, 1993; Song et al, 1995)
and long term use results in superficial venous dilatation (Ludwig et al, 1982). Of the
patients who elected not to continue with the LNG IUS beyond three months,
breakthrough bleeding was the commonest reason cited and this may limit the
widespread acceptance of the system.
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High dose exogenous progestagens offer a very effective medical approach to the
treatment of menorrhagia. If oral norethisterone is to be effective, it should be
prescribed at a dose of 5mg tds from day 5 to 26 of the cycle, however patient
compliance is restricted by this regimen with only 22% of the patients studied electing
to continue with the treatment beyond three months. The levonorgestrel intrauterine
system is associated with higher rates of patient satisfaction and continuation with
treatment and offers a valid alternative to surgery as long-term treatment for
menorrhagia. Breakthrough bleeding is common in the first few months of use and
further research is required to understand the mechanisms underlying this.
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Expression of endothelial and inducible nitric oxide synthase in
non-pregnant and decidualized human endometrium
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Immunocytochemistry was used to localize endothelial (eNOS) and inducible (iNOS) nitric oxide synthase in
human uterine tissues collected at various stages of the menstrual cycle, after exposure to exogenous
progestagens, and in early pregnancy. Endothelial NOS-like immunoreactivity was detected in ail specimens
in endothelial ceils lining blood vessels in the myometrium and endometrium, and in endometrial glandular
epithelial cells. Inducible NOS-like immunoreactivity was also demonstrated in glandular epithelial cells. For
both elMOS and iiMOS there was considerable variation in the intensity of epithelial cell staining between
samples, which was not related to the stage of the menstrual cycle at which the tissue was collected.
Messenger RNA for eNOS and iNOS was detected by reverse transcription-polymerase chain reaction
(RT-PCR) using total RNA purified from isolated endometrial gland fragments. Immunoreactivity for eNOS
and iNOS was not present in endometrial stroma throughout the menstrual cycle, but iNOS-like immuno¬
reactivity was seen in decidualized stromal cells both following treatment with exogenous progestagen
(intrauterine L-norgestrel) and in tissues obtained in the first trimester of pregnancy. The detection of protein
and mRNA for eNOS and iNOS in normal human endometrium suggests that NO may play a role in the local
control of endometrial function.
Key words: decidua/endometrium/nitric oxide/progestagen
Introduction
Nitric oxide (NO) is a crucial mediator of paracrine interactions,
especially within the vascular system. It is a powerful inhibitor
of platelet aggregation and a potent vasodilator (Palmer et al.,
1987). Nitric oxide also functions as a neurotransmitter and
plays a role in cell-mediated cytotoxicity (Lowenstein and
Snyder, 1992). This signalling molecule is therefore likely to
have an important role within the endometrium where changes
in vascular function occur throughout the course of the
menstrual cycle and at the time of implantation. Although it
is difficult to determine which cells produce NO in vivo.
circumstantial evidence of its production by particular cell
types can be obtained by localizing the enzymes which
synthesize it.
NO is produced by nitric oxide synthases (NOSs), a family
of isoenzymes that catalyse the oxidation of L-arginine to nitric
oxide (NO) and citrulline. There are two functional classes of
NOS, based on the requirement of these enzymes for calcium
(Moncada et ai, 1991). Inducible NOS (iNOS or type II),
which is calcium-independent, binds calmodulin tightly at
resting intracellular calcium concentrations. Endo¬
thelial NOS (eNOS or type III), originally described in
endothelial cells, and neuronal NOS (nNOS or type I) are both
dependent on calcium for activity.
The production of NO in the endometrium has not been
widely addressed, but iNOS protein has been reported in
endometrial epithelial cells in the mouse (Huang et al., 1995)
and neuronal NOS protein has been detected in rat endometrial
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epithelium (Schmidt et al., 1992). We have previously
described the presence of eNOS protein and mRNA, and
NADPH diaphorase activity, in human endometrium (Telfer
et al., 1995). In addition, recent work has shown that human
endometrial glandular cells expressed eNOS mRNA throughout
the menstrual cycle, whilst the expression of iNOS mRNA
was confined to epithelial glands isolated from menstrual
endometrium (Tseng et al., 1996).
The onset of menstruation is characterized by intense vaso¬
constriction (Markee. 1940). Most of the functional endo¬
metrium is shed within 20 h of the onset of bleeding, and
subsequent haemostasis is thought to be achieved not by the
deposition of platelet-fibrin plugs, but by vasoconstriction
(Christiaens et al.. 1980). Nitric oxide produced in the human
endometrium may play a role in the control of menstruation
(and implantation) by virtue of its roles as a vasodilator and
an inhibitor of platelet aggregation. Animal studies have
suggested that NO. acting via second messenger cGMP, may
contribute to the maintenance of uterine quiescence during
pregnancy (Natuzzi et al., 1993; Sladek et al., 1993). Thus
NO produced in the endometrium may also have an effect on
the underlying myometrium.
The aim of the present study was to determine the localization
of eNOS and iNOS protein in human endometrium by immuno¬
cytochemistry, and to detect the presence of mRNA for eNOS
and iNOS using the reverse transcription-polymerase chain
reaction (RT-PCR) on enriched preparations of glandular




of NOS in the endometrium was investigated by immunocyto-
chemical analysis of tissue collected both at different time
points in the normal menstrual cycle and from women receiving
exogenous progestagens (oral norethisterone or intrauterine l-
norgestrel) for the treatment of dysfunctional uterine bleeding.
Localizadon of eNOS and iNOS in decidualized stroma was
also studied in tissues from women with normal pregnancies
undergoing induced abortion in the first trimester.
Materials and methods
Collection of tissue from women with normal menstrual
cycles
Tissue was obtained from 34 premenopausal women with regular
menstrual cycles undergoing hysterectomy for benign disease at the
West Glasgow Hospitals University NHS Trust and Glasgow Royal
Infirmary University NHS Trust, UK. In nine cases menstrual blood
loss was measured by the alkaline haematin method (Hallberg and
Nilsson. 1964). Informed consent was obtained in each case and the
study was approved by the local ethics committees.
Histological assessment of endometrial morphology was carried
out by local pathologists according to standard criteria (Noyes
et oL, 1950).
Collection of tissue from menorrhagic women treated with
exogenous progestagens
Endometrial biopsies were collected from 12 women with regular
menstrual cycles and objectively measured menorrhagia (menstrual
blood loss >80 ml per month, median 99 ml. range 83-245 ml). Six
women subsequently received oral norethisterone (5 mg three times
daily from days 5 to 26 of the cycle) and six received l-norgestrel,
as the l-norgestrel intrauterine system (LNG-IUS. Mirena®; Leiras
Oy, Turku. Finland). The LNG-IUS, which releases 20 ug LNG daily,
was inserted within 5 days of the onset of menstruation. Endometrial
biopsies were taken using a Z-Sampler endometrial suction curette
(Zinnanti, Chatsworth. CA, USA) at a median of 21 days (range
19-25) after the onset of menstruation during a pre-treatment control
cycle. A second post-treatment biopsy was taken after a median of
18 days (range 13-24) exposure to l-norgestrel and 17 days (range
13-20) exposure to norethisterone.
Collection of first trimester decidua
Decidual tissue was collected from 10 women with normal pregnancies
undergoing surgical termination in the first trimester.
Isolation of endometrial gland fragments
Biopsies of endometrium were transported to the laboratory in cold
Roswell Park Memorial Institute (RPMI) 1640 medium containing
100 IU/ml penicillin and 100 ug/ml streptomycin (Life Technologies.
Paisley, UK). The tissue was washed three times in RPMI medium
and chopped into small pieces using a sterile scalpel. Tissue pieces
were placed in a sterile tube with 1 mg/ml collagenase (Type I;
Sigma. Poole, Dorset. UK) in RPMI medium, supplemented with
penicillin and streptomycin, and incubated at 37°C for 2-4 h.
Undigested tissue was removed using a sterile 400 pm woven
polyester mesh (Lockertex: Locker Wire Weavers Ltd.. Warrington,
UK) and the filtrate was collected. This filtrate was passed through
a 30 pm mesh and trapped epithelial gland fragments were back-




Tissue biopsies obtained at hysterectomy, comprising endometrium
and myometrium, were fixed in 10% neutral buffered formalin (BDH,
Poole, Dorset, UK) and embedded in paraffin. Sections were cut
(5 pm thick) and mounted on silane-coated slides, heated to 60°C
for 35 min, deparaffinized in xylene and rehvdrated in a graded
alcohol series. The sections were pre-incubated with 3% (w/v)
immunoglobulin-free bovine serum albumin (BSA; Sigma) in PBS
(10 mM sodium phosphate, pH 7.5, 120 mM sodium chloride) for
20 min at room temperature. They were then incubated for 1 h at
room temperature with a monoclonal antibody against human eNOS
(Affiniti, Nottingham, UK), diluted 1/500 in 3% BSA. Sections were
then washed in 0.1% Triton-XlOO, followed by two washes in PBS.
Antibody binding was detected with an anti-mouse immunoglobulin
peroxidase kit (Vectastain Elite ABC Kit; Vector. Peterborough, UK)
in which the biotinylated bridging antibody was diluted in 3% (w/v)
BSA and 1.5% (v/v) normal human serum (Sigma). After application
of the biotinylated antibody the sections were washed in PBS and
placed in 0.3% H202 (Sigma) in methanol for 30 min at room
temperature. The sections were then washed thoroughly in PBS
and incubated for 30 min with avidin DH/biotinylated horseradish
peroxidase H reagent (Vector) in PBS. Immunoreactive eNOS was
localized using 1 mg/ml diaminobenzidine tetrahvdrochloride (DAB;
Sigma) and 0.02% H202 in 50 mM Tris-HCl. pH 7.6. Sections were
washed in distilled water, counterstained with Harris haematoxylin
and mounted in DPX (BDH).
Negative control sections were incubated without primary antibody,
or with an irrelevant IgGi mouse monoclonal antibody against glucose
oxidase from Aspergillus niger (Dako Ltd.. High Wycombe. UK), an
enzyme which is not present in mammalian tissue.
Immunocytochemistry for iNOS
Immunocytochemistry was performed on paraffin-embedded sections
using a polyclonal antibody raised against amino acids 1131-1144
of murine iNOS (Cambridge Biosciences. Cambridge, UK) diluted
1/400 in PBS. Antibody binding was detected using an anti-rabbit
immunoglobulin (Ig)G peroxidase kit (Vectastain Elite ABC Kit:
Vector) and DAB substrate (Sigma), according to the manufacturer's
instructions. Control slides were incubated without primary antibody.
Human DLD-1 colorectal adenocarcinoma cells ( European Collection
of Animal Cell Cultures. Porton Down. UK), which have previously
been shown to express iNOS (Sherman et al.. 1993). were cultured
in RPMI 1640 (Life Technologies) supplemented with 10% heat
inactivated fetal calf serum. 100 |Ug/ml interferon (Sigma), 10 ng/ml
tumour necrosis factor (Sigma) and 0.5 ng/ml interleukin-1 (Sigma)
for 24 h. and used as a positive control.
Immunocytochemistry was also performed on frozen sections with
a polyclonal anti-human iNOS antibody raised against amino acids
1135-1153 (Santa Cruz. Heidelberg, Germany). The antibody was
diluted 1/200 in PBS and immunocytochemistry was carried out using
an anti-rabbit IgG peroxidase kit (Vectastain Elite ABC Kit: Vector)
according to the manufacturer's instructions.
Detection of endothelial cells using Ulex europaeus
agglutinin 7 (UEA V lectin
Lectin binding was carried out on 10 um frozen sections of endomet¬
rium and myometrium mounted on silane-coated slides. The sections
were fixed in acetone at room temperature for 20 min. air-dried and
rehydrated in 10 mM HEPES, pH 7.5. 0.15 M NaCl. then placed in
0.3% H202 in methanol for 30 min to remove endogenous peroxidase
activity. Biotinylated Ulex europaeus agglutinin 1 (UEA 1) lectin
(5 ,ug/ml. Vector) was applied to the section in HEPES. NaCl buffer
for 1 h at room temperature. Avidin-biotin-peroxidase complex
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(Vectastain Elite ABC Kit: Vector) and DAB substrate were then
used to detect lectin binding.
Identification of decidual stromal cells in first trimester
decidua
Cryostat sections were fixed in acetone at 4°C for 10 min, air-dried
and rinsed in PBS for 10 min. Decidual cells were identified with a
polyclonal antibody against vimentin (Euro-Path Ltd, Bude, UK).
Glands and trophoblast were localized using a monoclonal antibody
against cytokeratins (clone MNF 116, Dako, High Wycombe, UK).
The sections were pre-incubated for 20 min in D-PBS supplemented
with 1.5% BSA. The primary antibodies were applied for 60 min
(anti-cytokeradn 1:400; anti-vimentin 1:130, diluted in D-PBS
supplemented with 1.5% BSA). After washing in D-PBS 3 times for
5 min, biotinylated secondary rabbit anti-mouse antibody (1:500,
Dako UK) or biotinylated goat-anti rabbit antibody (Vector) were
applied for 30 min. Sections were then incubated in 1% HiOt in
absolute methanol for 10 min to inactivate endogenous peroxidase
followed by incubadon with streptavidin-peroxidase-conjugate
(StreptAB-compiex/HRP; Dako) for 20 min. The streptavidin-biotin
complex was visualized with DAB (Sigma). Negative control sections
were treated in the same way as for eNOS.
Reverse transcription-polymerase chain reaction
Endometrial gland fragments and DLD-1 cells were centrifuged at
100 g for 5 min and lvsed in Trizol reagent (Life Technologies). Total
RNA was prepared by solvent extraction following the manufacturer's
instructions.
Reverse transcription (RT) was carried out on 2 ug of total RNA
extracted from gland fragments of three proliferative and three
secretory endometria and DLD-1 cells. The RNA was annealed to
250 ng of pd(T) 19-24 (Pharmacia. Milton Keynes. UK) by heating
to 70°C for 10 min. After chilling on ice. 1IU RNAguard (Pharmacia,
Milton Keynes), 1 mM dNTPs, first strand buffer (Life Technologies)
and 200 IU of Superscript II RNase H" reverse transcriptase (Life
Technologies) were added, made up to a total volume of 20 pi with
water and incubated at 37°C for 1 h. The reaction was terminated by
heating to 80°C for 10 min. cDNA products were stored at —20°C
until amplification.
Polymerase chain reaction (PCR) was undertaken with primers
(Oswell DNA Service. Southampton. UK) for human eNOS which
spanned exons 8-11 (Marsden et ai, 1993); 5'-CAG TGT CCA ACA
TGC TGC TGG AAA TTG-3' (1004-1030) and 5'-TAA AGG TCT
TCT TCC TGG TGA TGC C-3' (1490-1464, Weiner et al., 1994).
Amplification of iNOS was carried out with primers (P.Romanowski.
L. Wallman. and D.J. Williamson. St Vincent's Hospital. Darlinghurst.
Australia: personal communication) which spanned exon-intron
boundaries (Chartrain et al.. 1994); 5'-GGA ATT CAC TCA GCT
GTG CAT CG-3' (1077-1099) and 5-GTT TCC AGG CCC ATT
CTC CTG C-3' (1433-141-2). Amplifications were carried out using
a programmable thermal cycler (TLA-2 Hybaid. Teddington. UK) in
a total volume of 50 pi containing 60 mM Tris-HCl, pH 8.5, 15 mM
(NH4)2S04, 250 M dNTPs, 0.5 M of each primer and 5 IU of Taq
polymerase. A HotWax Mg2"*" bead (Invitrogen, Abingdon, UK) was
added to each tube. Amplifications were carried out with an initial
denaturation step at 94°C for 2 min, followed by 30 cycles of 1 min
at 94°C, 1 min at 55°C and 1 min at 72°C. The final cycle
was followed by strand extension at 72°C for 10 min. Amplified
products were analysed by electrophoresis using 1.5% agarose gels
and visualized by ethidium bromide staining.
The PCR products were sequenced with an ABI PRISM dye
terminator cycle sequencing kit (Perkin Elmer, Warrington) using
AmpliTaq DNA polymerase, FS and the sequencing products were
analysed on an automated 373A DNA sequencer (Applied Biosystems.
Warrington, UK)
Results
eNOS and iNOS immunocytochemistry across the
normal menstrual cycle
Immunocytochemistry for eNOS and iNOS was carried out
on paraffin sections from 21 women. Six were in the prolifera¬
tive phase of the cycle, 11 were in the secretory phase [early
secretory (days 14-18) n = 6, mid-secretory (days 19-24)
n = 3, late secretory (days 25-28) n = 2] and 4 were in the
menstrual phase.
Endothelial NOS protein was detected in endothelial cells
lining blood vessels (Figures 1A,B) in the myometrium and
endometrium, and in endometrial glandular epithelial cells in
all specimens examined. UEA 1 lectin staining confirmed that
eNOS antibody stained endothelial cells (Figure 1C), but
suggested that eNOS protein was not present in all endothelial
cells. There was a difference both in the intensity of staining
of endothelial cells and the number of blood vessels which
stained positive for eNOS in endometrium and myometrium
between different sections. There was also inter-individual
variation in the intensity of eNOS antibody staining in glandular
epithelial cells which was not related to the stage in the
menstrual cycle.
In five of the 21 specimens there was marked variation in
the intensity of staining of endometrial epithelial cells in the
same specimen, ranging from very faint in the functional
endometrium to intense in the basal region. This gradation in
staining was observed in four secretory phase samples and in
one sample taken in the late proliferative phase. Five tissue
samples which showed no such gradation exhibited a marked
reduction in staining of their surface epithelium.
Immunolocalization of eNOS on crvosections from 11
specimens confirmed eNOS was present in vascular endo¬
thelium and glandular epithelium. Although the pattern of
localization was similar to that obtained on wax sections, the
staining on cryosections was less extensive within the cyto¬
plasm of individual epithelial cells.
Amongst the nine women in whom menstrual blood loss
was measured before hysterectomy, five had a normal monthly
blood loss (median 35 ml, range 28-76 ml) and four had
menorrhagia (median 202 ml. range 98-265 ml). The intensity
of immunostaining for eNOS in these samples did not appear
to be related to the degree of menstrual blood loss.
Inducible NOS-like immunoreactivitv was investigated in
paraffin sections using the murine polyclonal antibody.
Immunostaining was not present in endothelial cells, but was
detected in glandular epithelial cells (Figure ID). Once more
there was a considerable difference in the intensity of staining
between samples which was not related to the stage of the
menstrual cycle. As with the eNOS immunocytochemistry, a
gradation in staining was also observed between basal and
functional layers of the endometrium in four biopsies, two of
which were obtained in the proliferative phase and two in
the early to mid-secretory phase of the menstrual cycle.




Figure 1. Localization of endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) protein in human uterus.
(A) eNOS localized to the endothelium of a spiral arteriole (arrows) in a secretory phase specimen and also to the glandular epithelium
with variable intensity. (B) eNOS was found in glandular epithelium and endothelial cells of microvessels (arrows) in menstrual tissue.
(C) Localization of UEA 1 binding glycans in endometrium and myometrium (m) confirmed the vascular localization of eNOS. (D) iNOS
was localized in glandular epithelium and the smooth muscle of spiral arterioles (arrows), but was absent from the microvascular
endothelium. (E) iNOS was also expressed in myometrial smooth muscle and vascular smooth muscle within the endometrium. (F) Human
DLD-1 adenocarcinoma cells stimulated with cytokines expressed iNOS and acted as a posiuve control for the anti-murine iNOS antibody.
Nuclei were visualized with haematoxylin. The negative controls, without primary antibody or with an irrelevant primary antibody (see
Materials and methods) exhibited no reactivity. Bar = 30 jam.
and of the myometrium itself, was seen in tissues from nine
women (Figure IE). Control cultures of human DLD-1 cells
treated with cytokines stained intensely with the anti-murine
iNOS antibody (Figure IF).
The pattern of immunolocalization obtained with the anti-
human iNOS antibody on cryosections was identical to that
obtained with the anti-murine iNOS antibody on paraffin
sections.
Immunocytochemistry for eNOS and iNOS after treat¬
ment with exogenous progestagens
The pattern of localization of eNOS and iNOS protein in the
pre-treatment biopsies of 12 menorrhagic women was not
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distinguishable from that observed in the biopsies from the 21
who underwent hysterectomy for benign disease. Endothelial
NOS-like immunoreactivity was confined to vascular endo¬
thelium and glandular epithelium, whilst iNOS-Iike immuno¬
reactivity was seen in glandular epithelium and in some
vascular smooth muscle cells. Though immunoreactivity was
present in all sections, there was marked variability in the
intensity of staining for both vascular and epithelial cells. NOS-
like immunoreactivity was not detected in endometrial stroma.
Administration of norethisterone resulted in the appearance
of small areas of decidualization in tissues from two of the
six patients, whereas a pronounced decidual reaction was seen
in all endometrial specimens taken from the six women
NOS expression in human endometriui
Figure 2. Expression of nitric oxide synthase (NOS) in endometrium after exposure to exogenous progestagens. (A) Endothelial NOS
localized to blood vessels after exposure to oral norethisterone for 21 days. The glandular epithelium was reduced in height and in this
biopsy did not express eNOS. (B) A highly decidualized patch of endometrial stroma after exposure to LNG-IUS showing weak expression
of inducible NOS (iNOS) within the stromal cells. (C) Stromal cells within first trimester decidua also expressed iNOS. The negative
controls, without primary antibody or with an irrelevant primary antibody (see Materials and methods) exhibited no reactivity. Bar = 30
pm.
receiving LNG-IUS. Treatment with progestagen abolished
eNOS immunoreactivitv in glandular epithelial cells in all of
the patients treated with the LNG-IUS and in three of those
treated with norethisterone (Figure 2A). Similarly, treatment
with the LNG-IUS caused an attenuation or loss of iNOS
immunoreactivity within glandular epithelium. By contrast,
weak iNOS immunoreactivity appeared in the decidualized
stromal cells after exposure to LNG-IUS (Figure 2B).
NOS immunoreactivity in stromal cell of first
trimester decidua
Endothelial NOS-like immunoreactivity was localized to endo¬
thelial cells in five out of five biopsies of decidual tissue in
which eNOS localization was carried out. Localization of
iNOS was examined on 10 decidual biopsies using both the
murine and human iNOS antibodies. With both antibodies,
weak immunoreactivity was observed in decidual stromal cells
(Figure 2C) which expressed vimentin but not cytokeratin, and
in vascular smooth muscle.
Reverse transcription-polymerase chain reaction
Messenger RNA for both eNOS and iNOS was detected
by RT-PCR in total RNA extracted from enriched gland
preparations from proliferative and secretory phase endometria
(Figure 3). Sequencing of the amplified products revealed 95
and 99% homology with the published sequences of eNOS
and iNOS respectively. RT-PCR for iNOS in control cultures
of DLD-1 cells produced one intense band of the expected
size and equivalent to that observed in isolated gland fragments.
Discussion
This study has demonstrated the presence of mRNA and
protein for both eNOS and iNOS in normal human endo¬
metrium. Besides localization to the vascular compartmei
(eNOS to vascular endothelium and iNOS to vascular smoot
muscle in some sections), eNOS- and iNOS-like immunoreac
tivity and mRNA were detected in endometrial glandul;
epithelium. Whilst the intensity of immunostaining varie
markedly between individuals, there was no clear relationshi
with either the stage of the menstrual cycle at which tissue
were obtained, or objectively-measured menstrual blood los:
Endothelial NOS or iNOS mRNA or protein were not found i
endometrial stroma, but iNOS immunoreactivity was present i
decidualized stroma in specimens obtained after the administrt
tion of synthetic progestagen and in the first trimester c
pregnancy.
In our previous work which assessed immunoreactivity i
six women using a different monoclonal antibody raised i
mice against bovine eNOS, staining was detected in endc
metrial stroma and myometrial blood vessels, with wea
staining in glandular epithelium in secretory endometriur
(Telfer et ai. 1995). The present study with an anti-huma
eNOS monoclonal antibody revealed a consistent pattern c
eNOS-like immunoreactivity in vascular endothelium an
glandular epithelium. Localization of eNOS protein t
glandular epithelium is supported by the distribution c
NADPH diaphorase activity (Telfer et al., 1995), the detectio
of mRNA for eNOS in glandular epithelium by Norther
analysis (Tseng et al., 1996) and RT-PCR as described here
Demonstration of iNOS-like immunoreactivity in endo
metrial glandular epithelium was also supported by the detec
tion of iNOS mRNA in glandular epithelial cells by RT-RCP
In addition, Tseng et al. (1996) detected mRNA for iNOS i:
enriched endometrial gland preparations by Northern blc
analysis. However, in contrast to eNOS. iNOS message wa
only found in glandular epithelia derived from menstrua




Figure 3. Reverse transcription-polymerase chain reaction (RT-PCR) for (A) endothelial nitric oxide synthase (eNOS) and (B) inducible
nitric oxide synthase (iNOS) using total RNA extracted from freshly isolated gland fragments. Lanes 2-4 represent the proliferative phase
and lanes 5-7 the secretory phase. Lane 1 is a 123 bp ladder and lane 8 is a negative control from which cDNA was omitted. Five out of
six specimens produced an intense band of the appropriate size (486 bp) for the eNOS amplimer. One proliferative phase specimen (lane 4)
produced a much fainter band of the same size. RT-PCR with iNOS primers produced a major band of the predicted size (375 bp) in five
out of six specimens. This product had 99% sequence homology with the published human iNOS sequence. Products of higher molecular
weight were also observed in three secretory phase specimens although their identity is unknown.
Northern blotting might be due to the different sensitivities of
these two techniques.
Although not found in stromal cells throughout the normal
cycle, iNOS-like immunoreactivity was present in stromal
cells which had undergone decidualization following either
the administration of synthetic progestagen in vivo, or the
establishment of pregnancy. This in-vivo study does not
discriminate between a direct effect of progesterone on iNOS
expression or a secondary effect of local paracrine mediators
that are induced by progesterone. In this study we have
obtained no evidence for effects of oestrogen on eNOS and
iNOS expression in human endometrium. Similarly in the
sheep uterus exogenous oestrogen had no effect on NOS in
the endometrium although it increased Ca2~-dependent NOS
in the myometrium (Figueroa and Massmann, 1995).
Identification of eNOS and iNOS in human endometrium
suggests that NO may be involved in the local control of
uterine function. Moreover, localization of NOS to vascular
and non-vascular tissues would not preclude a predominant
action on the uterine vascular bed. For example, the renal
tubular epithelial cells of the macula densa release NO
which dilates the neighbouring afferent artery to increase the
glomerular filtration rate (Wilcox et ai, 1992). Nitric oxide
might participate in both the initiation and control of menstrual
bleeding. According to Markee (1940), the onset of
menstruation is preceded by endometrial regression, vaso¬
constriction and then vasodilatation. Nitric oxide could
contribute to these events as the most potent known vasodilator.
Next, along with the vasodilatory prostanoids, prostaglandin
Ei and prostacyclin (prostaglandin I2), NO might play a role
in determining the degree of menstrual bleeding (Smith et al.,
1981), though a relationship between the intensity of immuno-
staining and objectively-measured menstrual blood loss was
not found in the present study. In addition. NO may play
a part in the inhibition of platelet aggregation within the
endometrium. During the first few days of bleeding, haemo-
stasis is achieved mainly by vasoconstriction and not by the
deposition of platelet-fibrin plugs (Christiaens et ai, 1980).
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Thus, the endometrium is thought to heal not by clot
organization and subsequent scarring, but by vasoconstriction
followed by the growth of new blood vessels.
Endometrially-derived NO could also contribute to the
local control of mvometrial contractility (Izumi et al., 1993;
Buhimschi et al., 1995). Much attention has focused on
the part that NO might play in maintaining myometrial
quiescence during pregnancy, suggesting NO administration
as a therapeutic approach for the treatment of pre-term labour
(see Norman and Cameron, 1996 for review). Nitric oxide
also appears to relax the non-pregnant myometrium, an action
which could be exploited for the medical treatment of primary
dvsmenorrhoea (Pittrof et al.. 1996).
Nitric oxide can be released from vascular endothelium by
a range of stimuli, including endothelin (ET) binding to
the ETb receptor (Takayanagi et al.. 1991). Endothelin-like
immunoreactivity is found on vascular endothelium and
glandular epithelium in human endometrium (Cameron et al..
1992; Salamonsen et al., 1992). Furthermore. ETB receptors
are predominantly localized to the same cell type as NOS-
like immunoreactivity in the endometrium, namely glandular
epithelium (Collett et al.. 1996). The precise relationships
between NO, ETs and other locally-produced mediators of
endometrial function remain to be elucidated.
Acknowledgements
We thank Mr Roth Tait of the Molecular Biology Laboratory,
Department of Physiology and Pharmacology, Strathclyde University
for carrying out DNA sequencing, Dr Mike Jeffers and the consultants
from the Department of Pathology, Glasgow Royal Infirmary for
histological assessment of endometrial biopsies, the consultant
gynaecologists at the West Glasgow Hospitals University NHS Trust
and Glasgow Royal Infirmary University NHS Trust for assistance
with patient recruitment, and Dr James Williamson for supplying the
iNOS primer sequence. The study was supported by grant number
G9309196PA from the Medical Research Council (JFT), EC Human
Capital and Mobility Fellowship number 9030364 (GK) and Leiras Oy,
Turku, Finland by providing the LNG-IUS and financial sponsorship.
208
NOS expression in human endometrium
References
Buhimschi. I., Yallampalli. C., Dong, Y.-L. and Garfield. R.E. (1995)
Involvement of a nitric oxide-cyclic guanosine monophosphate pathway in
control of human uterine contractility during pregnancy. Am. J. Obstet.
Gynecol. 172. 1577-1584.
Cameron, I.T., Davenport. A.P., van Papendorp, C. et al. (1992) Endothelin-
like immunoreactivity in human endometrium. J. Reprod. Fertil.. 95,
623-628.
Chartrain. N.A., Geiler. D.A.. Koty, P.P. et al. (1994) Molecular cloning,
structure, and chromosomal localization of the human inducible nitric oxide
synthase gene. J.Biol. Chem.. 269, 6765-6772.
Christiaens, G.C.M.L.. Sixma, J.J. and Haspels. A.A. (1980) Morphology of
haemostasis in menstrual endometrium. Br. J. Obstet. Gynaecol.. 87,
425-439.
Collett, G.P., Kohnen. G.. Campbell. S. era/. (1996) Localization of endothelin
receptors in human uterus throughout the menstrual cycle. Mol. Hum
Reprod., 2, 439—144.
Figueroa. J.P. and Massmann. G.A. (1995) Estrogen increases nitric-oxide
synthase activity in the uterus of nonpregnant sheep. Am. J. Obstet. Gvnecol.
173, 1539-1545.
Haliberg, L. and Nilsson. L. (1964) Determination of menstrual blood loss.
A population study. Scand. J. Clin. Lab. Invest.. 16, 244—248.
Huang, J., Roby, K.F.. Pace. J.L. et al. (1995) Cellular localization and
hormonal regulation of inducible nitric oxide synthase in cycling mouse
uterus. J. Leukocyte Biol.. 57, 27-35.
Izumi, H„ Yallampalli. C. and Garfield, R.E. (1993) Gestational changes in
L-arginine-induced relaxation of pregnant rat and human myometrial smooth
muscle. Am. J. Obsret. Gynecol. 169, 1327-1337.
Lowenstein. C. and Snyder, S.H. (1992) Nitric oxide: a novel biologic
messenger. Cell. 70, 705-707.
Markee. J.E. (1940) Menstruation in intraocular endometrial transplants in the
rhesus monkey. Contrib. Embryol.. 28, 219-308.
Marsden. P.A.. Heng. H.H.Q., Scherer. S.W. et al. (1993) Structure and
chromosomal localization of the human constitutive endothelial nitric oxide
synthase gene. J. Biol. Chem.. 268, 17478-17488.
Moncada. S.. Palmer R.M.J. and Higgs, E.A. (1991) Nitric oxide: physiology,
pathophysiology and pharmacology. Pharmacol. Rev.. 43, 109-142.
Natuzzi. E.S., Ursell. P.C.. Harrison, M. et al. (1993) Nitric oxide synthase
activity decreases at parturition. Biochem. Biophys. Res. Commun.. 194,1-8.
Norman, J. and Cameron. I.T. (1996) Nitric oxide in the human uterus. Rev.
Reprod.. 1, 61-68.
Noyes. R.W., Hertig. A.T. and Rock. J. (1950) Dating the endometrial biopsy.
Fertil. Steril.. 1, 3-25.
Palmer, R.M.J., Ferrige. A.G. and Moncada. S. (1987) Nitric oxide release
accounts for the bioloaical activity of endothelium-derived relaxing factor.
Nature. 327, 52-4—5267
Pittrof. R.. Lees. C.. Thompson. C. et al. (1996) Crossover study of glyceryl
trinitrate patches for controlling pain in women with severe dvsmenorrhoea.
Br. Med. J.. 312. 884.
Salamonsen. L.A.. Butt, A.R.. Macpherson. A.M. et al. (1992)
Immunolocalization of the vasoconstrictor endothelin in human
endometrium during the menstrual cycle and in umbilical cord at birth.
Am. J. Obstet. Gynecol.. 167, 163-167.
Schmidt. H.H.H.W.. Gagne. G.D.. Nakane. M. et al. (1992) Mapping of neural
nitric oxide synthase in the rat suggests frequent co-localization with
NADPH diaphorase but not with soluble guanvlyl cyclase, and novel
paraneural functions for nitrinergic signal transduction. J. Histochem.
Cytochem.. 40, 1439-1456.
Sherman. P.A.. Laubach. V.E., Reep, B.R. and Wood. E.R. (1993) Purification
and cDNA sequence of an inducible nitric oxide synthase from a human
tumor cell line. Biochem.. 32, 11600-11605.
Sladek. S.M.. Regenstein. A.C., Lykins, D. and Roberts. J.M. (1993) Nitric
oxide synthase activity in pregnant rabbit. Am. J. Obstet. Gynecol., 169,
1285-1291.
Smith, S.K.. Abel. M.H.. Kelly, R.W. and Baird, D.T. (1981) Prostaglandin
synthesis in the endometrium of women with ovular dysfunctional uterine
bleeding. Br. J. Obsret. Gynaecol.. 88, 434—142.
Takayanagi, R„ Kitazumi. K.. Takasaki. C. et al. (1991) Presence of non¬
selective endothelin receptor on vascular endothelium and its linkage to
vasodilation. FEBS Lett.. 282, 103-106.
Telfer. J.F.. Lyall. F. Norman. J.E. and Cameron. I.T. (1995) Identification of
nitric oxide synthase in human uterus. Hum. Reprod.. 10, 19-23.
Tseng, L., Zhang, J.Z.. Peresleni. T.Y. and Goligorskv, M.S. (1996) Cyclic
expression of endothelial nitric oxide synthase mRNA in the epithelial
glands of human endometrium. J. Soc. Gynecol. Invest.. 3, 33-38.
Weiner, C.P.. Knowies, R.G.. Nelson. S.E. and Stegink. L.D. (1994) Pregnancy
increases guanosine 3',5'-monophosphate in the myometrium independent
of nitric oxide synthesis. Endocrinology. 135, 2473-2478.
Wilcox. C.S., Welch. W.J., Murad. F. et al. (1992) Nitric oxide synthase in
macula densa regulates glomerular capillary pressure. Proc. Natl. Acad.
Sci. U.S.A.. 89, 11993-11997.
Received on July 9, 1996: accepted on October 15. 1996
75
209
